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Abstract 
 
One third of the world’s population is estimated to be infected with M. tuberculosis, a 
pathogen which causes more human death and misery than any other bacterial 
disease.  Whilst treatment is available, resistance to commonly used antimicrobials is a 
growing problem.  Thus there is an urgent need to identify new compounds that can 
kill drug resistant isolates and are able to potentiate the activity of currently available 
antibiotics. 
   
The plant kingdom is a rich source of antibacterial compounds and a plant which has 
attracted particular interest is Humulus lupulus, more commonly known as the hop,   
which has been used as an antibacterial in beer for hundreds of years. Its antibacterial 
properties are thought to be due to the combined action of alpha and beta acids and 
polyphenols such as xanthohumol although the precise nature of their interactions and 
relative importance has yet to be determined. 
 
An optimised agar antimicrobial assay was developed and employed based on 
Mycobacterium smegmatis, to characterize the antibacterial activity of fifty 
commercially available hop varieties with a view to identifying novel antibacterial 
compounds.  
 
Surprisingly, no correlation was found between alpha and beta acid content and 
antibacterial activity. Chemical analysis of the most (Citra) and least (Galena) active 
hop variants using a combination of bioactivity based thin layer chromatography, mass 
spectrometry and HPLC revealed differences in the relative amounts of  antimicrobial 
compounds such as humulone (alpha acid), lupulone (beta acid) and xanthohumol  but  
failed to identify the presence of novel antibacterial compounds. 
Whilst no new antimicrobial compounds were identified, the Citra hop extract was 
able to potentiate the activity of the antibiotics imipenem and ciprofloxacin against 
clinical isolates of M. abscessus, a fast growing member of the mycobacterium family 
which infects individuals suffering from cystic fibrosis. The Citra hop extract also 
inhibited the growth drug resistant isolates of M. abscessus suggesting that it may 
have activity against other antibiotic resistant mycobacteria such as M. tuberculosis 
 
With regards to the mode of action, scanning electron microscopy revealed distinct 
changes to the outer cell structure of the bacteria, suggesting that hops contain 
compounds that interact with the bacterial cell membrane and/or cell wall. These 
changes were more profound in the presence of sub-inhibitory concentrations of 
imipenem, a compound which also targets the cell wall.  
 
Overall hops were shown to contain compounds which inhibited the growth of 
mycobacterium and were able to potentate the activity of antibiotics currently used to 
treat these pathogens. These findings suggest hops may be a fruitful source from 
which to isolate next generation compounds with which to treat increasingly drug 
resistant strains of mycobacteria. 
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“In wine there is wisdom, in beer there is 
strength, in water there is bacteria” 
- German Proverb 
 
 
 
  
 
 
 
 
 
Chapter One 
 
 
 
 
 
 
General Introduction, Aims and Objectives 
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1.0 General Introduction 
1.1 Summary 
Primarily a self-funded studentship, this thesis explored the potential of hops 
(Humulus lupulus) as an antimicrobial against clinically relevant Gram positive, Gram 
negative and Mycobacterial organisms. Hops are primarily used in the brewing of beer 
and influence the final flavour and aroma of beer as well as having an inhibitory effect 
on beer spoilage bacteria.  
To determine if the hop plant did possess antibacterial activity, agar based methods 
were used to determine the minimum inhibitory and bactericidal concentrations of 50 
commercially available hop variants. Previous research has suggested that the hop 
alpha and beta acids were directly responsible for the levels of antibacterial activity, 
however no correlation was observed. Chemical evaluation of the most active and 
least active hop extracts revealed differences in the known antimicrobial components, 
although not directly antimicrobial a novel compound was isolated.   
Some plant species and their extracts are known to potentiate the activity of 
antibiotics and in this thesis several methods of determining antibacterial synergy are 
investigated. Furthermore, the potential mode of action of both the hop extracts and 
antibiotics alone and in combination was investigated using scanning electron 
microscopy.  
  
2 
 
1.2 The history of medicinal plants  
The pharmacological properties of plants and plant extracts have been documented 
since ancient times. A Sumerian clay tablet dated over 4000 years old from Nagpur, 
India listed 12 herbal medicines and remedies for drug preparation which were derived 
from over 250 various plant species (Rooney, 2009). 
It is estimated that the ancient Egyptians used over 700 different formulas of plant 
extracts and honey in a systematic and controlled way (Gurib-Fakim, 2006). There is 
also evidence that plants have been used for their medicinal qualities in China since 
5000 B.C, indeed the Pen T’Sao the Chinese book on roots and grasses written around 
2500 B.C describes over 365 plant derived preparations for medicinal use (Petrovska, 
2012; Wang, 2000).  
The Greeks and Romans further utilised the plants around them, Hippocrates (460-370 
B.C) who is considered the father of medicine, described the importance of preventive 
medicine and is often regarded as the author of the following quote: 
“Let food be thy medicine and medicine be thy food” (Kagan-Zur, 2014) 
In the first century (circa 77 A.D) Discorides studied the properties of over 1000 plants 
and produced a synopsis of their chemical properties within the Materia Medica, a 
medicinal plant catalogue, which became the prototype for early pharmacopoeias 
(Cowan, 1999). The Materia Medica gave descriptions of the plant locations, their 
appearance and perhaps most importantly the recipes of medicinal preparations with 
potential therapeutic effects (Petrovska, 2012). Moving forward to around 1200 – 
1500 AD the international trade in herbs, spices and plants from Asia, and the 
discovery of America in 1498, prompted an exponential increase in the availability of 
medical plant preparations (O’Hara et al., 1998). 
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It was not until the 18th and 19th centuries that that development of pharmacologically 
active pure natural products increased. One of the first of these was the opium poppy 
(Papaver somnifernum); originally used for its psychoactive and anaesthetising 
properties since Neolithic and Bronze ages, by extraction of the dried sap from the un-
ripened seed pods. It was from this plant only 200 years ago that the compound 
morphine was isolated and is still in use today (Rauter et al., 2002; Sumner, 2000). 
This was one of many discoveries that began an era in which potential bioactive 
compounds from plants could be purified, studied and administered in precise 
dosages. As such natural products provided a foundation for the discovery of many of 
today’s longstanding medicinal treatments (Newton et al., 2000). As a consequence, 
over the last 20 years natural products or analogues inspired by them form the basis of 
90% of therapeutics, approximately two thirds of the world’s population relying on 
plants as their primary source of medicine (Cragg and Newman, 2013; McChesney et 
al., 2007; Newman and Cragg, 2007; Newton et al., 2000) 
The use of plants is not restricted solely to developing medicines however, over the 
last 30 years there has been a growth of nutraceuticals (foods that aid health) and the 
use of natural compounds in food and drink preservation. This market is estimated to 
surpass revenues of $220 billion worldwide in 2014.  (King, 2014; Hammer et al., 1999; 
Martindale et al., 1996). 
It is estimated that there are at least half a million species of flowering plants in the 
world. Of these, fewer than 5 % have been investigated for their medicinal potential. 
However, over the last 25 years there has been a surge in the research of natural 
products and as such modern medicine is becoming increasingly receptive to the 
identification of novel compounds such as antimicrobials, from plants. This rise in the 
interest of natural products has coincided with an increase of drug resistant strains of 
bacteria and a rapid extinction of plant species (Borris, 1996; Lewis and Elvin-Lewis, 
1995; Moerman, 1996). This interest has seen extracts of plants such as garlic, ginseng, 
valerian and soy, exceed sales of over $500 million in the US alone  (Lewis and Elvin-
Lewis, 1995). 
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1.3 Humulus lupulus  
With the discovery of antibiotics came the announcement from the US secretary 
general that ‘now the golden age of antibiotics is upon us, the war against bacterial 
infections is over’ (Rooney, 2009). Their effectiveness and hence popularity among the 
world’s population has led to years of over use and misuse which has left a vast array 
of drug resistant micro-organisms and antibiotics which are no longer effective (Gould, 
2009). The cost of developing a new antimicrobial combined with the likelihood of 
bacterial resistance means that here are no new antibiotics in the developmental 
pipeline; in fact, no new classes of antibiotics have been developed since the 1980’s 
(Alanis, 2005). 
Plants and their derivatives represent a diverse resource from which discovering new, 
efficient and safe antibiotics is a priority. Increasingly, research is looking into early 
pharmacopeia’s for plants or extracts which were once effective but fell out of favour 
with the introduction of antibiotics (Borris, 1996). The plant Humulus lupulus, known 
as the hop, is one such plant. The hop plant has been utilised throughout history for its 
flavouring, aroma and antibacterial qualities, primarily in the process of brewing beer 
(Hieronymus, 2012). 
The genus Humulus is part of the Cannabacae family of plants, including hemp and 
cannabis. Three species of the hop exist; Humulus lupulus, Humulus scandens, and 
Humulus yunnanensis; the latter two of these do not produce resinous cones and 
therefore are of no use in brewing (Hieronymus, 2012; Stavri et al., 2004).  
The first usage of the hop plant is difficult to accurately determine; workers widening a 
drainage ditch in Kent during 1970, found an Anglo-Saxon boat abandoned circa 949 
A.D. Upon inspection, the cargo contained huge quantities of hops. This is believed to 
be the earliest record of hop growing and trade (Hieronymus, 2012; Wilson, 1975).  
Whilst this predates any previous mention of hops used in the brewing of beer it is 
presumed that the transport of such large quantities was destined for the brew kettle 
(Hieronymus, 2012).  
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Widely recognised as the first recorded history of the use of hops in brewing, is the 
writings of Abbess Hildegard of St. Rupertsberg in Physia (circa 1150-1160). She wrote:  
“If thou desirest to make a beer from oats and hops boil it also … as such a beer purges 
the stomach of the drinker and easest his chest, its bitterness prevents in the latter 
putrefecation and gives a longer durability” –  Adapted from (Arnold, 2005) 
This early recording not only mentions the use of hops in beer, but recognises its 
importance as an antibacterial, increasing the longevity of the final brew.  By the 18th 
century the use of hops as a household remedy as well as its addition in beer, was 
clear to the general public. Markets where hops were imported and sold from different 
regions were popular places (Figure 1.1) (Neve, 1991).  
 
Figure 1. 1 Engraving of a central London hop market from 1779 
Reproduced with permission from (Neve, 1991)  
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1.3.1 Hop cultivation 
The origins of the hop plant and the growth of the original plants is a matter of 
speculation. It is assumed that the plants were originally isolated from the wild and 
were grown in private gardens. The original gardens would have contained a mixture 
of several genotypes and the plants which had the highest yield would have been 
selected as a source for new plants. This selection process favoured different hop 
variants in different parts of the respective country; therefore each garden eventually 
had different hop variants with a diverse range of bitterness and aroma properties. 
Head brewers therefore were able to identify differences in the hops based on the 
taste of the beer; this lead to the selection of hops based on their suitability for the 
brew (Arnold, 2005; Barth et al., 1994; Hieronymus, 2012; Neve, 1991).  
Although this selection process led to around 60 different hop varieties being available 
around Europe circa 1900, there was a demand for bitterer, higher aroma hop 
varieties. Diseases were also becoming a problem and causing destruction to hop 
cultivars; indeed diseases such as downy mildew, hop mosaic virus, hop stunt viroid, 
powdery mildew and verticulum wilt were leading to a shortage of hops (Barth et al., 
1994). 
The risk of losing the hop plant in Europe to disease inspired several hop breading 
programmes. The first of these began in 1904 at Wye College in Kent and focused on 
improving hops by hybridizing several cultivars (Moir, 2000). Selecting hop varieties 
based on disease resistance and hybridizing existing German and English varieties led 
to twenty three sets of different seeds being obtained in the first year (Moir, 2000). 
This research is ongoing; based around Hüll, Germany, the hop research laboratory is 
provided with €1.8 million annually from the German government. This meant that 
between 2001 and 2007 over 15,000 hops were screened for resistance to disease 
(Hieronymus, 2012). Hop varieties which exhibited disease resistance were examined 
for the chemical constituents; varieties which had different levels of bitter acids 
differed in their ability to resist disease (Bajaj, 1989). 
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1.3.2 The hop 
One of the advantages of growing hops is the quick development of oil and polyphenol 
rich resinous cones (Ceh et al., 2007). The plant is a perennial on a permanent 
rootstock, consisting of an underground structure of both rhizomes (with buds) and 
true roots (without buds). The roots penetrate the soil to a depth of 15 feet or more 
and in the first year of growth the hop plant concentrates on building an extensive root 
system and few flowers are produced. In the second year prolific growth is usually 
expected (Hieronymus, 2012; Simmonds, 1897; Stavri et al., 2004). 
When supported with poles, the hop plant naturally twines to a height of six metres or 
more (Figure 1.2). The hop plant is dioecious and thus has separate male and female 
plants; only the females produce the cone shaped ‘hops’ used in brewing (Figure 1.2). 
The male plant serves as a polliniser, but is not essential for the female plant to 
produce the hop cones (Neve, 1991). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 2 The hop plant grown traditionally on supporting twines (top) and detailing of the 
individual hop cones (left) with a cross section (right) – adapted from (Hieronymus, 2012) 
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The hop cones of the female plant are the only part of the plant which is utilised in the 
brewing industry and this is the focus of the brewer. The cone or strobili develops from 
inflorescences (cluster of flowers). A strig extends through the centre of the strobili 
and bears a pair of bracts (outer leaves) and four bracteoles (inner petals) at each 
node (Neve, 1991). Lupulin glands develop at the base of the bracteoles. The lupulin 
glands contain hard and soft resins, hop oils and polyphenols. The soft resins include 
the alpha and beta acids, both of which contribute to the bitterness of beer (Neve, 
1991). 
1.3.3 Chemical components of hops  
Research has been focused on identifying the bioactive ingredients of hops and to 
elucidate the underlying molecular mechanisms by which they exert the bioactive 
properties (Van Cleemput, 2009a). Much of this research has concentrated on the 
polyphenolic components of hops, such as xanthohumol and 8-prenylnaringenin, 
which have been shown to have multiple bioactive properties (Chadwick et al., 2006; 
Gerhäuser, 2005; Stevens and Page, 2004). Moreover, increasing evidence has shown 
that the hop bitter acids, namely the alpha and beta acids, also exhibit several 
bioactive properties (Acworth, 2012; Everard, 2012; Van Cleemput, 2009). 
The following Table (2.1) details the average composition of lupulin glands of air dried 
hops. 
Components % m/m 
α - acids 2 – 17 
β – acids 2 – 10 
amino acids 0.1 
Ash/Salts 10 
Cellulose - lignin 40 -50 
Monosaccharides 2 
Oils and fatty acids 1 -5 
Pectins 2 
Polyphenols and tannins 3 -6 
Proteins 15 
Volatile oil 0.5 – 3 (v/m) 
Water 8 -12 
Table 1. 1 The average chemical composition of dried hops. 
Sources: (Acworth et al., 2012; Cornelison, 2008) 
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From a brewer’s point of view, the hop acids, the alpha (humulones) and beta 
(lupulones), are the most important class of hop compounds (Gerhäuser, 2005). The 
relative amounts of the alpha and beta acids depend entirely on both the hop variety 
and the conditions of growth. Therefore, even hops of the same variety can have 
widely different levels of bitter acids if grown in different regions (Van Cleemput et al., 
2009a).  
The term alpha acid is used as a single product, but it in fact refers to a number of 
compounds which are structurally similar but are significantly different. The alpha 
acids are a mixture of the analogues humulone, cohumulone and adhumulone that 
differ only in the nature of the acyl side chain (R).  The beta acids are a similar mixture 
of analogues lupulone, colupulone and adlupulone. Both the alpha and beta acids can 
exhibit tautomerism and exist as a mixture of readily interconvertible structures 
(Almaguer et al., 2014; Baker et al., 2008) 
Isomerisation, the changing of the arrangement of molecules of both the alpha and 
beta acids occurs during exposure to heat or light. The analogue therefore, is a 
precursor to its isomerisation products; in the case of humulone it is transformed to cis 
and trans isohumulone (Jaskula et al., 2008). The process of isomerisation involves 
contraction of the six-membered alpha acid ring (through acyloin rearrangement) to 
form the five-membered iso-alpha-acid ring with two chiral centres, resulting in cis and 
trans diastereomers (Acworth et al., 2012; Jaskula et al., 2008) . 
Recent research suggests that it is the hop bitter acids which account for the 
antibacterial qualities of hops (Cornelison, 2008; Larson et al., 1996; Van Cleemput et 
al., 2009a). This action has been attributed to the interference of the prenyl group, 
characteristic of the side chains of the hop acids. This bioactivity is of importance for 
killing micro-organisms during wort boiling, which ultimately leads to sterile beer 
(Arnold, 2005; Stevens and Page, 2004) 
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Prior to the development of successful breeding programmes, the average alpha acid 
content of UK sourced hops rarely exceeded 4%. With the need for more successful 
preservatives and bittering agents that figure has been increased.  A variety of hop 
named Northern Brewer, a seedling of the Golding variety derived from the USA, was 
the first to combine high alpha acid content (>8% w/w on average) with a good 
European aroma (Hieronymus, 2012; Neve, 1991; Woodske, 2012). 
The development of breeding programmes has allowed higher alpha acid (AA) varieties 
to be developed such as Target (the most commonly used hop in the UK), Chinook 
(12.7 % AA), Simcoe (12.2 % AA) and Magnum (14.5 % AA). This increase and need for 
alpha acids led to the development of alpha acid oil which eliminated the need for hop 
processing altogether and now over 85 % of the world’s hops are now processed into 
pellets, extracts or other products; improving delivery, packaging, ease of use and 
storage (Simpson and Smith, 1992; Woodske, 2012). 
 
The analogues of the alpha acids humulone, cohumulone and adhumulone represent 
35−70 %, 20−65 %, and 10−15 % (w/w), of the total levels found within hops 
respectively. The relative amount of humulone is dependent on hop variety, while the 
amount of cohumulone and adhumulone is fairly constant throughout all varieties, 
even when there are changes in the environment. High levels of cohumulone and 
adhumulone are associated with lower quality hops and are not favoured by the 
brewer (Haseleu et al., 2009; Moir, 2000). 
 
In contrast, the hop beta acids are considered of lower importance to the brewer as 
they have been shown to contribute less to the flavour of the final product (De 
Keukeleire, 2000). It has been recognised that most hop varieties contain 
approximately equal levels of lupulone and colupulone, which are extremely sensitive 
to oxidation (Zanoli and Zavatti, 2008). These compounds differ from the other beta 
acids in that they are very bitter and are usually present in quantities of a few mg L-1.  
Beta acids are of little interest to the brewer as far as the flavouring and aroma 
characteristics are concerned. The alpha acids are more important for beer bittering 
than the beta acids. However, neither class remains unchanged in the finished product 
(De Keukeleire, 2000; Simpson and Smith, 1992). 
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1.3.4 Hop harvesting and storage 
Hops in the northern hemisphere are usually harvested in August and September and 
are immediately dried to a water content below 10 %, vacuum packed and kept 
between 2-3 °C to increase longevity (De Keukeleire, 2000). It has been shown that if 
the hop material is not stored under these conditions the alpha acid concentration can 
breakdown rapidly during storage by as much as 70 % within 6 months (Baker et al., 
2008; Malowicki and Shellhammer, 2005a; Neve, 1991). 
The degradation of hop compounds is not only related to the storage conditions but 
also differs by variant and the environmental conditions that the plant was exposed to 
during growth. Despite the limited stability of dried hops, they are non-homogenous 
and have a low bulk density. However, only about 5% of the total annual harvest is 
used without further processing with around 60% converted into pellets (Hieronymus, 
2012; Malowicki and Shellhammer, 2005a). 
 
The process of pelleting the hops involves the inflorescences being cut, milled, 
homogenised and pressed into granules. The density of the granules, when tightly 
pressed and stored in correct conditions, increases their stability significantly (Nance 
and Setzer, 2011). For this reason pelleted versions of hops (1.3 right) are commonly 
used over their unaltered counterparts (Figure 1.3 left) in the brewing process 
(Hieronymus, 2012) 
 
  
 
 
 
 
 
Figure 1. 3 The difference between whole unprocessed hops (left) and those which have 
undergone pelleting (right). Taken from (Brewmaster, 2014) 
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1.3.5 The brewing of beer 
The primary use of hops is in the brewing of beer. Beer is a fermented aqueous drink 
based on four main ingredients; water, malted barley (grains), hops and yeast. Its 
production, known as brewing, has been understood since antiquity. Indeed, the 
Mesopotamians are famous for recognising the nutritional benefits of beer and also 
for noticing the side effects of an ‘exhilarated, wonderful and blissful feeling’ 
(Hieronymus, 2012). In the following Figure (Figure 1.4) the traditional brewing process 
is summarised. 
 
Figure 1. 4 Schematic of the traditional brewing process detailing the addition of hops.  
Adapted from (Poston, 2006) 
The steps involved in the brewing of beer include; malting, milling, mashing, brewing, 
cooling, fermentation and maturation. The first, malting, is the preparation of barley 
and it is used as a starch base for the wort. It is the addition of wort and its subsequent 
germination during heating which leads to the beer having a pale or dark colouring. 
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The second stage, milling, mills the various grains (of which barley comprises around 
40%). This ensures that the grains and their subsequent sugars will be more easily 
absorbed into the water of the mash tun. (Arnold, 2005; Jackson, 1998) 
The next stage, mashing, turns the malt into a sweet liquid by converting starches to 
sugars that can be fermented. The previously milled grain is added to the brew and 
heated to around 75 °C in the mash tun. It is at this point that the grain and water 
create a cereal mash to dissolve the starch into water, transforming it into sugar. The 
water itself is then strained through the bottom of the mash and is now termed, “the 
wort” (Arnold, 2005; Jackson, 1998). 
The next step, brewing, is the most important process. The simplest brew house layout 
has two principal vessels. The first, the mash tun for mashing, and the second, the 
brew kettle is where the infusion is boiled with hops. On average this process takes 
between 60 and 90 minutes; strong beers can require longer (Jackson, 1998). The main 
function of this step is to introduce the aroma and bitterness properties of the hops to 
the brew. Some beers are only made with the addition of only one hop variant, others 
multiple. The hops don’t contribute alcohol, however, the aromas and flavours are 
powerful. As such, even in large breweries the hops are usually often added by hand 
and in relatively small amounts (kilos) compared to the malt (tonnes). Hop variants 
intended to impart dryness or bitterness are added early in the boil, with some having 
a second addition mid boil to impart a stronger flavor (Jackson, 1998; Stevens and 
Page, 2004). 
When the brewing is completed the hop leaves and sediment are removed. This is 
either done through centrifugal force or through a strainer. In some cases the wort is 
filtered through layers of hops, imparting further hop aromas and oils. Commonly, 
aroma hops are added in the maturation vessel. In the UK, this is known as dry hopping 
and hops within a muslin sack are added to the cask in which the beer matures 
(Jackson, 1998) 
Finally, the beer is fermented, allowing for the sugar to be converted into alcohol. 
Once fermented, the beer is transferred to a conditioning tank where the taste ripens 
and the liquid clarifies which is usually completed within a few days. The beer, almost 
ready is filtered and bottled (Hornsey, 2003). 
14 
 
1.3.6 The medicinal qualities of hops 
Although hops main use is in beer, whole hops and their extracts have been developed 
into a diverse range of products around the world. These products include non-
alcoholic beverages, sleeping aids, aphrodisiacs and as treatments for a variety of 
maladies (Woodske, 2012). The traditional use of hops as a mild sedative stems from 
the observation of sleepiness and fatigue in hop pickers apparently due to the transfer 
of hop resin from their hands to their mouths (Foster and Tyler, 2000). In 1998 the 
German commission approved hops for the treatment of mood disturbances, such as 
restlessness and anxiety (Bundesinstitut für Arzneimittel und Medizinprodukte 
(Germany), 1998). Hops are also known to possess estrogenic activity, first recognised 
when female hop pickers had frequent menstrual disturbances during the early days of 
hop cone harvesting. In Germany, hop baths were frequently used as a treatment for 
gynaecological disorders (Chadwick et al., 2006; Milligan et al., 2000). 
Beer was originally produced without the addition of hops, however it is thought that 
during the summer months ‘unhopped’ beer was seen to spoil much faster than its 
‘hopped’ counterpart (Filmer, 1982). Due to this, hops were added to many beers. 
Circa mid-19th century drinking water was heavily contaminated and unsanitary due to 
the lack of sterilisation techniques and understanding. During this time beer was 
considered a safer alternative to water; due to the facts that the wort is boiled, thus 
destroying the bacteria, combined with the antibacterial effects of the hops during the 
brewing process and subsequent storage. The alcohol level of beer at this time was  
typically between 2-6% (v/v) and it has been shown that an alcohol concentration of 
this level would have no effect on the majority of pathogenic bacteria (Jackson, 1998; 
Rooney, 2009) 
 
For the brewing industry beer spoilage bacteria have been problematic for centuries 
(Sakamoto 2003). Beer is generally a poor and hostile environment for most 
microorganisms as the typical pH (3.8-4.7) is unfavourable for bacterial growth. 
However this allows for the growth of specific organisms such as Lactobacillus and 
yeasts (Langezaal et al., 1992; Sakamoto and Konings, 2003a). 
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Haas and colleagues (1994) investigated the antibacterial role of isomerised alpha and 
beta hop resins against Streptococcus salivarius, Staphylococcus aureus, Bacillus 
megaterium, Escherichia coli B, and Bacillus subtilis. The study showed that the 
isomerised alpha and beta acid resins inhibited the growth of all of the organisms at 
concentrations from 0.01% to 0.03% (w/v). The inhibition of growth is generally 
thought to be due to primary membrane leakage by the interaction between the 
hydrophobic areas of alpha and beta acid molecules with the bacterial cell wall (Haas 
and Barsoumian, 1994; Teuber and Schmalreck, 1973). 
 
A further study by Stavri et al (2004) investigated the anti-mycobacterial effectiveness 
of hop extracts and hypothesised that activity was associated with the alpha and beta 
acids.  After a non-polar extraction process and preparative thin layer chromatography 
(TLC) on silica gel, several bands were isolated, all of which had activity against 
Mycobacterium tuberculosis at concentrations ranging from 8 to 16 µg mL-1 (Stavri et 
al., 2004). Originally, it was hypothesised that each separation on TLC resulted in a 
singular molecular species. However, nuclear magnetic resonance (NMR) indicated 
that in fact the separated fractions were a mixture of different components. As these 
components were difficult to separate using conventional techniques, individual 
components could not be identified as having inhibitory activity against mycobacteria 
(Stavri et al., 2004). 
A study by Serkani and colleagues investigated the antibacterial effect of polar hop 
extracts against 37 drug resistant and susceptible isolates of Mycobacterium 
tuberculosis. The research found that both drug sensitive and resistant strains of the 
bacterium were inhibited by the presence of the hop extract (Serkani et al., 2012), 
further establishing that the hop plant is potentially a useful resource for undiscovered 
novel antimicrobials.  
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1.4 Mycobacterium 
Mycobacteria are members of the genus Mycobacterium which are slow growing, 
aerobic, rod shaped bacteria.  The organism is made distinctive by a staining property 
known as acid-fastness. This property is due to the presence on the mycobacterial cell 
wall of unique lipids called mycolic acids, found only within this genus. It was first 
discovered by Robert Koch during his investigations into tuberculosis and acid fast 
staining allowed for the identification of the organisms within tuberculosis lesions 
(Black, 2004; Mims and Goering, 2013). 
 
Figure 1. 5 Acid fast/ Ziehl Neelson stain of M. smegmatis 8159 
as first demonstrated by Robert Koch 
 
Mycobacteria are also categorised by other factors such as the production of specific 
pigments. For example, species such as M. tuberculosis and M. smegmatis do not 
produce a pigment, whereas, photo chromogenic species such as M. kansasii form a 
pigment only when cultured in light. Scotochromogenic species such as M. gordonae 
can form pigments when cultured in the dark (Mims and Goering, 2013). 
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Mycobacteria are pleomorphic and may undergo branching or filamentous growth. In 
general, Mycobacteria can be separated into two major groups, slow growers and fast 
growers. The difficulty in culturing slow growing bacteria in the laboratory has been a 
problem since their discovery. Mycobacteria do not grow readily on standard agar and 
due to the slow growth of the organism media can become contaminated (Madigan, 
2003). 
Slow growing species such as Mycobacterium tuberculosis have a doubling time of 
twenty hours and others can take up to ten weeks for cultures to become visible. 
Whereas faster growing species such as Mycobacterium smegmatis have a doubling 
time of 2 hours and colonies are visible within 72 hours. This shorter growth time and 
the advantage of being non-pathogenic allow for M. smegmatis being a useful tool 
within the laboratory as a simulant for Mycobacterium tuberculosis (Chaturvedi et al., 
2007a; Madigan, 2003) 
1.4.1 Mycobacterium tuberculosis 
It is currently estimated that one third of the world’s population is infected with the 
bacterium M. tuberculosis (Dooley et al., 2013). Tuberculosis (TB) on average is 
responsible for over 2 million deaths worldwide per annum, more than any other 
bacterial infection (WHO, 2010). The bacterium is successful as it is able to reside 
dormant within its hosts immune cells undetected; only causing symptoms when the 
patient is immunocompromised. As such, co-infection within HIV positive patients is 
increasing (Murray et al., 2014). 
If left untreated, each person with an active TB infection will, on average, infect 10-15 
other people per year (Murray et al., 2014; Pauli et al., 2005). The Health Protection 
Agency (HPA) has found that over the last 5 years there has been a 5% rise in the 
number of new cases of TB in the UK, with the majority of cases in London presenting 
6,000 new cases of TB in 2011 (HPA, 2012). 
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Mycobacterium tuberculosis is only one of many similar organisms within the 
Mycobacterium tuberculosis complex (MTC). The group comprises of closely related 
organisms such as M. africanum, M. microti, M. caprae, M. pinnipedi, M. bovis along 
with the widely used vaccine strain M. bovis bacillus Calmette-Guerin (BCG) (Brosch et 
al., 2002; Cole et al., 1998). 
The genetic similarities between the members of the MTC complex group of bacteria 
show an unusually high degree of conservation of housekeeping genes. It has been 
shown that members of the MTC group share around 85-100 % of their DNA 
(Frothingham et al., 1994). Paleopathogenic evidence suggests that tuberculosis 
afflicted humans as early as 3700 BC in Egypt and 2000 BC in Europe. The mutation 
frequency of M. tuberculosis, which is similar to that of other bacteria, has led to the 
speculation that MTC isolates may have diverged from a common ancestor 15,000 
years ago, as demonstrated in the following Figure (2.5) (Raviglione et al., 2006). 
 
Figure 1. 6 Common lineage of the Mycobacterium tuberculosis complex (MTC) showing 
differences in the RD genes from one common ancestor and the subsequent development of 
different species. Source: (Brosch et al., 2002) 
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Polymorphism in M. tuberculosis complex bacteria has been found to be associated 
with repetitive DNA, such as transposable elements and short perfect or imperfect 
repeats. The direct repeat locus (DR locus) is currently the only well studied single 
locus in the MTC (Cole, 2002; Cole et al., 1998). The DR locus is composed of 36 bp DR 
copies which are interspersed by non-repetitive short sequences of about equal length 
known as spacers. The absence or presence of one or more of the spacers form the 
main differences in M. tuberculosis and M. bovis and this property has been exploited 
for identification of the bacteria within the MTC group (Fang et al., 1999; van Embden 
et al., 2000). 
Due to the relationship between the genomics of M. bovis and M. tuberculosis, it was 
thought that human tuberculosis evolved from the bovine disease by adaption of an 
animal pathogen to a human host (Stead et al., 1995).  However work carried out by 
Brosch et al, (2002) shows that M. bovis has undergone numerous deletions relative to 
MTB through its evolution. It has been speculated that the successive loss of DNA may 
have contributed to clonal expansion and the appearance of more successful 
pathogens in certain new hosts as shown in Figure 2.6 (Brosch et al., 2002). 
 
 
Figure 1. 7 Lineage of other non-tuberculosis mycobacteria (NTM) in comparison with MTB, 
detailing the range of hosts. Source: (Galagan, 2014) 
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1.4.2 Human infection  
In primary infection, the mycobacteria, unlike other bacteria, do not avoid uptake by 
macrophages, instead they survive within the macrophage by blocking fusion of the 
phagosome with late endosomes and lysosomes. This is crucial for pathogenic 
mycobacteria as they can survive for long periods within these host cells (Armstrong 
1971). Uptake of mycobacteria by macrophages requires recognition of the bacteria 
through receptor molecules such as complement receptors, (CR’s), mannose receptor, 
scavenger receptors and immunoglobulin (Fc) receptors. Whilst precise uptake of the 
bacteria via receptors in vivo remains to be established, one of the most important 
receptors in vitro is CR3 (Ferguson et al., 2006; Velasco-Velázquez et al., 2003). 
 
Phagocytosis of mycobacteria by CR3 requires the accumulation of cholesterol at the 
site of entry; the CR3-mediated uptake is specific for mycobacteria because cholesterol 
depleted macrophages can still internalise other microorganisms. The role of 
cholesterol remains unknown, but it has been suggested that it may aid in the 
rearrangement of the membrane-cytoskeletal network during phagocytosis or be 
involved in signal-transduction reactions following the engagement of CR3 (Peyron et 
al., 2000; Velasco-Velázquez et al., 2003). 
1.4.3 Evasion of host immune defences 
To prevent destruction within the macrophage, mycobacteria have developed several 
methods to prevent phagosome maturation utilising both the host and mycobacterial 
molecules (Pieters and McKinney, 2013). One such host molecule is coronin 1 (P57), 
which is expressed exclusively within the leucocytes and utilises cholesterol within the 
cell to associate with mycobacterial phagosomes. P57 has been shown to function in 
actin-cytoskeleton remodelling, phagocytosis, cell division and polarity and vesicular 
trafficking from the endoplasmic reticulum to the golgi apparatus (Pieters and 
McKinney, 2013). P57 is retained exclusively on phagosomes of macrophages infected 
with live mycobacteria, whereas in cells with dead mycobacteria, P57 rapidly 
dissociates from phagosomes leading to fusion of phagosomes to lysosomes and 
destruction of the bacteria. This suggests an essential role of P57 in the protection of 
the mycobacteria within the cell (Ferrari et al., 1999; Tailleux et al., 2003). 
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Another important defence mechanism is the inhibition of phosphatidylinositol 3-
phosphate (PI3P). Biosynthesis of PI3P is required for phagosome maturation, and is a 
membrane trafficking regulatory lipid essential for phagolysosome biosynthesis. PI3P is 
synthesised by PI3-Kinase on endosomal and phagosomal membranes, and has been 
observed to move on the phagosomal membrane in temporally scheduled waves 
(Roth, 2004; Vergne et al., 2003; Wurmser et al., 1999). PI3P functions as a ligand for 
many proteins that may be involved in phagosome maturation such as hepatocyte 
growth factor (HGF) regulated tyrosine kinase substrate (Hrs), which has a key role in 
the regulation of traffic in the endosomal pathway (Raiborg et al., 2002; Chin et al., 
2001; Komada and Soriano, 1999).  
Mycobacteria are able to cause a reduction in the waves of PIP3 which results in the 
depletion of Hrs, and in turn halts phagosome maturation. This eventually leads to 
dissociation of Hrs with phagosomes preventing the mycobacteria being destroyed 
(Vieira et al., 2004) 
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1.4.4 Non-tuberculosis mycobacterium  
There are other pathogens within the mycobacterial community which are not part of 
the MTC group. Non tuberculosis mycobacterial disease (NTM) was first recognised in 
a small minority of patients with TB in the 1950’s (Cook, 2010). But it was not until 
disseminated Mycobacterium avium complex (MAC) was recognised as the most 
common opportunistic bacterial infection in AIDS patients that the low prevalence 
problem of pulmonary NTM disease attracted attention. Opportunistic NTM infections 
are acquired from environmental (water, soil) reservoirs and are not transmitted 
between humans or animals and humans. They notably cause disease in patients who 
are immunosuppressed and/or have pre-existing lung abnormalities (Al Jarad et al., 
1996; Mims and Goering, 2013; Thomson and Yew, 2009). 
 
Bacteria that fall within this group are MAC, M. kansasii, M. xenopi, M. malmoense, M. 
simiae, M. abscessus, M. chelonae and M. fortuitum. NTM that cause pulmonary 
disease have been shown to vary greatly between geographic regions (Cook, 2010). 
 
 MAC is the predominant pathogen in most regions worldwide. M. kansasii disease is 
relatively more common in the USA and the UK. M. xenopi is more common in the 
USA, Canada, the UK and some regions of Europe. Mycobacterium malmoense disease 
is common in the UK and northern Europe but is uncommon in the USA. It has been 
suggested that the differences in these geographical regions has been associated with 
variations in environmental conditions which favour the predominant NTM 
populations (Tan et al., 2013; Thomson and Yew, 2009).  
 
Infection with NTM can vary between regions but it has been shown that NTM 
commonly contaminate domestic water supplies, swimming pools and hospitals. 
Hospitals particularly suffer from nosocomial infections with NTM namely M. absessus, 
M. fortuitum and M. gordonae. Infections associated with these bacteria are 
associated with the skin and soft tissue acquired during surgical procedures; there are 
even reports of NTM infection from bronchoscopes (Wallace et al., 1992). 
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1.4.5 Mycobacterium smegmatis 
Mycobacterium smegmatis was first identified in 1884 from syphilitic chancres and 
was originally thought to be the agent that caused syphilis, but was eventually 
identified as a common environmental mycobacterium. M. smegmatis rarely causes 
disease in humans, with less than 30 infections ever recorded. Infection, if caused, is 
via skin or soft tissue infections following traumatic surgery (Best and Best, 2009). Its 
common use is within research facilities as a simulant organism of M. tuberculosis. The 
organism is successful as it can be handled within a category II laboratory and grows at 
a much faster rate than that of M. tuberculosis. A recent study also found that 
antibiotic sensitivities were similar between M. smegmatis and M. tuberculosis 
(Chaturvedi et al., 2007a). 
 
1.4.6 Mycobacterium abscessus  
M. abscessus is a rapid growing mycobacteria (RGM), which was first described in 
1953. It was not until the 1990’s however, that M. abscessus was recognised as an 
important human pathogen responsible for a wide spectrum of soft tissue infections 
and disseminated infection in immuo-compromised patients (Griffith et al., 2007; 
Moore and Frerichs, 1953; Nessar et al., 2012). Importantly M. abscessus is considered 
the prominent Mycobacterium, along with Mycobacterium avium, involved in 
infections with cystic fibrosis patients. The major concern of M. abscessus infection is 
its increasing drug resistance to first and second line antimicrobials, which has led to 
an increased mortality rate (Cullen et al., 2000; Jeon et al., 2009; Sanguinetti et al., 
2001). 
The current recommended regime for the treatment of M. abscessus infection relies 
on a combination of clarithromycin, with an aminoglycoside such as amikacin and an 
injectable antibacterial such as imipenem (Griffith et al., 2007). However, it has been 
shown that these combinations are becoming increasingly unsuccessful, highlighting 
the need for novel antimicrobials to combat the disease and potentiate the activity of 
redundant antibiotics. 
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Recently M. abscessus has been sub-classified into three sub-species on the basis of 
rpoB sequences: M. abscessus sensu stricto, M. massiliense and M. bolletii. Recent 
research has shown that differentiation between these species is problematic as each 
species shares ribosomal sequences (Tan et al., 2013). 
It has been shown that although similar in genomic terms, the bacterial subspecies 
differs in antibiotic resistance (Cole et al., 1998). This leads to the treatment of M. 
abscessus and its subspecies notoriously difficult to treat. Treatment using multiple 
antibiotics with several modes of action can reduce the microbial population but can 
lead to the selection of resistant organisms (Jeon et al., 2009). Furthermore, M. 
abscessus has been shown to be resistant to many of the anti-tuberculosis drugs in 
clinical use today.  Indeed the major pathogenicity factor of mycobacteria is the ability 
of the bacterium to be intrinsically resistant or acquire resistance to antibiotics 
(Fairhurst et al., 2002).  
Acquired resistance as a result of genotypic changes within mycobacterial clinical 
isolates is generally thought to be the result of spontaneous mutations affecting the 
key targets of antibiotics but resistance may result from alteration in the function of 
more than one gene.  Alteration in chromosomal gene function represents the main 
mechanism of acquired resistance in clinical strains of mycobacteria species; however, 
resistance has been observed in species which lack the absence of mutations within 
drug target genes suggesting other mechanisms can be involved (Cole, 2002; Rattan et 
al., 1998). The intrinsic resistance of mycobacteria is well understood, with the major 
contribution being the mycobacterial cell wall which consists of a complex matrix of 
fatty acids and lipids (following Figure 2.7) that can hinder the penetration of 
antimicrobial compounds (Cohn et al., 1997; Cole, 2002). 
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It is well documented that the cell envelope acts synergistically with antibiotic 
inducible internal systems in competing against the effect of drugs. The internal 
system, known as the intrinsic resistome, includes efflux pumps, antibiotic-
modifying/inactivating enzymes, target modifying enzymes and genes conferring metal 
resistance. One of many inactivating enzymes that has been observed in M. abscessus 
and M. tuberculosis is β-lactamase, which can assist the bacterium in nullifying the 
effect of β-lactam antibiotics such as imipenem (Raviglione et al., 2006; Tailleux et al., 
2003). 
The intrinsic resistance of MTB to most antibiotics is generally attributed to the low 
permeability of the mycobacterial cell wall because of its specific lipid-rich composition 
and structure. This low permeability limits drug uptake and seems to be one of the 
main factors involved in resistance. Along with cell permeability, which limits drug 
uptake, active efflux systems also provide resistance by extruding the drug molecules 
that enter the cell, which therefore lowers the intracellular concentration of a given 
drug.  In mycobacteria the two main efflux pumps associated with drug resistance are 
the lfrA efflux pump of M. smegmatis and the Rv1634 efflux pump of M. tuberculosis 
which are able to remove drugs from the cell before the drug can take effect (Brennan, 
2003; Niederweis, 2003). 
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1.4.7 Mycobacterial cell wall  
The cell wall of mycobacteria differs from that of other bacteria and due to this has a 
distinctive staining property known as acid fastness. This property is due to the 
presence of the lipid rich wall as shown in Figure 1.8. The cell wall of mycobacteria has 
been recognised as providing the bacilli with an effective innate immune defence 
against lysososomal degradation. In particular, the Mycobacterium tuberculosis PI3P 
analog glycosylated phosphatidylinositol lipoarabinomannan (ManLAM) has been 
reported to block phagosome maturation; the LAM binding site is also highlighted in 
Figure 2.7 (Black, 2004; Mims and Goering, 2013; Nguyen and Pieters, 2005). 
 
 
Figure 1. 8 Differences in Bacterial Cell Wall Morphology. Adapated from (Akira, 2006) 
 
ManLAM has several different effects within the macrophage, such as blocking the 
PI3P-dependant pathway, which halts phagolysosome biogenesis, and inhibiting 
calcium uptake in the macrophage cytosol, which is necessary for the accumulation of 
PI3P on the phagosomal membrane (Fratti et al., 2003; Sturgill-Koszycki et al., 1996). 
One of the most important macrophage combating molecules is interferon gamma 
(IFN-ƴ), which is secreted by activated T cells and natural killer cells during infection. 
IFN-ƴ signalling is used in many cellular processes, such as antigen presentation, 
leukocyte-endothelium cell interactions, cell growth and apoptosis, and phagosome-
lysosome fusion. Indeed, it has been shown that both mice and humans with IFN-ƴ 
genetic defects are extremely susceptible to mycobacterial diseases (Adams and 
Hamilton, 1992; Murray et al., 2014; Stout, 1993). 
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In addition to the adaptive immune response, macrophage activation can be mediated 
through activities of the toll-like receptors (TLR’s), of which TLR-2 and TLR-4 have key 
roles.  Activation of the TLRs via cell wall constituents leads to the activation of 
mitogen-activated protein kinases (MAPKs). The MAPKs initiate signalling cascades 
that activate transcription factors, which lead to the synthesis of tumour necrosis 
factor (TNF-α), chemokine’s and other inflammatory mediators. These signalling 
cascades boost antibacterial and inflammatory immune responses of macrophages 
including phagosome maturation. However, these pathways are exploited by 
pathogenic mycobacteria to promote mycobacterial survival within the macrophages. 
Mycobacterium tuberculosis in particular uses ManLAM to inhibit activation of MAPK 
in human monocytes (Means et al., 1999; Schaible et al., 1998; Schorey and Cooper, 
2003). 
  
Mycobacteria, and especially those of the MTC, has evolved many different strategies 
for evading the host immune systems to either cause infection, or to lie dormant 
within the cell until conditions are favourable for the bacteria to be reactivated. 
Reactivation of the bacteria relies upon the host defence systems to be lowered in 
cases such as malnutrition or in immunocompromised patients such as those with 
HIV/AIDS (Lawn, 2005; Murray et al., 2014). 
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1.4.8 HIV Co-Infection  
The high prevalence of tuberculosis co-infection with HIV/AIDS remains a common 
complication, with an estimated 10 million people being infected. Most instances of 
co-infection are seen in the developing nations, with sub-Saharan Africa exceeding 
1000 infected per 100,000 population. Worldwide, TB is the most common cause of 
death among patients with HIV/AIDS, killing 1 in every 3 individuals (Espinal et al., 
2001; Lawn, 2005; Murray et al., 2014) 
 
HIV enters macrophages and CD4+ T cells by the adsorbtion of glycoproteins on its 
surface to receptors on the target cell followed by fusion of the viral envelope with the 
cell membrane and the release of the HIV capsid into the host cell. Shortly after this 
the enzyme reverse transcriptase liberates the single stranded RNA genome from the 
attached viral proteins and copies it into complementary DNA molecules. This process 
leads to the depletion of M. tuberculosis specific CD4 lymphocytes and functional 
impairment of CD4 lymphocyte-macrophage interactions resulting in impaired 
granuloma formation. This ultimately leads to failure to restrict M. tuberculosis 
replication (Mims and Goering, 2013; Gandhi et al., 2010; Friedland et al., 2007; Lawn, 
2005). 
 
The interaction between TB and HIV is bidirectional. The activation of mononuclear 
cells during the host response to TB leads to accelerated HIV replication, which may 
increase HIV load at anatomical sites involved with TB and systemically (Friedland et 
al., 2007).  The bacteriological response to anti tuberculosis treatment is not 
significantly affected by HIV status. Standard therapy (Table 1.2), is used to treat the 
patients within the first months and cure rates are similar to those without HIV 
infection. However, mortality rates remain high for HIV infected individuals and can be 
associated with developing countries with little or no resources for MTB infection, 
poor compliance or lack of patient management (Rieder et al., 2009). In patients with 
advanced immunodeficiency (define by a CD4 count of less than 100/µl) anti 
tuberculosis treatment is complicated by the fact that finding Mycobacterium within 
clinical specimens may result from infection of M. avium-intracellulare or other NTM 
which require different treatment methods (Mims and Goering, 2013; Gandhi et al., 
2010; Friedland et al., 2007; Lawn, 2005). 
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Anti-HIV treatment, namely highly active antiretroviral therapy (HAART), leads to 
dramatic reductions in the incidence of opportunistic infections, including TB as 
pathogen-specific immune responses are restored. Concurrent administration of 
HAART and anti-tuberculosis drugs is complicated by the fact that rifamycins 
(rifampicin, rifapentine and rifabutin) tend to reduce serum concentrations of non-
nucleoside reverse transcriptase inhibitors and protease inhibitors, which may lead to 
increased replication of the virus (Rieder, 2009). 
1.4.9 Testing for tuberculosis  
The tuberculin or Mantoux skin test (TST) is the primary standard method for the 
determination of TB infection within individuals (Mims and Goering, 2013) (Goering, 
2008). Tuberculin was first discovered by Robert Koch from a glycerine extract of M. 
tuberculosis and was initially, but unsuccessfully, used as a remedy for MTB infection. 
It wasn’t until Clemens Von Pirquet discovered that patients who had been vaccinated 
against smallpox, but who were again injected, developed severe reactions, that the 
importance of the tuberculin skin test could be noticed. The glycerol extract of M. 
tuberculosis is still in use today and is known as purified protein derivative (PPD). This 
extract is derived from proteins on the surface of the mycobacterial cell, which are 
non-specific to mycobacteria. By using the same methods of injection, previous 
exposure to MTB can be determined (De Keyser et al., 2014; Mims and Goering, 2013; 
Rieder et al., 2009; Rooney, 2009)  
 
Infection with TB leads to the development of an allergy to the tuberculin protein. 
Therefore, during testing, 5 tuberculin units (TU) of PPD are injected into the inner 
surface of the forearm. If the patient has had infection with TB, the tuberculin protein 
produces a hypersensitivity reaction namely, inflammatory swelling, within 72 hours 
(Rieder et al., 2009). 
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The TST is classified based on the size of the induration (palpable, raised, hardened 
area of swelling) within 72 hours. And is based on 3 scales; 
 
1. An induration of 5 or more millimetres is considered positive in: 
 HIV infected individuals. 
 Patients who have had recent contact with TB infected individuals. 
 Patients with abnormal chest radiographs consistent with prior TB.  
 Patients with organ transplants. 
 Patients who are immunosuppressed. 
 
2. An induration of 10 or more millimetres is considered positive in: 
 Recent immigrants (< 5 years) from high prevalence countries. 
 Injecting drug users. 
 Mycobacterial laboratory workers. 
 Children <4 years of age. 
 
3. An induration of 15 millimetres or more is considered positive in: 
 Any persons – including those that have no known risk factors for TB. 
(Adapted from National centre for HIV/AIDS, Viral hep, STD and TB prevention) 
  
In some cases, the TST may produce no skin reaction at all even in patients who are 
known to be infected with M. tuberculosis, which can lead to false negative results 
(Goering 2008).  This however, does not exclude the active MTB infection, as the TST 
can be suppressed by a number of factors, such as malnutrition, viral infections, HIV 
infection, measles, chickenpox, glandular fever, cancer, corticosteroids and similar 
drugs (Madigan 2009). A false positive result may be caused by non-tuberculosis 
mycobacteria or previous administration of the BCG vaccine and in some cases, 
vaccination with the BCG vaccine can lead to false positive results for many years 
afterwards. This is due to the use of nonspecific proteins derived from M. tuberculosis 
being recognised by the immunised host’s immune system (De Keyser et al., 2014; 
Mims and Goering, 2013; Rieder et al., 2009). 
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In some patients with a latent TB infection, the immune response will gradually wane 
over time and may show a negative TST. However, the initial skin test, although 
negative, may stimulate the bodies’ reactions to tuberculin in further tests. To combat 
false positives, a two-step testing method is used for adults who will be re-tested 
periodically (e.g. health care workers) so that any future positive tests can be related 
to a new infection.  The two step testing relates to two separate TST; if the first TST is 
negative a second test is given 1-3 weeks later, and if the second is negative the 
patient is uninfected. If positive, the patient is considered previously infected (De 
Keyser et al., 2014; Morán-Mendoza et al., 2013) 
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1.5 Treatment of tuberculosis 
Treatment of TB relies on a combination of isoniazid, rifampicin, pyrazinamide, 
ethambutol and streptomycin. The combinations and duration of course are 
summarised in Table 2.1.  
TB patients 
TB treatment regimens 
Initial phase 
Continuation phase 
Daily 
New patients never previously 
treated 2 HRZE 4RH or 6HE 
Previously treated for longer than 1 
month 
2 HRZES/ 
1 HRZE 5HRE or 5HREZ 
Patients with drug resistant TB Patient specific regimens 
 
Table 1. 2 Standard treatments for TB 
KEY – H = isoniazid; R = Rifampicin; Z= pyrazinamide; E = ethambutol; S = streptomycin 
The number indicates the duration in months that drug combinations should be 
administered 
(Adapted from Rieder et al., 2009) 
 
Drugs are most frequently administered daily. The number before the drug 
combination shows for how many months a drug combination is given. For example, 
2HRZE indicates that isoniazid, rifampicin, pyrazinamide and ethambutol are given in a 
single dose daily for 2 months (Rieder et al., 2009). Drugs are most frequently 
administered daily. The number before the drug combination shows for how many 
months a drug combination is given. For example, 2HRZE indicates that isoniazid, 
rifampicin, pyrazinamide and ethambutol are given in a single dose daily for 2 months 
(Reider, et al., 2009). Isoniazid is a prodrug that is activated by a bactericidal catalase-
peroxidase enzyme in MTB termed KatG. KatG, promotes the coupling of isonicotinic 
acyl with NADH to form the NADH complex which binds to the enoyl-acyl carrier 
protein reductase. This blocks the action of fatty acid synthase. Fatty acid synthase is 
needed for the synthesis of mycolic acids within the mycobacterial cell wall leading to 
cell death (Carel et al., 2014; North et al., 2013). 
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Isoniazid is normally given by mouth and highly effective concentrations of the drug 
are achieved in all tissues including the cerebrospinal fluid. There is no cross resistance 
with other drugs. Dosage varies upon treatment program but generally for daily use 5 
mg kg-1 up to a maximum of 300 mg is given in a single dose. When used intermittently 
(three times per week) the standard treatment is 10 mg kg-1 (Dooley et al., 2013; 
Espinal et al., 2001). 
 
Rifampicin inhibits bacterial DNA-dependant RNA synthesis by inhibiting bacterial 
DNA-dependant RNA polymerase thus preventing extension of RNA products beyond a 
length of 2-3 nucleotides; it is bactericidal and acts on both intracellular and 
extracellular organisms. There is no cross resistance with other anti-TB drugs. Highly 
effective concentrations are obtained in all tissues and moderate levels are found 
within the cerebrospinal fluid. Dosage varies upon individual circumstances but in 
general, for daily or intermittent use, 10 mg kg-1 up to a maximum 600 mg is the 
accepted regimen. Rifampicin has several adverse effects, especially in older patients 
or those with HIV/AIDS, leading to recurrence of hepatitis infections (Cole, 2002; 
Espinal et al., 2001; Zhang et al., 1992). 
 
Pyrazinamide is also an effective general bactericidal prodrug. Pyrazinamide diffuses 
into M. tuberculosis where the enzyme pyrazinamidase converts pyrazinamide to the 
active form pyrazinoic acid. Pyrazinoic acid slowly leaks out of the cell and converts to 
protonated conjugate acid, which easily diffuses back into the bacilli and accumulate. 
The overall effect is fatty acid synthesis is reduced by pyrazinoic acids binding to the 
ribosomal protein S1 (RpsA) and inhibiting trans-translation. In daily use, dosage is 
restricted to mg kg-1, and for intermittent, 35 mg kg-1is used and is taken orally. There 
are many adverse effects with the use of pyrazinamide, such as liver damage and pain 
in the joints (Gie 2003; Storia 2008; WHO 2003).  
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Streptomycin is a protein synthesis inhibitor. It binds to the small 16S rRNA of the 30S 
subunit of the bacterial ribosome, interfering with the binding of formyl-methionyl-
tRNA to the 30S subunit. This leads to codon misreading leading to frame shift 
mutations, defective protein synthesis and ultimately cell death. Streptomycin is not 
absorbed from the intestine so is most often administered by intra-muscular injection, 
where it readily diffuses into most body tissues.  Dosage is commonly 15 mg kg-1 to a 
maximum of 1 g, as it is excreted almost entirely through the kidney; the dose has to 
be lowered in patients with poor renal function and in older age groups. There are 
several adverse reactions; streptomycin can cross the placenta and cause deafness in 
unborn children and, as such, use of streptomycin during pregnancy is not 
recommended (Gie 2003; Storia 2008; WHO 2003). 
 
Ethambutol is a bacteriostatic drug, and is mainly used to prevent the emergence of 
drug resistance to the other drugs mentioned and its mode of action relies upon the 
disruption of arabinogalactan. Arabinogalactan attaches to the mycolic acids of the 
mycobacterium cell wall to form mycolyl-arabingalactan peptidoglycan in the cell wall. 
Ethambutol inhibits the enzyme arabinosyl transferase, which is essential for 
arabinogalactan synthesis and leads to increased permeability of the cell wall. It is 
given orally at a dosage of 20 mg kg-1 for daily use and for intermittent 30 mg kg-1 three 
times per week. Ethambutol has serious adverse reactions and as such, large doses are 
no longer given. The main side effect is progressive loss of vision caused by retrobulbar 
neuritis. It has been reported that some patients notice decreased vision within the 
first few days of treatment. If unnoticed and the treatment continues, the likelihood of 
the patient going blind is extremely high. Eye damage is exaggerated in patients with 
renal failure and as such, treatment is not recommended for these patients (Rieder et 
al., 2009) 
 
As mentioned, ethambutol is used mainly to prevent the emergence of drug resistant 
MTB and forms the basis of combination therapy against MTB. If anti-TB drugs were 
given alone, resistant bacteria would replace the sensitive organisms. However, in 
combination therapy, resistant species can be killed earlier in treatment with the other 
drugs, preventing an abundance of resistant species in the host (Gie 2003; Storia 2008; 
WHO 2003).  
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1.6 The burden of drug resistance 
Ever since the discovery of antibiotics and their use against bacteria, resistance has 
been a problem. In most cases, the time between antibiotic deployment and the 
antibiotic resistance is less than 10 years. In the following Figure (2.8) a timeline of the 
deployment of several antibiotics is shown against a timeline of observed bacterial 
resistance.  
 
 
Figure 1. 9 Timeline of antibiotic deployment and subsequent antibacterial resistance. 
Adapted from (Meziane-Cherif and Courvalin, 2014) 
 
The first antibiotic that was discovered to be inhibitory towards the growth of M. 
tuberculosis was streptomycin. Streptomycin was first introduced during 1943 and 
consequently the first resistant strain was observed by Pyle in 1947. In 1948 the British 
Medical Research Council (MRC) published a report which stated that streptomycin 
therapy for pulmonary TB had similar mortality rates for treated and untreated 
patients.  Among patients who had been treated with streptomycin the majority who 
had died had experienced relapse that was the result of an antibiotic resistant strain      
(Gandhi et al., 2010). 
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Resistance mechanisms are either intrinsic or acquired. In the case of MDR TB, 
acquired resistance is seen in genetic mutations, encoding either the drug target or the 
enzymes involved in drug activation. The basis of resistance in some anti-TB agents is 
still not fully understood, as in the case of streptomycin. Streptomycin resistance 
emerges through a change in the bacterial binding site for streptomycin in the 
ribosome; this process has only been seen in half the strains studied to date (Espinal et 
al., 2001; Zhang et al., 1992). 
Mutations in the pncA gene (encoding pyrazinamidase), are thought to be a major 
mechanism of PZA resistance in MTB, but resistant strains containing the wild type 
gene have been described. Moreover, the primary targets of activated isoniazid are 
enzymes involved in the biosynthesis of cell wall mycolic acids. Mutations associated 
with changes in these targets have been shown to contribute to isoniazid resistance 
(Stewart et al., 2003; Zhang et al., 1992). 
 
Resistance to anti-TB drugs continued to be recognised as a clinical problem through 
the latter part of the 21st century. As a result, MDR and XDR TB are now becoming a 
major threat to health worldwide, accounting for almost 3 % of all newly reported 
cases of TB (Sayer, 2009). There have been several reports speculating the emergence 
of totally drug resistant TB (TDR-TB) in India, Iran and Italy (Miglori, 2007; Rowland, 
2012; Udwadia et al., 2012; Velayati et al., 2009). 
 
Multidrug resistant TB is classed as MTB that is resistant to at least isoniazid and 
rifampicin. In comparison, extensively drug resistant TB (XDR-TB) is MDR-TB that is also 
resistant to one or more of; quinolones, kanamycin, capreomycin and/or amikacin. The 
principles for treatment are the same for both types; however, XDR-TB is associated 
with a much higher mortality rate because of the reduced number of effective 
treatment options. Epidemiology of XDR TB is not very well understood, but it is 
generally believed that it transmits easily between populations which are more 
susceptible to MTB infection (Miglori, 2007; Rowland, 2012; Udwadia et al., 2012; 
Velayati et al., 2009). 
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It has been hypothesised that without the development of new antimicrobials there 
will be an exponential increase in the numbers of bacterial related deaths due to 
resistant strains of antibiotics. Currently, strains of MRSA and C. difficile continue to be 
a major cause of healthcare associated infection (HAI) which is proving difficult to 
treat. (Gould, 2009) 
 
To encourage the development of the new antimicrobials, the UK government has 
recently published a review of current drug resistance and the predicted effects on 
mortality rates worldwide by 2050 if no new classes of antibiotics are developed 
(Figure 2.9). 
 
Figure 1. 10  Predicted mortality rates due to antibiotic resistant bacterial infection by 2050 
(O’Neil, 2014) 
It is apparent from Figure 1.10 that without the development of antibacterials, or 
indeed finding ways to potentiate the activity of redundant antibiotics, then mortality 
rates of over 10 million per annum could be expected by 2050 (O’Neil, 2014).  
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1.7 Using natural products to potentiate the activity of antibiotics  
When antibiotics first became available over a century ago their popularity led to their 
overuse and misuse; as such, over the last 20 years it has become clear that their 
effectiveness is reducing as pathogens evolve resistance against them. Bacteria can 
acquire multiple drug resistance, which requires the need of antibiotics with multiple 
modes of action. Due to increased drug resistant strains of bacteria such as M. 
tuberculosis and methicillin resistant Staphylococcus aureus there has been renewed 
interest in natural products as potential sources of novel antibiotics (Cragg and 
Newman, 2013; Coates and Hu, 2007; Pauli et al., 2005) 
Natural products are a novel source of resistance modifying agents (RMAs); these are 
sets of compounds which have multiple modes of action combating the bacterium’s 
intrinsic and acquired resistance mechanisms. The discovery and development of 
RMA’s could pave the way to reduce the spread of resistant bacteria and to ‘recycle’ 
well established antimicrobials, which are often cheaper and less toxic than newly 
derived antimicrobials (Abreu et al., 2012; Lewis and Elvin-Lewis, 1995). 
 
Antimicrobial synergy implies the beneficial interaction between two antimicrobial 
drugs. Exceeding additive effects can take several forms. One compound may 
potentiate the activity of the other at a biochemical level; one may assist the other in 
order to penetrate the bacterial cell; one may protect the other from destruction; or 
the two compounds may act on separate sections of the bacterial population (Acar, 
2000) 
 
The use of natural products with commonly used antimicrobials is a well-established 
principle and is the reason for combination therapy in TB (Rieder et al., 2009). By using 
two or more agents that have different targets in the bacterial cell, resistance can be 
reduced. Synergy between these compounds could result in greater efficacy using two 
agents than individually and may lead to lower host exposure to potentially toxic 
compounds (Acar, 2000; Hemaiswarya et al., 2008). 
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Plants are known to produce a number of low molecular weight (MW <500) 
compounds which have been shown to be antibacterial, albeit in some cases 
considerably weaker than antibiotics produced by bacteria and fungi (Abreu et al., 
2012) 
A study undertaken by Stermitz and colleagues reviewed the interaction between 
berberine and 5o methoxyhydnocarpin, both of which are produced by berberry plants. 
Berberine, a hydrophobic alkaloid that intercalates into DNA, is ineffective as an 
antibacterial because it is readily extruded by pathogen encoded multidrug resistance 
pumps (MDPs). Hence, the plant produces 5o -methoxyhydnocarpin that blocks the 
MDP pump. This combination is a potent antibacterial agent (Lewis and Ausubel, 2006; 
Stermitz et al., 2000). 
Another way of overcoming resistance mechanisms such as β-lactamase enzymes; 
modification of target sites and efflux pump inhibition is to use a combination of 
antibiotics with multiple mechanisms of action. Inhibitors of beta lactamases have 
been long known and therefore are administered with antibiotics as co-drugs 
(Chambers et al., 1995). This has been especially seen in overcoming the resistance of 
penicillinase, by administering clavulinc acid with the drugs sulbactam and tazobactam 
(Lee et al., 2003)  
However, tuberculosis and other mycobacterial infections continue to rise and are 
currently considered a primary health threat. Coupled with the long treatment regime 
is the lack of new antibiotics with different modes of action (O’Neil, 2014; Stewart et 
al., 2003) 
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Current antimycobacterial treatment is the same as that over 40 years ago, requiring a 
minimum of 6 months of multidrug chemotherapy. Novel targets are being identified 
alongside developing better drugs for known targets. Synergistic interaction between 
plant derived natural products and anti-tuberculosis drugs is gaining attention from 
the scientific community, but reports of synergistic combinations are still limited. 
Totarol, ferulenol and plumbagin were observed to increase the potency of 
isonicotonic acid hydrazide by fourfold against Mycobacterium sp. A napthoquinone 7-
methyljuglone, isolated from the roots of Euclea natallensis, in combination with 
isoniazid or rifampicin, resulted in a four to six fold reduction in the MIC of the 
synthetic drugs (Mossa et al., 2004). 
Several methods of detecting synergy are known but it has been reported that the 
accurate prediction of a synergistic, additive, indifferent or antagonistic combination 
between a drug and a natural product is crucial. The recognised gold standard is the 
checkerboard method where combinations of two antimicrobials in concentrations 
equal to, above and below their minimal inhibitory concentrations for the test 
organisms are assayed (Acar, 2000). 
The drug combination in which growth is inhibited is taken as the effective MIC of the 
combination. Taking the effective MICs of each test compound in combination allows 
for the fractional inhibitory concentration (FIC) to be calculated. The FIC values can 
then accurately predict synergism, additive, indifferent or antagonism (Hall et al., 
1983a). 
Therefore, whilst screening plants for antibacterial activity is promising, there is a need 
for identifying potential resistance modifying agents, which alone may show little 
antibacterial activity but in combination with antibiotics can increase the susceptibility 
of resistant organisms. Little research has been undertaken in identifying plant and 
antibiotic combinations active against species of mycobacterium. This could be due to 
limited understanding of the mechanism of action of drugs and plant products or the 
lack of plant extracts inhibitory towards the growth of these organisms.   
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1.8 Aim and objectives of this study 
1.8.1 Thesis Aim  
The aim of this these was to determine if hop extracts have inhibitory activity towards 
clinically relevant bacteria such as Mycobacteria, identify active compounds and 
determine if these compounds can potentiate the activity of antibiotics against drug 
resistant organisms.  
 
1.8.2 Thesis objectives 
The objectives of this thesis were to: 
 Develop and optimise a hop extraction process. 
 
 Develop assays to determine the antibacterial activity of hop extracts 
against a range of clinically relevant bacteria. 
 
 Identify differences in antibacterial activity between hop variants.  
 
 Identify compounds responsible for antibacterial activity. 
 
 Determine the inhibitory effect of hop extracts against multidrug resistant 
Mycobacteria. 
 
 Develop and optimise assays to determine synergy, co-action, indifference 
and antagonism between antibiotics and hop extracts 
 
 Examine the ability of hop extracts to potentiate the activity of antibiotics 
against multidrug resistant Mycobacterium 
 
 Investigate the antibacterial mode of action of hop extracts and antibiotics 
using scanning electron microscopy.  
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2.0 General Materials and Methods 
2.1 General Materials 
2.1.1 Sources of chemicals and reagents 
All chemicals and reagents were purchased from Sigma Aldrich Ltd, UK, unless 
otherwise stated in the text. 
All solvents were from purchased from Thermo Fischer Scientific Ltd, UK unless 
otherwise stated in the text.  
2.1.2 Biological culture media 
Middlebrook 7H10 agar and Middlebrook 7H9 broth (for the growth of 
mycobacterium) and Luria broth (LB) and Luria agar (LA) for the growth of all other 
organisms were purchased from Thermo Fischer Scientific Ltd, UK. These agars and 
broths were made according to the manufacturer’s instructions and sterilised at 121 °C 
for 15 minutes at 15 pounds per square inch (psi) pressure (Prestige, 9 L classic bench 
top autoclave, LabShop, UK) 
2.1.3 Diluents 
Deionised water (diH2O) was obtained from an ELGA purelab option BP15 dispenser 
(ELGA labwater, UK). The inorganic content of the water at 25°C was between 1-15 
MΩ-cm with a total organic carbon content of <30 ppb.  It was sterilised at 121 °C for 
15 minutes at 15 psi (Prestige, 9 L classic bench top autoclave, LabShop, UK) to form 
sterile distilled water (SDW).   
Phosphate buffered saline (PBS) was prepared by dissolving 2 tablets in 500 mL of 
diH2O once mixed, the solution contained 0.01 M phosphate buffer at pH 7.4 
(composed of 0.0027 M potassium chloride and 0.137 M sodium chloride). Solutions 
were sterilised by autoclaving at 121 °C for 15 minutes at 15 psi (Prestige, 9 L classic 
bench top autoclave, LabShop, UK). 
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2.2 General Methods 
2.2.1 Revival of bacterial cultures from Microbank™ Cryo-protective 
beads 
To generate a working culture, vials containing Cryo-protection beads (Pro-Lab 
Diagnostics Ltd, UK) of the appropriate bacterium were removed from storage at -80 
°C and defrosted on ice for 15 minutes. Once partially defrosted a single bead was 
removed using a sterile 10 µL inoculation loop (Fisher Scientific, UK) and inoculated 
into the appropriate broth for the appropriate time (Section 2.2.2). 
2.2.2 Production of a bacterial suspension  
Bacterial cultures were grown at 37 °C in broth within a shaking incubator (Thermo 
Fischer, UK) at 150 revolutions per minute (RPM) for 72 hours (M. bovis var. BCG; M. 
abscessus (all strains) and M. smegmatis); 18 hours (Escherichia coli NCTC 1093T; 
Bacillus subtilis NCTC 10073; Staphylococcus aureus NCTC 13277 and methicillin 
resistant Staphylococcus aureus NCTC 10442.  
2.2.3 Determination of the concentration of bacterial suspensions 
Centrifuge tubes containing 20 mL of LA or Middlebrook broth were inoculated from a 
bacterial slope culture using a 10 µL inoculation loop. The inoculated broths were then 
incubated ta 37 °C for the desired amount of time (2.2.2) in a shaking incubator at 150 
RPM. After incubation the broths were centrifuged at 2600 x g for 15 min (Avanti J-20 
XP, Beckman Coulter Inc. UK). The supernatant was removed and the pellet re-
suspended in sterile PBS to produce a stock solution with an optical density (OD) of 0.8 
as determined by a spectrophotometer (Ultrospec 3100 Pro, Amersham Biosciences 
Ltd., USA) set a wavelength of 600 nm (OD600). The neat bacterial culture stock was 
diluted with PBS to produce a range of OD600 between 0.1 – 0.8.  
Simultaneously, a viable count of the colony forming units (CFU)/mL for each dilution 
was performed using the drop counting method by Miles et al., (1938). The method by 
Miles et al., (1938) was performed as follows. A 10 μL aliquot of each culture dilution 
was pipetted onto a sector of a circular TSA plate in triplicate and incubated for 24 h. 
Following incubation, colonies were counted on each sector that contained between 3 
- 30 countable cfu’s per spot and the average of the three spots was calculated. 
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The log cfu/mL-1 was then calculated by the following equation: 
  
 
 
 
 
 
 
The results were then recorded into an Excel® spread sheet and an OD600 versus 
CFU/mL graph was constructed for each bacterium. This produced a linear equation to 
predict the cfu/ml in a sample based on the optical density of the solution at 600 nm. 
This was repeated for each bacterium six times.  
 
2.2.4 Preparation of a working culture 
Bacteria were cultured as described in Section 2.2.3 and diluted in PBS to an OD₆₀₀ 
indicative of a concentration of 1 x 109 cfu/mL-1. This working culture was then further 
diluted in PBS using serial dilution to achieve the cfu/mL-1 required for subsequent 
assays.  
2.2.5 Production of a bacterial slope culture 
Bacterial slopes are routinely used as a long-term working culture (Reed, 2007). Firstly, 
60 ml of the appropriate agar solution was prepared as per manufacturer’s instructions 
and cooled to 60° C in a water bath (Thermo Fischer, UK). After cooling, 20 ml of 
molten agar was aseptically dispensed into each, of three, 50 mL centrifuge tubes 
(Fischer scientific, UK). Each tube was then positioned at a 45° gradient so that the 
agar had the greatest surface area and then allowed to set.  
The agar slope was then inoculated with a 10 µL loop of the desired bacterial 
suspension (Section 2.2.2) and incubated statically at 37° C until colonies were visible. 
The bacterial suspension had been checked for purity, using the streak plate method 
(Section 2.2.6). Isolated colonies were then Gram stained (Section 2.2.8.1) or acid fast 
stained (Section 2.2.8.2) dependant on test bacteria. Cultures were then stored for 
periods no longer than 21 days at 2° - 5° C.  
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2.2.6 Streak plate method for determination of culture purity 
To ensure bacterial purity and isolate individual colonies, the streak plate method was 
used. The method comprises of removing 10 µL of a bacterial suspension (Section 
2.2.2) and transferring this to an appropriate agar plate. A series of streaks then 
spreads the concentrated suspension across an agar plate in order to obtain individual 
colony forming units (CFU’s) on the last streak. After the procedure was completed the 
agar plate was incubated at 37 °C for the appropriate amount of time and colonies 
were inspected for uniformity.  
2.2.7 Staining methods to determine purity and identity of micro-
organisms 
The Gram stain, developed by Hans Christian Joachim Gram in 1884 is the primary 
identification tool used in microbiology (Reed, 2007). The Gram stain and the Ziehl-
Neelson (acid fast stain) are used to differentiate between Gram positive, Gram 
negative and Mycobacterium species. The Gram stain bases bacteria into two groups; 
bacteria that retain the initial crystal violet stain (purple) are said to be Gram positive, 
whereas those that are decolourised and stain red with safranin/carbol fuschin are 
said to be Gram negative (Beveridge, 2001). As previously described Mycobacteria 
possess mycolic acids in the outer cell membrane and are therefore not stained by the 
Gram stain (Reed, 2007). In this case the Ziehl Neelson stain is used (Section 2.2.8.2). 
(Beveridge, 2001) 
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2.2.8 Preparation of bacterial cultures for both Gram stain and Ziehl-
Neelson stain 
 
Colonies were isolated from a bacterial suspension and grown on solid media using the 
streak plate method. A single colony of the chosen organism was then mixed with 50 
µL of sterile distilled water (SDW) on the centre of a sterile glass slide (Fisher-Scientific, 
UK). This turbid suspension was then spread across the slide using a fresh 10 µL 
inoculation loop, the slide was then allowed to air dry within a laminar flow cabinet for 
5 minutes, then it was passed through a Bunsen burner 3 times to heat fix the colony 
to the slide.  
2.2.8.1 The Gram Stain 
1. The single bacterial colony is heat fixed  
2. The slide is flooded with 2 % crystal violet (in 20 % ethanol / SDW solution) for 
no longer than 60 seconds. 
3. The crystal violet was then poured off and the slide flooded with Grams iodine, 
for no longer than 60 seconds. 
4. Slides were then rinsed with SDW to remove excess iodine. 
5. Acetone was then added drop wise, and was left for a maximum of 3 seconds. 
6. The slide was then rinsed with SDW 
7. 2.5 % safranin (95 % ethanol/SDW) was then added as a counter-stain which 
was then left for 10-15 seconds and was then rinsed with SDW to remove 
excess safranin. 
8. The smear was then left to air dry within a laminar flow cabinet, before being 
examined under oil immersion x 100 magnification.  
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2.2.8.2 Ziehl-Neelson Stain for Mycobacterium 
1. The single bacterial colony is heat fixed  
2. The inoculated glass slide is then flooded with carbol fuchsin and held over a 
breaker of steaming SDW at 60°C . 
3. The slide was then steamed for 5 minutes whilst carbol fuschin was added to 
ensure that the slide remained flooded.  
4. The slide was then rinsed with dH2O to remove excess carbol fuchsin. 
5. The slide was then decolourised with 95% ethanol containing 5% hydrochloric 
acid. 
6. Slide was then immediately rinsed with dH20. 
7. The slide was then counter-stained with methylene blue, and left for 20-30 
seconds. 
8. The slide was then rinsed with dH2O to wash away excess methylene blue. 
9. The slide was then allowed to air dry within a laminar flow cabinet.  
10. After the staining procedure, the slides were examined directly under oil 
immersion at x 100 magnification (Reed, 2007). 
 
 
Figure 2. 1 Demonstration of a Ziehl-Neelson (acid fast) stain of 
 Mycobacterium smegmatis 8159 
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2.3 Statistical Analysis 
All results presented in this study are a mean of at least three separate repeats unless 
otherwise stated. All statistics were performed using IBM SPSS Statistics version 20. 
2.3.1 Independent samples t-test 
To determine the statistical difference in the means between two groups, the 
parametric independent students t-test was used if the following assumptions were 
met (Cohen, 1988). 
1. The observations of the data were independent from each other. 
2. The results follow normal distribution and pass normality tests. 
3. The data sets to be compared show homogeneity of variance. 
To assess normality, a histogram plot of the data was inspected to determine if a 
normal bell shaped curve was observed with minimal skewedness. The Q-Q plots and 
de-trended Q-Q plots were alos reviewed in conjunction with the results of the 
Kolomogorov-Smirnov and Shapiro-Wilk tests for normality.  
Levines test of the equality of variances was conducted to determine if the data sets 
showed homogeneity of variance.  
If any of the assumptions were violated, an appropriate transformation of the data was 
attempted (Log₁₀, square root, etc)  to normalise the data or the equivalent non-
parametric test will be used (e.g. Mann-Whitney U). 
To determine the effect of size between the two groups, or the magnitude of 
difference, the eta-squared value (N2) was determined by the following equation: 
 
Where t= t value from t-test, n1 = sample size of group 1 and n2 – sample size of group 
2. To interpret the N2 value the guidelines set out by Cohen (1988) shown in Table 2.1 
were implemented.  
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Effect Size N2 
Small 0.10-0.29 
Moderate 0.30 – 0.49 
Large >0.5 
 
Table 2. 1 Interpretation of effect size of N2 between two statistically different groups 
(Cohen 1988). 
2.3.2 One Way Analysis of Variance (ANOVA) 
The parametric one-way ANOVA test was used to determine if there was a significant 
difference in the means between two or more groups of data if the assumptions 
described in Section 2.3.1 were met.  
If a significant difference between groups was found, Tukeys honestly significant 
difference (HSD) test was used to determine which groups were significantly different 
from each other.  
2.3.3 Pearson’s Correlation 
Correlation analysis was used to determine the strength and direction of a linear 
relationship between two variables. Pearson’s correlation of parametric correlation 
was used if the following assumptions were met (Cohen 1988): 
1. The relationship between two or more data sets is linear. 
2. Observations in the data sets were independent. 
3. Each data set in the analysis followed normal distribution. 
4. The data sets showed homoscedasticity. 
The strength of the relationship between variable was determined by the guidance set 
of by Cohen (1988). The coefficient of determination (R2) was calculated by squaring 
the Pearson product-moment correlation coefficient (r) obtained between two 
variables.   
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3.0 Determination of the antibacterial effects of hops against 
clinically relevant bacteria 
3.1 Introduction 
Hops (Humulus lupulus) have been recognised for centuries as an important means of 
flavouring beer (Cornelison, 2008). Recent research has focussed on using hop extracts 
to improve the aroma, the stability of beer foam and as a preservative in a diverse 
range of food products such as meat products (Hieronymus, 2012). Indeed, the reason 
for using hops in beer is due to the fact that they contain antibacterial compounds 
such as humulone (alpha acid) and lupulone (beta acid). Both acids are released into 
the beer during the brewing process and increase both the shelf life of the product and 
the taste of the beer. The bitterness of the beer is proportional to the concentration of 
alpha acids, it is for this reason that a range of hop variants have been developed to 
allow brewers to tailor the flavour of a particular beer. 
Given that alpha and beta acid content of hops has been linked to antibacterial activity 
(Acworth et al., 2012; Shen and Sofos, 2008) it is expected that the hop variants with 
the highest alpha and beta acid content would demonstrate the greatest antibacterial 
activity. In addition to being used in brewing, hops have a long history in herbal 
medicine and have been used to treat a variety of conditions such as stomach cramps, 
indigestion, insomnia and bacterial infections (Batchvarov and Marinova, 2001; 
Sumner, 2000). In this chapter, the medicinal properties of this plant, specifically its 
antibacterial activity against a range of medically important bacteria is investigated.  
Of particular interest in the context of this study is the bacterium Mycobacterium 
tuberculosis. As previously described it is an acid fast organism with a thick waxy outer 
cell wall comprised of several mycolic acids, these contribute to the survival of the 
pathogen within human macrophages.     
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Due to the virulence and long incubation times of M. tuberculosis, a simulant 
organism, Mycobacterium smegmatis was employed to model the sensitivity of the 
pathogen to antibacterial compounds. M. smegmatis is well described as a model 
organism used within many screening assays. Unlike M. tuberculosis, M smegmatis is 
fast growing, requiring 72 hours incubation at 37 °C to reach 1 x 108 cfu/ml compared 
to M. tuberculosis which requires up to 6 weeks to achieve a similar level of growth 
(Chaturvedi et al., 2007b).  
Mycobacterium smegmatis is non-pathogenic for healthy humans and as a 
consequence can be handled and manipulated in a Category II laboratory (Chaturvedi 
et al., 2007b; Tyagi and Sharma, 2002). Finally studies have shown that both bacteria 
demonstrate a similar level of sensitivity to antibacterial compounds and thus M. 
smegmatis has been used by a number of groups as a tool with which to identify 
compounds with the potential to be active against M. tuberculosis (Chaturvedi et al., 
2007b).  
A related organism, M. bovis is responsible for the animal form of the disease; bovine 
tuberculosis (bTB). As previously described, bovine infection with this pathogen is 
estimated to cost the UK economy over £100 million per year.  M. bovis like M. 
tuberculosis is also classed as a Category III pathogen and replicates at a similar rate 
making it an impractical bacterium to use in high through put screening assays.  In 
contrast,  the  vaccine strain of M. bovis, Mycobacterium bovis Bacillus Calmette- 
Guérin (BCG)  rarely causes disease in healthy individuals (Category II  organism)  and  
replicates in the laboratory  at a similar rate to M. smegmatis (Fitzgerald et al., 2010)   
In vitro studies have shown that  BCG has a similar level of antibacterial sensitivity to 
anti-tuberculosis compounds making it a suiTable model organism with which to 
screen for antibacterial activity (Fitzgerald et al., 2010; Taneja and Tyagi, 2007). 
Aside from Mycobacteria the sensitivity of other pathogenic bacteria to hop 
compounds was also determined:   
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Staphylococcus aureus is a Gram positive cocci and considered a  commensal organism 
that is also an opportunistic pathogen within humans (Enright, 2003). One of the ways 
M. smegmatis differs from S. aureus is in the nature of its cell wall; mycobacteria have 
a thick waxy outer layer comprised of mycolic acids, which has been shown to increase 
their virulence (Murray et al., 2014), whereas Gram positive organisms have an outer 
layer of peptidoglycan. This difference in the cell wall has been shown to have an 
effect on the sensitivity of the organism to antibacterial compounds found in beer 
(Caballero et al., 2009). 
Unfortunately the wide spread use of antibiotics has resulted in the emergence of 
variants of this pathogen which are resistant to a wide range of antibiotics.  One such  
variant,  Methicillin resistant Staphylococcus aureus (MRSA),  has developed resistance  
to  beta-lactam antibiotics such as penicillin and has become a major cause of 
healthcare acquired infection (Archer, 1998; Enright, 2003).  
It is routinely used in clinical laboratories to determine the efficacy of antibiotics and 
was included in this study as a reference strain with which to assess the antibiotic 
activity of hop derived compounds. A second representative of Gram positive bacteria, 
Bacillus subtilis was also included in this study.  In contrast to Staphylococci these 
bacteria form rods rather than cocci and rarely cause disease in healthy individuals 
(Reed, 2010). The bacteria has previously been used to screen plant extracts for the 
presence of antibacterial compounds (Rojas et al., 1992). 
The final organism examined in this chapter, Escherichia coli, is considered a model 
bacterium for Gram negative bacteria which differ from Gram positive and acid fast 
organisms in that the cell wall contains an additional layer called the outer membrane 
(Jackson, 2014). This outer membrane contributes to antibiotic resistance by  hindering 
the  uptake and passage of compounds to the interior of the cell (Duffy et al., 2008). 
  
55 
 
This group of bacteria is made up of a large number of different serotypes the majority 
of which are harmless to healthy individuals, however some serotypes such as E. coli 
0157, can lead to morbidity (Duffy et al., 2008). As with B. subtilis;  E. coli is 
inexpensive to grow on routine media,  grows relatively quickly compared to 
Mycobacteria and  non-pathogenic variants are routinely used to determine  antibiotic 
sensitivity (Duffy et al., 2008). The antibacterial compounds found in hops have been 
reported to show little, if any, antibacterial activity against Gram negative organisms 
(Beutler, 2009; Colegate and Molyneux, 2007; Dias et al., 2012). 
This chapter describes the optimisation of an aqueous extraction and agar based assay 
that was used to determine the antibacterial activity of 50 hop variants against a range 
of bacterial species including Mycobacterium. The correlation of observed antibacterial 
activity and (supplier) stated alpha and beta acid content of each hop variety was 
investigated, assessing the hypothesis of (Caballero et al., 2009; Simpson and Smith, 
1992) that the alpha and beta acid concentration make a major contribution to the 
antibacterial activity of beer.  
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3.2 Materials 
3.2.1 Bacterial cultures  
3.2.2 Mycobacterium smegmatis NCTC 8159 T 
Mycobacterium smegmatis was purchased from the Health Protection Agency (HPA) 
culture collections service (Public Health England, Porton Down, UK). The strain was 
first identified by Trevisan, 1889 and isolated from smegma found in soil and water 
(Dostal et al., 2003). The bacterium has successfully been used as a safer, faster 
growing simulant of M. tuberculosis (Chaturvedi et al., 2007a; Tyagi and Sharma, 
2002). Cultures were stored in 10 % glycerol on Microbank™ Cryo-protective beads 
(Pro-Lab Diagnostics Ltd, UK) at -80 °C until required.  
3.2.3 Mycobacterium bovis Var. BCG NCTC 5692 
A culture of Mycobacterium bovis BCG (Bacillus Calmette-Guerin) was purchased from 
the HPA culture collections service (Public Health England, Porton Down, UK).  The 
original M. bovis BCG strain was developed by Calmette and Guerin between 1908 and 
1919 by carrying out 231 passages of virulent M. bovis leading to spontaneous 
attenuation resulting in a strain of M. bovis that was no longer virulent in humans or 
animals. M. bovis BCG has been used as a surrogate organism for M. bovis and M. 
tuberculosis (Khan and Sarkar, 2008; Ritz et al., 2009). M. bovis BCG strains are all 
known to be resistant to pyrazinamide (Ritz 2009). 
The culture was stored in 10 % glycerol on Microbank™ Cryo-protective beads (Pro-Lab 
Diagnostics Ltd, UK) at -80 °C until required. 
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3.2.4 Escherichia coli NCTC 1093 
A culture of Escherichia coli NCTC 1093 was purchased from the HPA culture 
collections service (Public Health England, Porton Down, UK).  Escherichia coli 1093 is a 
facultative anaerobic Gram negative bacterium which was originally isolated from 
human faeces by Dudgeon, 1921 at St. Thomas’s hospital UK. The bacterium grows on 
nutrient broth (NB) and agar (NA) and forms smooth, cream colonies of 3 µm in length.  
The bacterium has routinely been used in antibacterial assays (Khalil et al., 2013; 
Shami et al., 2013) and has no known resistance to antibiotics routinely used to treat  
Gram negative organisms. E.coli is used within this study as a comparison from acid 
fast (Mycobacteria) strains and Gram positive strains.  
3.3.5 Bacillus subtilis NCTC 10315 
A culture of Bacillus subtilis NCTC 10315 was purchased from the HPA culture 
collections service (Public Health England, Porton Down, UK). Bacillus subtilis NCTC 
10315 is an aerobic Gram positive bacterium. The bacterium can be grown on NA and 
NB at 37 °C to form rough, cream, circular colonies of 2 µm in length. The strain used 
has been studied extensively and is a standard bacterial strain used to represent the 
Bacillus genre; indeed it has routinely been used to screen potential antibacterial plant 
extracts (Rojas et al., 1992) 
3.3.6 Staphylococcus aureus (MSSA) NCTC 13277 
Staphylococcus aureus NCTC 13277 is a gram positive facultative anaerobic organism 
that was originally isolated from a human nose (Davies, 1988). The bacterium is grown 
using NA and NB at 37 °C and forms smooth, cream, circular colonies of 1 µm in length. 
This organism is a well-established standard strain used as a comparison for other 
Gram positive organisms or comparing bactericidal susceptibility against the drug 
resistant strain, methicillin resistant S. aureus (MRSA). 
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3.3.7 Methicillin resistant Staphylococcus aureus (MRSA) NCTC 10442 
A culture of methicillin resistant Staphylococcus aureus NCTC 10442 was purchased 
from the HPA culture collections service (Public Health England, Porton Down, UK). The 
strain was originally isolated from a human finger at St. Lukes hospital Guilford, UK. It 
is a facultative anaerobe which grows on NA and NB at 37 °C. It is well known 
healthcare associated infection (Enright, 2003), resistance to methicillin or indeed 
other penicillin class antibiotics is considered genetic and has been understood for 
over 50 years (Enright, 2003) and requires the resistance gene mecA that encodes a 
penicillin binding protein PBP2a (Enright, 2003).  
MRSA was stored in 10 % glycerol on Microbank™ Cryo-protective beads (Pro-Lab 
Diagnostics Ltd, UK) at -80° C until required.  
  
59 
 
3.4 Hop varieties   
The hop varieties used in this study are shown in Table 3.1. They were purchased from 
(themaltmiller.com) and were provided in vacuum sealed, non-transparent packages. 
Table 3. 1The hop varieties used in this study including country of origin, year of harvest and 
stated alpha and beta acid content (% w/w) 
 
Hop Name/Type 
Average estimated 
alpha acid content (% 
w/w) 
Average estimated  
beta acid content (% w/w) 
Year of 
Harvest 
Country of 
Origin 
Syrian Goldings 2.75 6.40 2010 Slovenia 
Hallertauer  3.20 6.60 2010 Germany 
Bobek 3.90 N/A 2010 New Zealand 
Sonnet 4.10 6.60 2010 USA 
Liberty 4.50 5.00 2009 USA 
Tettnang 4.50 6.40 2009 Germany 
Willamette 4.50 3.00 2011 USA 
Fuggles 4.90 N/A 2010 UK 
Fuggles Pellets 4.90 N/A 2010 UK 
Cascade 5.50 6.70 2010 USA 
Cascade Pellets 5.50 6.70 2010 USA 
Progress 5.50 N/A 2009 UK 
Goldings 5.80 3.80 2010 UK 
Boadicea 6.00 3.80 2009 USA 
Brambling Cross 6.00 N/A 2011 UK 
Summer Pellets 6.00 N/A 2011 Australia 
NZ Pacifica 6.10 8.80 2011 New Zealand 
Delta 6.50 N/A 2010 USA 
Glacier 6.70 3.50 2007 USA 
Motueka Pellets 6.70 N/A 2011 New Zealand 
Amarillo 6.90 3.40 2010 USA 
Amarillo Pellets 6.90 2.50 2009 USA 
Challenger 7.60 3.70 2011 UK 
Aurora 7.80 2.30 2010 USA 
First Gold 7.90 3.50 2011 UK 
Northdown 8.00 N/A 2010 UK 
Northern Brewer 8.00 N/A 2010 Germany 
Centennial Pellets 8.60 N/A 2011 UK 
Centennial 8.60 4.40 2010 USA 
Perle 9.60 5.40 2010 Germany 
New Zealand Rakau 10.80 N/A 2011 New Zealand 
Chinook Pellets 11.00 N/A 2010 USA 
Simcoe 12.20 N/A 2010 USA 
Target 12.50 N/A 2009 UK 
Chinnok 12.70 N/A 2011 USA 
Nelson Sauvin 12.80 N/A 2012 New Zealand 
Galena 13.00 N/A 2010 USA 
Green Bullet 13.70 N/A 2010 New Zealand 
Summit 14.30 N/A 2011 USA 
Magnum 14.50 2.50 2010 Germany 
Sorachi Ace 14.90 4.20 2010 Japan 
Citra (whole) and Pellets 15.00 N/A 2011 USA 
Galaxy 15.10 N/A 2012 Australia 
Pacific Jade 15.10 N/A 2011 New Zealand 
Colombus 16.20 N/A 2010 USA 
Pacific Gem 17.00 N/A 2011 New Zealand 
Warrier 18.20 N/A 2010 USA 
Apollo 19.50 N/A 2010 USA 
Savinjski Goldings 20.75 N/A 2010 Slovenia 
60 
 
3.5 Methods 
3.5.1 Maceration of hop material 
Prior to the extraction of antibacterial compounds the hop material was macerated to 
increase surface area and maximise the extraction of compounds. For this, hop 
material was added to a processor (one touch power grater™, DKB Household, UK), 
fitted with a 4 inch, double blade attachment. The processor was used at full power 
(400 rpm) for 3 minutes at room temperature and pressure. After processing, the 
resulting hop material was passed through a 2 mm mesh.  
Another method of hop maceration using a pestle and mortar was also employed. Hop 
material was ground using a pestle until no large fragments of hop material remained. 
These two methods were compared to identify the most effective maceration method.  
3.5.2 Aqueous hop extraction method 
To identify the optimum extraction conditions 5 g samples of macerated hop material 
were suspended in 200 mL of SDW and incubated at a range of temperatures (25, 50, 
75 and 100 °C) in a water bath (Thermo Scientific, UK) for a range of times (30, 60, 120, 
180 and 240 minutes). Following extraction the solutions were allowed to cool and 
were then filtered through a Whatman® grade 1 paper using vacuum filtration to 
remove any solids. The resulting extract was then used immediately in antibacterial 
assays.  
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3.6 Antibacterial Assay Methods 
3.6.1 Agar Well Diffusion Assay 
This is a well-established method and is commonly used to determine antibacterial 
activity against bacteria and fungi (Kim et al., 1995; Ríos and Recio, 2005) 
Firstly, a range of agars (typtone soya agar, nutrient agar, lysogeny agar and brain 
heart infusion agar) were assessed for their ability to support the growth of test 
organisms and to allow the diffusion of antibacterial compounds. Agars were prepared 
as per manufacturer’s instructions and autoclaved at 121 °C for 15 minutes at 15 PSI 
(Prestige, 9 L classic bench top autoclave, LabShop, UK), after which agar was allowed 
to cool to 45 °C in a water bath (Princeton, Thermo-Scientific). The agar was then 
inverted gently and 20 mL aliquots were decanted into 45 x 90 mm petri dishes (Fisher 
Scientific, UK) and placed in a lamina flow cabinet where they were allowed to cool 
and set.   
Plates were then inoculated with 150 µL of a bacterial suspension (Method 2.2.2) 
standardised to 1 x 106 cfu mL-1 (Method 2.2.3) and an even spread was made across 
the plate using a sterile flat sided spreader (Fisher Scientific, UK), plates were then 
incubated statically at 37 °C (Thermo Scientific, UK) for 3 hours.   
A previously sterilised 6 mm borer (Fisher Scientific, UK) was then used to create 4 
wells per plate. For each hop extract or test bacterium, newly sterilised equipment was 
used. In each well 80 µL of the aqueous hop extract was pipetted; in addition to this, 
on each plate 80 µL of H₂O was also pipetted into a well as a negative control and 80 
µL of oleic acid (Sigma-Alrich, UK) at a concentration of 8 µg mL-1 in 50 % DMSO as a 
positive control. This was chosen as a control as it is a naturally derived unsaturated 
fatty acid which exhibits antibacterial properties (Zheng et al., 2005). Plates were then 
carefully transferred to a static 37 °C incubator (Thermo Scientific, UK) for 24 or 72 
hours depending on the test bacteria. Inhibition of bacterial growth was observed by a 
clear zone of inhibition around the test well. The size of the zone of inhibition was 
determined by measuring two diameters at right angles across the zone and 
subtracting the diameter of the well itself (6 mm). Each assay was performed on 3 
separate occasions on each bacterial species with each hop extract unless otherwise 
specified. 
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3.6.2 Agar Incorporation Assay to determine the Minimum Inhibitory 
concentration of hop extracts 
The agar well incorporation assay allows for the determination of antibacterial activity 
for different concentrations of hop extracts (v/v). In order to reduce the dilution effect 
of the hop extracts on the nutrient content of the medium each agar was made up at 
double its standard concentration (TSA 12 g 500 mL-1 diH₂O) and (Middlebrook 7H10   
19 g 450 mL-1 diH₂O) and was autoclaved at 121 °C for 15 minutes at 15 PSI (Prestige, 9 
L classic bench top autoclave, LabShop, UK) after which it was allowed to cool to 40 °C 
in a water bath (Thermo-Fischer, UK).  
Aqueous hop extracts, sterile distilled water and molten agar where then added to a 
24 well plate (Sterlin, UK) in amounts specified in Table 3.2 and mixed to give a final 
hop extract concentration as described in the table. The agar plates were then allowed 
to set within a laminar flow cabinet for 30 minutes.  
 
Well Number 
SDW 
Amount (µL) 
Agar Amount 
(µL) 
Hop Amount 
(µL) 
% volume of hop extract  
 
A1 0.00 2000 1000 33.00 
B1 100 2000 900  30.00 
C1 200 2000 800  26.00 
D1 300 2000 700  23.00 
A2 350 2000 650  21.60 
B2 400 2000 600  20.00 
C2 450 2000 550  18.30 
D2 500 2000 500  16.00 
A3 550 2000 450  15.00 
B3 600 2000 400  13.00 
C3 650 2000 350  11.60 
D3 700 2000 300 10.00 
A4 750 2000 250 8.00 
B4 800 2000 200 6.60 
C4 820 2000 180 6.00 
D4 840 2000 160 5.30 
A5 850 2000 150  5.00 
B5 860 2000 140 4.60 
C5 880 2000 120 4.00 
D5 900 2000 100  3.30 
A6 910 2000 90  3.00 
B6 920 2000 80 2.66 
C6 945 2000 55 0.83 
D6 0.00 3000 0 0.00 
 
Table 3. 2 The volumes of double concentrated agar, SDW, and aqueous hop extract used to 
generate a range of hop concentrations within the agar incorporation assay 
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After cooling, the plate was transferred to a static incubator (Thermo Scientific, UK) for 
3 h at 37 °C. A previously prepared bacterial suspension (Method 2.2.2) was then 
standardised to 1 x106 cfu mL-1 (Method 2.2.3) and two 20 µL aliquots were pipetted 
onto the surface of each well. Plates were then incubated for 24 or 72 h depending on 
the test bacteria. 
By using different concentrations of the hop extract against the test bacteria, the 
minimum inhibitory concentration (MIC) could be calculated. The MIC was determined 
by visually inspecting each well after incubation, the lowest concentration of hop 
extract which inhibited growth, was considered the MIC. To determine the minimum 
bactericidal concentration (MBC) the surface of each well was swabbed with a sterile 
wooden swab (Fisher Scientific, UK) and transferred to either 10 mL Middlebrook 7H9 
broth in the case of Mycobacteria or 10 mL TSB in the case of other bacteria. The 
inoculated media was then incubated with shaking at 150 rpm at 37 °C for 24 or 72 h 
dependant on the test bacteria.  
After incubation, the absorbance of each solution was read at 600 nm (UV -6010, 
Thermo Scientific, UK), using sterile broth as a negative control, the lowest 
concentration of hops that prevented the growth of bacteria was considered the 
minimum bactericidal concentration (MBC).  
The method was repeated on 3 separate occasions for each test bacteria unless 
otherwise specified.  
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3.7 Results 
Hops are employed in the brewing process to enhance the aroma and flavour of beer 
and to act as a natural preservative (Hornsey, 2003). It is known that the act of boiling 
hops with water, malt and barley releases antimicrobial compounds into the beer 
solution (Sakamoto and Konings, 2003b). This mixture, known as the wort, is heated 
for a specific length of time and temperature as determined by the brewer to achieve 
the desired aroma and flavour (Hornsey, 2003). 
Hops which are used in brewing are provided in two forms; as un-macerated whole 
hop cones or as macerated, compressed pellets. The whole hop cones undergo 
minimal processing. In contrast, the pelleting process involves the hops cones being 
broken down into a fine power by  hammer milling (maceration) after which they are 
compressed into 5 cm by 1 cm pellets (Hieronymus, 2012).  
3.7.1 Optimisation assays for the extraction of antibacterial 
compounds from hops this is an intro not the results  
The effect of hop cone processing along with the time and the temperature of the 
aqueous extraction of hop plants and the effect on antibacterial activity was 
determined by using the zone of inhibition assay against M. smegmatis.  
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3.7.2 The effect of maceration on the release of water soluble 
antibacterial compounds from hops 
The degree of maceration and its effect on the release of water soluble antimicrobial 
compounds from hops was determined. The release of antimicrobial compounds into 
sterile distilled water from the following substrates was compared; hand macerated 
whole hop cones, mechanically macerated whole hop cones and mechanically 
disrupted pelleted hop cones. As a control, non-macerated hop cones were included. 
Following aqueous extraction (Method 3.5.2) the presence of compounds with 
antibacterial activity against M. smegmatis was determined using a zone of inhibition 
assay using Middlebrook 7H10 agar (Figure 3.1).  
 
Figure 3. 1 The effectiveness of hand and mechanical maceration on the release of polar 
antimicrobial compounds from hops following aqueous extraction. Activity was determined 
using a zone of inhibition assay against M. smegmatis, positive controls and negative 
controls consisted of oleic acid (8 µg mL-1) and SDW. Each assay was repeated 3 times;  
results presented are the mean, error bars represent standard deviation ( ±SD). 
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As can be seen from the data presented in Figure 3.1 physical disruption of the hop 
cone structure either by hand or using mechanical means resulted in an increase in the 
antibacterial activity of hop extracts following aqueous extraction when compared to 
undisrupted whole hops. 
To determine if there were statistically significant differences between antibacterial 
activity and the level of maceration data was subjected to a one way ANOVA. A 
statistically significant difference (p = 0.026) between macerated and un-macerated 
hops in terms of antibacterial activity was observed. As a statistically significant 
difference was found a Tukey honest significant difference (HSD) post hoc analysis was 
used to determine if the type of maceration had an impact on antibacterial activity.  
 A statistically significant difference (p = 0.027) was observed between mechanically 
disrupted pelleted hop extracts (mean zone of inhibition (ZOI) 14.13 mm ±SD 1.203 
mm) and untreated whole hops (mean ZOI = 12.82 mm ±SD 1.29 mm).  In contrast no 
statistically significant difference was observed between hand (p = >0.05; mean ZOI 
10.66 mm ±SD 1.22 mm) and mechanical (p= > 0.05); mean ZOI = 12.82 mm ±SD 1.29 
mm) maceration of whole hops. 
This result is not surprising given that during the production of hop pellets the whole 
hop cones are reduced to a powdered form prior to being compressed into pellets 
(Hieronymus, 2012). This form of processing offers two distinct advantages over the 
use of whole hops. The first is that the tight compression of the powdered hop 
material is thought to slow degradation by minimising exposure to oxygen (De 
Keukeleire, 2000). The second is that the powdering process increases the surface area 
of the hop material across which, compounds could be extracted. 
Based on these results pelleted hops, when available, were used in all future 
antimicrobial assays.  When pelleted forms of a particular variety were not available 
then whole hops were subjected to mechanical maceration prior to extraction. 
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3.7.3 The effect of temperature on the release of water soluble 
antibacterial compounds from hops 
As previously mentioned hops are added to the wort and are heated at a temperature 
determined by the brewer. This heating process is essential as it leads to the thermal 
isomerisation of alpha and beta acids which enhances the taste of the beer and results 
in the generation of antibacterial isomers such isohumulone (Acworth et al., 2012; 
Jaskula et al., 2008; Stevens and Page, 2004). 
To identify the optimum temperature for the maximum extraction of antibacterial 
compounds, pelleted hop varieties were suspended in SDW for a period of 60 minutes 
at 25 °C, 50 °C, 75 °C and 100 °C. Antibacterial activity was assessed against M. 
smegmatis in a zone of inhibition assay, with +ve oleic acid 8 µg/mL-1 and –ve SDW 
controls (Figure 3.2). 
 
Figure 3. 2 The effect of extraction temperature on the release of antibacterial compounds 
from different varieties of hops.  Pelleted hop variants were suspended  in SDW at 25, 50 , 75  
and 100 °C for 60 mins.  Antibacterial activity was determined using a zone of inhibition 
assay against M. smegmatis. Each assay was repeated 3 times; results presented are the 
mean, error bars represent standard deviation ( ±SD). 
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It can be observed from Figure 3.2 that the antibacterial activity increased with the 
degree of heating for all hop variants tested.  
Using a one way ANOVA analysis it was found that there was a statistically significant 
difference (p= <0.05) between heated (50 °C, 75 °C, 100 °C) and unheated (25 °C) hop 
extracts and the level of antibacterial activity. To determine the optimum extraction 
temperature data was subjected to a Tukey HSD analysis. 
There was no statistically significant difference in activity between hops extracted at 
room temperature (25 °C) and 50 °C (p = 0.693); and between 75 and 100 °C (p = 
0.699). There was however a statistically significant difference between hops extracted 
at 25 °C and 75 °C (p = <0.05), between 25 °C and 100 °C (p = <0.05) and between 50 °C 
and 100 °C (p= < 0.05).  
It has long been understood that heating hops during the wort boiling process  
(approx. 100 °C ) leads to the release of the alpha and beta acids which are  
responsible for aroma and bitterness (Arnold, 2005).  It is these compounds which are 
isomerised to form cis and trans isomers which are also thought to be responsible for 
the antibacterial activity of beer (Caballero et al., 2009). Therefore it is possible that 
the heating during extraction could be directly affecting the isomerisation of the alpha 
and beta acids and thus the antibacterial activity.   
It can be concluded from this data that an extraction temperature of 100 °C does not 
have a detrimental effect on antibacterial activity; moreover heating leads to 
antibacterial activity. Based on these results it was decided to adopt an extraction 
temperature of 100 °C for all future studies.  
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3.7.4 The effect of extraction time on the release of polar antibacterial 
factors from hops 
In the previous assays the effect of maceration and temperature on the extraction of 
antibacterial compounds from hops was analysed. To determine if the time that hops 
were extracted influenced the recovery of antibacterial compounds pelleted hop 
material was extracted as previously described (Method 3.5.2) at a temperature of 100 
°C for 30, 60, 120 and 180 minutes and a zone of inhibition assay was used to 
determine antibacterial activity against M. smegmatis. With +ve oleic acid 8 µg/mL-1 
and –ve SDW controls 
 
Figure 3. 3 The effect of extraction time of hop extracts at 100 °C and the level of 
antibacterial activity. Macerated hop material was heated at 100 °C for 30, 60, 120 and 180 
minutes and after cooling to room temperature, were tested in a zone of inhibition assay 
against M. smegmatis on three separate occasions. Results represent the mean ZOI, error 
bars ± SD, positive control (oleic acid) and negative (SDW). 
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As can be seen from the results presented in Figure 3.3 the time that hops are exposed 
to 100 °C affects the magnitude of the resulting antibacterial activity and shows that 
some hop variants are more sensitive to the effects of time than others. The hop 
variant, Northdown failed to display any antibacterial activity following heating at 100 
°C for 30 minutes while all other hop variants (n=5) displayed some level of 
antibacterial activity. 
A one way ANOVA of the data compared the extraction time at 30, 60, 120 and 180 
minutes and the level of antibacterial activity; a statistically significant difference (p = 
<0.05) was observed. Therefore a Tukey HSD post hoc test was used to evaluate the 
statistical differences between each extraction time.  
Firstly the mean zone of inhibition of hop variants against M. smegmatis after heating 
at 100 °C for 30 minutes (mean 3.83 mm ± SD 0.935 mm) was compared to heating at 
60, 120 and 180 minutes; and a statistically significant difference was observed (p = < 
0.05). 
However, comparing heating at 100 °C for 60 minutes (Mean ZOI 12.71 mm ± SD 0.790 
mm) to 120 mins (mean ZOI  12.63 mm ± SD 0.686 mm) and 180 mins (mean ZOI was 
11.47 ± SD 0.895 mm); it was found that there was no significant difference in activity 
(p = 1.00; 0.652 respectively).  
Even though an increase in the overall antibacterial activity was observed after heating 
for 60 and 120 minutes, at 180 minutes there was a decrease in the mean zone of 
inhibition. Previous research (Caballero et al., 2009) has highlighted that hop 
compounds are heat sensitive; therefore prolonged heating further than 180 minutes  
could lead to thermal decomposition of the antibacterial compounds.  
Based on these results all future hop extractions were performed at 100 °C for 60 
minutes prior to antibacterial activity testing.  
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3.7.5 Identification of a common commercial agar based culture media 
with which to determine the sensitivity of MSSA, MRSA, E. coli and B. 
subtilis against aqueous hop extracts 
To determine if the antibacterial activity demonstrated by the hop extracts was 
specific to a particular bacterial species, the hop variant Green Bullet was assessed for 
its ability to inhibit the growth of the following bacteria. Gram positive organisms: 
Methicillin sensitive (NCTC 13277) and resistant (NCTC 10442) isolates of 
Staphylococcus aureus (MSSA; MRSA) and Bacillus subtilis (NCTC 10315) and Gram 
negative bacteria Escherichia coli (NCTC 1093).  
Due to the fact that these organisms grew poorly on Middlebrook 7H10 agar which 
was used to determine the sensitivity of Mycobacteria; a range of commercially 
available agars were compared for their ability to support growth and demonstrate 
antibacterial activity.      
 
Figure 3. 4 A comparision of the antibacterial sensitivity of MRSA, MSSA, E. coli and B. 
subtilis to an aqueous extract of Green bullet using an aqueous extract of Green Bullet hops 
using different culture media. Antibacterial activity was determined using a zone of 
inhibition assay. Each assay was repeated 3 times; results presented are the mean, error bars 
represent standard deviation (± SD). 
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All of the culture media supported the growth of the test bacteria. While the growth of 
the Gram positive bacteria was inhibited by the Green Bullet hop extract the growth of 
the Gram negative representative E. coli was not (Figure 3.4). This finding was not 
suprising given that antibacterial compounds found in hops have been reported to 
show little, if any, antibacterial activity against Gram negative organisms (Beutler, 
2009; Colegate and Molyneux, 2007; Dias et al., 2012). 
To determine if there was a statistically significant difference between the zone of 
inhibition against all test bacteria and the agar used, data was subjected to a one way 
ANOVA. No significant difference was observed between TSA and BHI (p=0.276); TSA 
and LB (p=0.142) and TSA and NA (p= 0.132). 
Due to the fact that TSA supported the growth of all test organisms and is regularly 
employed in antibacterial assays it was selected to support all future studies involving 
this selection of bacteria.  
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3.8 Comparison of the antibacterial activity of aqueous hop 
extracts with their average alpha and beta acid concentration  
The alpha and beta acid content of hops has been linked to the antibacterial properties 
of beer (Dorman and Deans, 2000; Hornsey, 2003). Therefore to determine if the 
stated alpha and beta acid content of a particular hop variant correlated with 
observable antibacterial activity two agar based screening assays were used. These 
assays consisted of a zone of inhibition assay and an agar incorporation assay which 
were used to determine both a minimum inhibitory and bactericidal concentration of 
each hop variant.  
 
3.8.1 A comparison of the antibacterial activity of hop extracts against 
M. smegmatis and their average alpha acid concentration using a zone 
of inhibition assay 
To determine if the stated alpha acid concentration of an individual hop extract 
correlated with its observed antibacterial activity against M. smegmatis the mean zone 
of inhibition (n =3) of each aqueous hop extract (n=50) was plotted against the stated 
alpha acid content of each hop variant (Figure 3.5). To determine if a relationship 
existed between these two variables a linear regression analysis was undertaken.  
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Figure 3. 5 Correlation of the stated alpha acid content of hop variants with the zone of 
inhibition against M. smegmatis using a zone of inhibition assay. Each assay was repeated 3 
times; results presented are the mean, error bars represent standard deviation (± SD). 
The R2 value (0.09) generated by the regression analysis of the data presented in 
Figure 3.5 indicates that there is no significant correlation between alpha acid content 
and antibacterial activity against M. smegmatis. The R2 value or coefficient of 
determination demonstrates how well data fits to a statistical model; the better the 
linear regression fits the data in comparison to the simple average the closer the 
R2 value will be to 1. Therefore an R2 value of 0.09 demonstrates that there is no 
correlation. To further determine if a statistical correlation existed the data was 
subjected to a Pearson’s two tailed correlation test. This test determines the 
relationship between two variables (0.5 - 1 = strong relationship; 0.1 - 0.5 weak 
relationship) and determines the statistical significance of the correlation in the form 
of a p value (< 0.05 not statistically significant; > 0.5 statistically significant. A Pearson’s 
R value of 0.104 was determined, showing a very weak relationship between alpha 
acid content and antibacterial activity. 
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3.8.2 A comparison of the antibacterial activity of aqueous hop extracts 
against M. bovis BCG and other non-Mycobacterial species with their 
stated alpha acid content using a zone of inhibition assay 
 
In order to determine if  there was a similar lack of correlation between the 
antibacterial activity against other bacteria and alpha acid content,  the same analysis 
was performed using  M. bovis BCG (NCTC 5692), the Gram positive bacteria; MRSA 
(NCTC 10442), MSSA (NCTC 13277), and  B. subtilis (10315)  and  the Gram negative 
bacteria E. coli (NCTC 1093).  The antibacterial activity of aqueous hop extracts was 
assayed against each organism using a zone of inhibition assay as previously described 
(Method 3.6.1). The mean zone of inhibition (n=3) was correlated against the stated 
alpha acid concentration of each hop variant. 
A summary of the results are presented in Table 3.4 which shows the calculated R2 
values along with Pearson’s two tail R values for each bacterial species. 
Bacterial 
Species 
Linear Regression 
Analysis R2 value 
Pearson’s Two tailed 
Correlation R value 
MRSA 
0.0030 0.1260 
NCTC 10442 
MSSA 
0.0014 0.1040 
NCTC 13227 
B. subtilis 
0.0746 0.1030 
NCTC 10315 
E. coli 
No inhibition No inhibition 
NCTC 1093 
M. bovis 
0.0040 0.0960 
BCG NCTC 5692 
 Table 3. 3 Statistical analysis of the correlation of the stated alpha acid 
content of hop variants (n=50) and the mean zone of inhibition against 
MRSA, MSSA, E. coli, B. subtilis and M. bovis BCG using a zone of inhibition 
assay (n=3). Table shows the linear regression analysis ( R2 value)  as well 
as Pearon’s R values. 
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From the results presented in Table 3.3, no obvious correlation between the alpha acid 
content of each hop variant and antibacterial was observed. As was previously 
observed, no antibacterial activity was demonstrated against E. coli.  
These results are surprising given that alpha acids are widely recognised as possessing 
antibacterial activity and as such it would be expected that they would contribute to 
the antibacterial activity of the aqueous hop extracts (Caballero et al., 2009; Cragg and 
Newman, 2013; Natarajan et al., 2008). The lack of correlation could be due to a 
problem with how the alpha acid concentrations are determined, or the fact that the 
alpha acids and their heat derived isomers only make a small contribution to the 
overall antibacterial activity observed from the hop extracts. 
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3.8.2. A comparison of the antibacterial activity of aqueous hop 
extracts against M. smegmatis with their stated beta acid content using 
a zone of inhibition assay 
To define if the stated beta acid concentration of an individual hop extract correlated 
with the antibacterial activity against M. smegmatis, the mean zone of inhibition (n=3) 
of each aqueous hop extract (n=50) was plotted against the stated beta acid content of 
each hop variant (Figure 3.6). To determine if a relationship existed, a linear regression 
analysis was undertaken on the data.  
 
Figure 3. 6 The correlation of the stated beta acid content of hop variants (n=21) and the 
mean zone of inhibition against M. smegmatis using a zone of inhibition assay. Each assay 
was repeated 3 times; results presented are the mean, error bars represent standard 
deviation (± SD). 
 An initial observation of Figure 3.6 and the linear regression analysis (R2 value 0.0567) 
suggests that there is no direct correlation between the beta acid content of hops and 
antibacterial activity against M. smegmatis.  To confirm this observation the data was 
subjected to a Pearson’s two tailed correlation which generated a Pearson’s R value of 
0.09 further suggesting no correlation.  
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3.8.3 A comparison of the antibacterial activity of aqueous hop extracts 
against M. bovis BCG and other non-Mycobacterial species with their 
stated beta acid content using a zone of inhibition assay 
In order to determine if  there was a similar lack of correlation between  antibacterial 
activity and beta acid content  with other bacteria  the same analysis was performed 
using  M. bovis BCG (NCTC 5692), the Gram positive bacteria; MRSA (NCTC 10442), 
MSSA (NCTC 13277), and  B. subtilis (10315)  and  the Gram negative bacteria E. coli 
(NCTC 1093).  The antibacterial activity of aqueous hop extracts was assayed against 
each organism using a zone of inhibition assay as previously described (Method 3.5.1). 
The mean zone of inhibition (n=3) was correlated against the stated alpha acid 
concentration of each hop variant. 
 A summary  of the results are presented in Table 3.4 which shows the results of the 
linear regression analysis (R2 values)  along with Pearson’s two tail R values for each 
bacterial species. 
 
Table 3. 4 Statistical analysis of the correlation of the stated beta acid content of hop 
variants (n=21) and the mean zone of inhibition against MRSA, MSSA, E. coli, B. subtilis and 
M. bovis BCG using a zone of inhibition assay (N=3). Table shows the linear regression 
analysis (R2 value) as well as Pearson’s R values. 
 
 
Bacterial Species 
Linear Regression Analysis     
R2 value 
Pearson’s Two tailed 
Correlation R value 
MRSA 
NCTC 10442 
0.0540 0.2150 
MSSA 
NCTC 13227 
0.0750 0.1470 
B. subtilis 
NCTC 10315 
0.0660 0.1100 
E. coli 
NCTC 1093 
No inhibition No inhibition 
M. bovis BCG 
NCTC 5691 
0.0550 0.1320 
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The results from all of the hop variants found no obvious correlation between the 
stated beta acid content and antibacterial activity.  As was previously observed no 
antibacterial activity was seen against E. coli.  
 
Again, these results are surprising given that lupulone, a beta acid found in hops and 
beer is known to be antibacterial (Erdmann, 1951; Siragusa et al., 2008). The beta acids 
comprise of 3 compounds,  lupulone, adlupulone and colupulone (Van Cleemput et al., 
2009a) and the stated beta acid content of a hop refers to the total concentration 
(w/w) of all three compounds. Thus, it may be the case that lupulone is present in 
much smaller amounts than the other beta acids, this may explain the lack of 
correlation. It may also be the case, given that beta acids have been described as being 
weakly non-polar (Shen and Sofos, 2008), that the aqueous extraction process used 
may not have efficiently extracted all of the available beta acids.  
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3.8.4 Comparison of the antibacterial activity of aqueous hop extracts 
with their average alpha and beta acid concentration against M. 
smegmatis using an agar well incorporation assay 
The zone of inhibition assay is a useful tool with which to rapidly screen the   
antibacterial activity of large numbers of hop extracts against all test bacteria. 
However, the information which can be obtained from this assay is limited when 
compared to a standardised agar incorporation approach which allows both the 
minimum inhibitory (MIC) and bactericidal (MBC) concentrations of the test agent to 
be determined. 
For this reason, an agar incorporation assay (adapted from previous research (Varela 
et al., 2008)) was employed. A comparison of the antibacterial activity of the various 
aqueous hop extracts using the agar diffusion and agar incorporation assays against 
M.smegmatis is shown in the following table (Table 3.5).  
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Table 3. 5 The antibacterial activity (ZOI, MIC and MBC) of aqueous hop extracts against M. 
smegmatis determined using a zone of inhibition and agar incorporation assay. (Results 
represent n=3) 
  
 Antibacterial  activity of hop extract 
Hop variant 
Mean Zone of inhibition 
(mm) 
Agar incorporation  
 
MIC 
 
MBC 
( % v/v hop extract) (As % v/v hop extract) 
Galena 2.60 33.00 33.00 
Styrian Goldings 4.15 33.00 33.00 
Cascade 5.50 13.00 15.00 
Simcoe 6.12 13.00 17.00 
Savinjski Goldings 6.16 6.60 8.00 
Summer Pellets 6.34 6.60 10.00 
Boadicea 6.72 5.30 5.30 
Perle 6.75 16.00 16.00 
Galaxy 7.35 5.30 6.00 
Summit 7.35 13.00 20.00 
NZ Pacifica 8.04 10.00 10.00 
Apollo 8.20 7.00 8.00 
Hallertauer  8.20 10.00 10.00 
Bobek 8.30 10.00 10.00 
Liberty 8.30 33.00 33.00 
Sonnet 8.37 4.60 5.00 
Sorachi Ace 8.62 15.00 16.00 
Motueka Pellets 8.95 13.00 15.00 
Tettnang 8.95 10.00 15.00 
Fuggles 9.25 13.00 15.00 
Colombus 9.50 10.00 10.00 
Delta 9.62 5.30 6.00 
Chinnok 10.25 10.00 10.00 
Centennial Pellets 10.65 11.60 13.00 
Northdown 10.66 13.00 15.00 
Amarillo 10.75 5.00 5.00 
Cascade Pellets 11.20 11.60 11.60 
Brambling Cross 11.33 7.00 7.00 
Pacific Jade 11.36 6.60 8.00 
Progress 11.52 10.00 10.00 
Challenger 11.55 10.00 10.00 
Northern Brewer 11.66 3.00 4.00 
Nelson Sauvin 11.68 4.00 4.60 
Aurora 11.72 5.30 6.00 
Amarillo Pellets 12.15 4.00 4.60 
Pacific Gem 12.37 16.00 20.00 
Target 12.37 18.30 18.30 
Williamette 12.50 3.00  5.50 
Fuggles Pellets 12.90 11.60 11.60 
Glacier 13.52 3.30 3.30 
First Gold 13.75 3.30 4.00 
Chinook Pellets 14.20 8.00 10.00 
Centennial 14.32 4.60 5.00 
Rakau 14.62 16.00 18.30 
Green Bullet 14.80 10.00 10.00 
Magnum 15.04 5.30 5.30 
Warrier 15.20 10.00 10.00 
Goldings 16.40 10.00 10.00 
Citra 16.45 2.66 2.66 
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Analysis of the results presented in Table 3.5 reveal that for several hop variants there 
was a marked difference in the results obtained using the zone diffusion and agar 
incorporation assays. 
For example the hop variants Goldings and NZ Pacifica had  identical MIC and MBC  
values (10 % v/v) yet there zones of inhibition differed markedly with diameters of  
16.4mm and 8.4mm respectively. 
A similar disconnection was observed between the Goldings and Citra variants which 
demonstrated similar mean zones of inhibition values (16.4 mm ±SD 0.13  and 16.45 
mm ±SD 0.11) but differed markedly with regards MIC and MBC levels  (Goldings 
MIC/MBC 10 % v/v and Citra MIC/MBC 2.66 % v/v ).   
To determine if the differences between the ZOI, MIC and MBC were statistically 
significant the mean zone of inhibition results were compared to the MIC and MBC 
values using a paired samples t test.  A significant difference was seen between the 
mean zone of inhibition and the MIC (p=0.001) and the MBC (p=0.001) respectively. 
From these results, it is possible to conclude that although the zone of inhibition assay 
is a useful method with which to detect antibacterial activity, the agar incorporation 
assay gives a more quantitative measure of the antibacterial activity of a hop extract. 
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3.8.5 A comparison of the antibacterial activity (MIC) of hops extracts 
against M. smegmatis and average alpha acid concentration 
determined using an agar incorporation assay 
 
To determine if the stated alpha acid concentration of an individual hop extract 
correlated with its observed antibacterial activity against M. smegmatis the MIC   (n=3) 
of each aqueous hop extract (n=50) was plotted against the stated alpha acid content 
of each hop variant (Figure 3.7).  To determine if a relationship existed between these 
two variables data was subjected to a linear regression analysis. 
 
 
Figure 3. 7  A comparison of the antibacterial activity  (MIC) of aqueous  hop extracts with 
their stated alpha acid content.  Antibacterial activity was determined using an agar 
incorporation assay against M. smegmatis grown on Middlebrook 7H10 agar Each assay was 
repeated 3 times; results presented are the mean. 
The linear regression analysis suggests that there is no correlation between the stated 
alpha acid content and MIC. To confirm this observation the data was subjected to a 
Pearson’s two tailed correlation which generated an R value of 0.681 suggesting no 
correlation.  
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3.8.6 A comparison of the antibacterial activity (MBC) of hops extracts 
against M. smegmatis and average alpha acid concentration 
determined using an agar incorporation assay 
 
To determine if the stated alpha acid concentration of an individual hop extract 
correlated with its observed antibacterial activity against M. smegmatis the MBC (n=3) 
of each aqueous hop extract (n=50) was plotted against the stated alpha acid content 
of each hop variant (Figure 3.8). To determine if a relationship existed between these 
two variables linear regression analysis of the data was performed. 
 
Figure 3. 8 A comparison of the antibacterial activity (MBC) of aqueous hop extracts with 
their alpha acid content. Antibacterial activity was determined using an agar incorporation 
assay against M. smegmatis grown on Middlebrook 7H10 agar Each assay was repeated 3 
times; results presented are the mean 
The linear regression analysis suggests that there is no correlation between the stated 
alpha acid content and MBC. To confirm this observation the data was subjected to a 
Pearson’s two tailed correlation which generated an R value of 0.546 suggesting no 
correlation.  
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3.8.7 A comparison of the antibacterial activity (MIC) of hop extracts 
against M. smegmatis and the average beta acid concentration 
determined using an agar incorporation assay 
 
To determine if the stated beta acid concentration of an individual hop extract 
correlated with its observed antibacterial activity against M. smegmatis the MIC (n=3) 
of each aqueous hop extract (n=50) was plotted against the stated alpha acid content 
of each hop variant (Figure 3.9). To determine if a relationship existed between these 
two variables a linear regression analysis of the data was performed. 
  
 
Figure 3. 9 A comparison of the antibacterial activity (MIC) of aqueous hop extracts with 
their beta acid content. Antibacterial activity was determined using an agar incorporation 
assay against M. smegmatis grown on Middlebrook 7H10 agar Each assay was repeated 3 
times; results presented are the mean. 
The linear regression analysis suggests that there is no correlation between the stated 
Beta acid content and MIC. To confirm this observation the data was subjected to a 
Pearson’s two tailed correlation which generated a P value of 0.254 suggesting no 
correlation.  
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3.8.8 A comparison of the antibacterial activity (MBC) of hop extracts 
against M. smegmatis and the average beta acid concentration 
determined using an agar incorporation assay 
 
To determine if the stated beta acid concentration of an individual hop extract 
correlated with its observed antibacterial activity against M. smegmatis the MBC  (n=3) 
of each aqueous hop extract (n=50) was plotted against the stated alpha acid content 
of each hop variant (Figure 3.10). To determine if a relationship existed between these 
two variables a linear regression analysis of the data was performed. 
 
Figure 3. 10 A comparison of the antibacterial activity (MBC) of aqueous hop extracts with 
their beta acid content. Antibacterial activity was determined using an agar incorporation 
assay against M. smegmatis grown on Middlebrook 7H10 agar. Each assay was repeated 3 
times; results presented are the mean. 
The linear regression analysis suggests that there is no correlation between the stated 
Beta acid content and MBC. To confirm this observation the data was subjected to a 
Pearson’s two tailed correlation which generated a Pearson’s R value of 0.884 
suggesting no correlation.  
 
R² = 0.1893 
y = -102.28x + 13.536 
0
2
4
6
8
10
12
14
16
18
0.00% 1.00% 2.00% 3.00% 4.00% 5.00% 6.00% 7.00% 8.00% 9.00% 10.00%
Th
e
 M
B
C
 (
%
 v
/v
) 
o
f 
h
o
p
 e
xt
ra
ct
s 
 
Stated beta acid concentration of hop varinats (w/w) 
87 
 
3.8.9 A comparison of the antibacterial activity (MIC and MBC) of 
aqueous hop extracts against M. bovis BCG and non-Mycobacterial 
species with their stated alpha acid content using an agar 
incorporation assay 
 
In order to determine if there was a similar lack of correlation between MIC and MBC 
and alpha acid content with other bacteria the same analysis was performed using M. 
bovis BCG (NCTC 5692), the Gram positive bacteria; MRSA (NCTC 10442), MSSA (NCTC 
13277), and B. subtilis (10315) and the Gram negative bacteria E. coli (NCTC 1093). The 
MIC and MBC of each organism was plotted against the stated alpha acid 
concentration of 50 hop variants and a linear regression analysis was performed. The 
data was then subjected to a Pearson’s two tailed correlation.  A summary of the 
results are presented in Table 3.6 which shows the results of the linear regression 
analysis ( R2 values) along with Pearson’s two tail  R values for each bacterial species. 
 
Bacterial species 
Linear regression analysis 
of MIC and alpha acid 
(R2 value) 
Linear regression analysis 
of MIC and alpha acid 
(R2 value) 
MSSA 
NCTC 13227 
0.0005 0.0635 
MRSA 
NCTC 10442 
0.0098 0.0012 
M. bovis BCG 
NCTC 5691 
0.0016 0.0014 
B. subtilis 
NCTC 10315 
0.0450 0.0016 
 
Table 3. 6 Statistical analysis (linear regression and Pearson’s two tailed correlation) of the 
MIC and MBC of aqueous hop extracts against MSSA, MRSA, M. bovis BCG and B. subtilis 
with stated alpha acid content. 
As displayed in Table 3.6, no correlation was found between the MIC and MBC of any 
organism and the stated alpha acid concentration of the hop variants. 
 
  
88 
 
3.8.10 Comparison of the antibacterial activity (MIC and MBC) of 
aqueous hop extracts against M. bovis BCG and non-Mycobacterial 
species with their stated beta acid content using an agar incorporation 
assay 
 
The MIC and MBC of each organism was plotted against the average beta acid 
concentration of 21 hop variants and a linear regression analysis was performed. The 
data was then subjected to a Pearson’s two tailed correlation.  A summary of the 
results are presented in Table 3.7 which shows the results of the linear regression 
analysis ( R2 values) along with Pearson’s two tail  R values for each bacterial species. 
 
Table 3. 7 The MIC and MBC of organisms MSSA, MRSA, M. bovis BCG and B. subtilis against 
aqueous hop extracts were correlated with the average beta acid concentration and the 
calculated R2 values are displayed. 
No correlation between the MIC and MBC of any organism and the stated beta acid 
concentration was observed.  
 
 
 
 
 
Bacterial species 
Linear regression analysis 
of MBC and beta acid 
(R2 value) 
Pearson’s two tailed 
correlation of MIC and beta 
acid 
(R value) 
MSSA 
NCTC 13227 
0.0038 0.142 
MRSA 
NCTC 10442 
0.0035 0.147 
M. bovis BCG 
NCTC 5691 
0.0016 0.284 
B. subtilis 
NCTC 10315 
0.0001 0.514 
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3.9 Discussion  
It is clear from this study that the level of maceration, extraction temperature and the 
time that the hop material is exposed to heat has a marked effect on antibacterial 
activity. Pelleted macerated hops demonstrated the greatest activity presumably due 
to increased surface area over which antibacterial compounds could be extracted and 
the fact that the pelleting process reduces the oxidation and thus the degradation of 
compounds. 
The effect of heat on the antibacterial activity of the hop extracts is likely to have been 
the consequence of two processes, energy driven release of compounds from plant 
material into the aqueous solution and the isomerisation of released compounds such 
as the alpha and beta acids.  
Heating of the hop extracts leads to the isomerisation of the alpha acids (humulone, 
cohumulone and adhumulone) into iso-α-acids via an acyloin type ring contraction. 
This isomerisation reaction has been understood since 1971 (De Keukeleire and 
Verzele, 1971), it has been shown that the isomerisation of hop acids leads to 
increased antibacterial activity in the beer (Caballero et al., 2009). The recovery of the 
cis and trans isomers of the alpha acids is comparatively low (utilising a maximum of 
60 % of starting concentration of hop alpha acids) when using traditional hopping 
techniques such as simply adding hops to boiling wort when compared to using 
prepared hop extracts (Jaskula-Goiris, 2010). Furthermore, the isomerisation of hops 
and thus their utilisation within the brew, can vary significantly between brewers and 
in some cases between brew to brew, this can be due to many factors including pH, 
temperature and the degree of maceration (Jaskula-Goiris, 2010).  
Indeed given that the hop plant is known to contain over 800 separate compounds it is 
not surprising that substances such as proteins and tannins may well interact with the 
hop acids resulting in a reduction of isomerisation  (Acworth et al., 2012).   
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In brewing, the isomerisation of the hop alpha and beta acids during the boiling of the 
wort is used to increase the aroma and bitterness properties of the beer. The main 
alpha and beta acids humulone and lupulone, are relatively hydrophobic and thus 
aqueous extraction is a relatively inefficient process. Heat induced isomerisation of 
these compounds into their respective cis and trans isomers increases there solubility 
in water and thus promotes the extraction process  (Acworth et al., 2012). 
While heating increased the antibacterial activity of hop extracts, prolonged heating (> 
60 mins) resulted in a loss of activity. Malowicki and colleagues observed that while 
isomerisation of alpha acids increased with time there was also increased thermal 
degradation. Suggesting that prolonged boiling at 100 °C could have an adverse effect 
on antibacterial activity (Malowicki and Shellhammer, 2005b).  
In this study, two agar based screening methods were used to determine the 
antibacterial activity of heat treated hop extracts. The broth based micro dilution 
method was considered. However, due to the inherent turbidity of the hop extracts 
following heating it was not practical (Zgoda and Porter, 2001). 
While the zone of inhibition assay proved a useful tool with which to rapidly determine 
the antibacterial of multiple hop extracts it does have limitations.  The size of zone of 
inhibition is affected by the concentration of antibacterial agent in the sample, the 
thickness and nature of the supporting agar and also the density of the bacterial 
inoculum. Thus while rapid, the assay is a relatively insensitive tool with which to 
identify differences in the antibacterial activity of different hop variants (Ashworth, 
2012, Brandon, 2014). 
For this reason, an agar incorporation assay was developed and employed which 
allowed for the determination of the minimum inhibitory concentration and minimum 
bactericidal concentration of each hop variant.  Agar incorporation methods have the 
advantaged of providing a more quantitative result than the zone of inhibition assay   
(Roberts 1998). 
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Using this assay it was observed that all hop variants demonstrated some level of 
antibacterial against the Mycobacterial isolates examined in this study.  The Citra 
variety demonstrated the greatest inhibitory activity against M. smegmatis and M. 
bovis BCG with the Galena variety showing the least. No correlation between the 
antibacterial activity of the hop varieties examined in this study and their stated alpha 
and beta acid content was observed. To determine if this lack of correlation was 
specific to mycobacteria, the activity of the hop varieties against selected Gram 
positive and Gram negative bacteria was determined. 
These organisms, unlike Mycobacterium require a more complex growth medium and 
for this reason I determined the ability of different commercial media, TSA, BHI, LB and 
NA, to support the growth of these organisms and to assess the antibacterial activity of 
the hop extracts.  
The use of a zone of inhibition assay and a Green Bullet hop extract showed that all 
four media were equally effective at supporting growth and demonstrating 
antibacterial activity. Due to availability, TSA was used to determine the relative 
antibacterial activity of all of the hop variants. The results for the Gram positive 
bacteria mirrored those seen for mycobacteria with no correlation observed between 
antibacterial activity and the stated alpha and beta acid content. 
As expected no antibacterial activity against E.coli was observed. As the only Gram 
negative bacteria the lack of activity is probably due to the nature of its cell wall 
(Cowan, 1999). In Gram negative bacteria, the outer cell membrane differs from the 
Gram positive by having a thick layer of lipopolysaccharides and proteins (Grayson, 
2009). There are essentially two distinct pathways that an antibiotic can take: a lipid-
mediated pathway for hydrophobic compounds and general diffusion porins for 
hydrophilic compounds. The lipid and protein compositions of the outer membrane of 
the Gram negative organism have a strong impact on the sensitivity of bacteria to 
antibiotics; rendering them less susceptible than Gram positive organisms (Delcour, 
2009).  
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Overall the lack of correlation between the hop acid content and antibacterial activity 
was surprising given that the hop alpha and beta acids have been described as 
antibacterial (In Acworth et al., 2012). It is hypothesised that other compounds in the 
hop extract contribute for the observed activity.  Hops have been shown to contain 
over 800 compounds some of which may be directly antibacterial or act in a synergistic 
manner to enhance the activity of other antibacterial compounds. Once such 
compound is  xanthohumol, a bioactive prenylated chalcone which  to date has only be 
found  in hops and is known to be antibacterial (Acworth et al., 2012; Ceh et al., 2007; 
Stevens and Page, 2004). The compound is also isomerised in the wort during the 
boiling stage to form iso-xanthohumol which is also antibacterial (Acworth et al., 
2012). The results  presented in this chapter supports earlier work which suggests that 
other compounds in addition to hops acids, contribute to the antibacterial activity of 
beer  (Acworth et al., 2012; Everard et al., 2012; Van Cleemput et al., 2009b). 
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Quantification of the antimicrobial components of hops 
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4.0 Quantification of the antimicrobial compounds of hops 
4.1 Chapter introduction  
Natural products and their derivatives have been identified for their medical 
importance for thousands of years. A search of the NAPRALAERT database (an alert 
network for published literature on novel natural products) lists 58,725 plant species, 
of which, 6350 have been shown to have antimicrobial activity. Contrarily, even though 
natural products continue to be a primary source of new antimicrobials (Bérdy, 2012) 
only 20 new antibacterial compounds from natural products have been brought to the 
market since the year 2000 (Butler and Cooper, 2011; Wright, 2012). 
Several reasons have been proposed for this decline in clinical development including; 
time of research and difficulty in extraction of the novel metabolite, the cost of taking 
the drug through clinical trials and the rise of bacterial resistance which can render the 
antimicrobial redundant before reimbursement of the initial investment (Abreu et al., 
2012).   
The importance of discovering novel antimicrobials has never been so significant. For 
example, the rise of multidrug resistant strains of M. tuberculosis (MDR-TB) has been 
linked to the acquired immunodeficiency syndrome (AIDS) epidemic, poor 
socioeconomic conditions, immigration and the lack of inhibitory antimicrobials. Due 
to a lack of novel antimicrobials, curing patients of MDR-TB is extremely low with 50% 
making a full recovery compared to more than 95 % of patients with antibiotic 
sensitive TB (Ahmad and Aqil, 2009; Mahady, 2005) 
For these reasons, conventional medicine is increasingly receptive to plant-based 
medicines. This is due to not only the rise of bacterial resistance to traditional 
antibacterials, but also the rapid rate of botanical species extinction (Cowan, 1999). 
Furthermore, the general public have been made increasingly aware of the overuse 
and misuse of antibiotics, and are now becoming interested in alternative medicines 
such as ‘medicinal plants’. It has been estimated that up to 80 % of the population of 
developed countries worldwide use botanical products and consider them to be safe 
and effective (Mahady, 2001) 
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While thousands of plant species have been tested against many different strains of 
bacteria, the most common are E. coli, B. subtilis, C. pneumonia and Methicillin 
Resistant S. aureus (MRSA). However, little research has been paid to species of 
mycobacterium even though many strains such as M. tuberculosis and M. abscessus 
have developed increased resistance to front line antibiotics such as rifampicin (Jeon et 
al., 2009; Petrini, 2006).  
In this chapter, the compounds which are directly responsible for the antibacterial 
activity against M. smegmatis was further investigated. Whilst it has been shown that 
several plant species are useful therapeutics (including; opium, belladonna and aloe) 
when used in their natural state, second generation natural products from the 
processing of the plant, to purified chemical compounds with an identified structure 
are now becoming more commonplace. Drugs such as taxol from Taxus brevifolia for 
the treatment of ovarian cancer followed the same development and evaluation as 
other pharmaceutical drugs (Ahmad and Aqil, 2009; Iwu, et al., 1999) 
In Chapter 3, the antibacterial activity of crude hop extracts against a range of clinically 
relevant bacteria was investigated and data correlated with the alpha and beta acid 
concentrations. No statistically significant correlation was observed so therefore this 
chapter describes the extraction and bioassay guided fractionation of the antibacterial 
component molecules within hops.  
In the production of beer, hops are primarily extracted in water during the wort boiling 
process and it has been shown that both the alpha- and beta-acids, as well as potential 
antibacterial compounds, are transferred to the brew during this stage (Caballero et 
al., 2009; Cornelison, 2008; Neve, 1991; Stevens and Page, 2004). For this reason, 
several volatile polar organic solvents such as methanol have been used in this project 
during the hop extraction process to mimic the polarity of water, while being simpler 
to manipulate in the laboratory. The use of solvents in plant extraction is well 
documented (Eloff, 1998; Parekh et al., 2005; Sharifa et al., 2008) and research by 
Wang et al. (2006) suggests that traditional solvent extraction is as efficient and 
reliable as other processes, such as supercritical CO2 extraction (Wang and Weller, 
2006).
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Following treatment with a solvent, the crude hop extract is a complex mixture of over 
800 compounds (Neve, 1991). The difficulties of separating this mixture further, not 
just in hops but many natural products, has been associated with the decline in drug 
discovery from nature (Vu et al., 2008). The key separation technique in natural 
product chemistry is chromatography (Colegate and Molyneux, 2007). Its most basic 
form, thin layer chromatography (TLC) has been used to separate crude hop extracts 
for over 50 years (Bhandari, 1964). 
This method is used to separate non-volatile mixtures, usually on a thin layer of 
adsorbent material (the stationary phase) such as silica gel coated on an aluminium or 
glass plate. The sample is added to the plate and a suitable solvent (mobile phase) 
draws the analyte up the plate by capillary action. Different analytes will elute up the 
TLC plate at different rates depending on their polarity, producing separation (Reed, 
2007). In this study, the use of TLC was combined with a bacterial assay to develop a 
bioassay-guided, bio autographic TLC technique originally described, and adapted from 
(Fleming, 1942). In summary, TLC methodology produces a separation of a complex 
mixture over which a thin layer of Mycobacterium smegmatis can be overlaid onto the 
surface of the TLC plate. Inhibition of growth can then be observed after bacterial 
exposure to a stain. Although not a quantitative method, it can locate potential 
antibacterial compounds (and eliminate inactive compounds) within the mixture 
(Rahalison et al., 1991).  
Further separation methods, such as preparative TLC and column chromatography, can 
then be used for high volume recovery of a specific compound as they are relatively 
time consuming, laborious and can be of low resolution (Andersen, 1969; Bhandari, 
1964; Hostettmann et al., 1998; Reed, 2007; Stavri et al., 2004; Zeković et al., 1994). 
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The primary method for analyte identification is high or ultra-pressure liquid 
chromatography (HPLC/UPLC) coupled to mass spectrometry (Acworth et al., 2012; 
Baker et al., 2008). HPLC utilises the development of high pressure pumps with 
reproducible, reliable flow rates to give rapid separation with reduced band 
broadening (Reed, 2007). To aid in the identification of separated compounds, the 
HPLC system is usually coupled to a mass spectrometer (MS). This method relies on 
splitting the eluent from the column so that only a small volume reaches the MS. 
Chromatograms show peaks which correspond to the elution of particular 
components. It is then possible to analyse individual peaks and obtain a mass for that 
component (Colegate and Molyneux, 2007; Koehn and Carter, 2005). 
In this chapter, the validity of the methods used have not only been confirmed, but 
antimycobacterial analytes from methanol hop extracts have been tested, purified and 
identified. Differences between the most antimicrobial and least antimicrobial hop 
extracts have been observed and reasons for the differences in antibacterial activity 
discussed. This chapter also highlights the difficulties in obtaining pure bioactive 
compounds from complex natural products.  
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4.2 Materials 
4.2.1 Sources of chemicals and reagents 
All chemicals and reagents were purchased from Sigma Aldrich Ltd, UK, unless 
otherwise stated in the text. 
All solvents were from purchased from Thermo Fischer Scientific Ltd, UK, unless 
otherwise stated in the text.  
4.2.2 Diluents 
Deionised water (diH2O) was obtained from an ELGA purelab option BP15 dispenser 
(ELGA labwater, UK). The inorganic content of the water at 25 °C was between 1-15 
MΩ-cm with a total organic carbon content of <30 ppb.  It was sterilised at 121 °C for 
15 minutes at 15 psi (Prestige, 9L classic bench top autoclave, LabShop, UK) to form 
sterile distilled water (SDW).   
4.2.3 Bacterial cultures 
Mycobacterium smegmatis 8159T was used as a simulant organism for M. tuberculosis 
and was grown and standardised as described in Section 2.2.2 and 2.2.3  
All growth media was purchased and produced as described previously in Chapter 2, 
unless otherwise stated.  
 
 
 
 
 
 
 
 
 
99 
 
4.3 Methods 
4.3.1 Organic solvent extraction of hop material 
Fresh hop material was machine macerated as previously described and 20 g 
transferred to a flat bottom 1500 mL conical flask, which was suspended in 1000 mL of 
methanol. Other organic solvents (ethyl acetate, acetone) were also trialled to 
determine the greatest yield. 
The solution was mixed continuously for 48 hours at 100 rpm at room temperature 
and pressure. After this time stirring was halted and solid hop material filtered through 
a Whatman® size 1 under vacuum pressure to remove any solid hop material. 
Resulting solvent was retained and solid hop material was re-suspended in 1000 mL of 
fresh methanol for a further 24 hours at room temperature and pressure with mixing 
at 100 rpm. Following this, hop material was filtered as previously described and 
weighed; hop extract solution was stored at room temperature in the dark until 
required.  
4.3.2 Hop solution evaporation 
Following extraction, both the 24 and 48 hour solutions were combined and re-filtered 
through a Whatman® size 1 filter to remove any remaining solids.  The resulting 
solution was decanted into a 1000 mL round bottom flask. This was then attached to a 
Buchi Rotavapor 200 (Buchi, Switzerland) under vacuum pressure (15 bar) and rotated 
at 50 revolutions per minute (rpm) at 30 °C. 
Waste solvent was firstly checked for compounds by using thin layer chromatography 
(Method 4.4.3) and if no compounds were found it was discarded. The resulting dry 
hop extract (crude hop extract) was removed from the flask, weighed and stored at 3 
°C in the dark until required.  
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4.3.3 Thin Layer chromatography separation of hop extracts 
Hops (n=50) detailed in (Section 3.1) were extracted using (Method 4.3.1) and dried by 
solvent evaporation (Method 4.3.2). Dry crude hop extracts (10 mg) were then re-
suspended in 1 mL of methanol to give a final concentration of 10 mg/mL-1; a 1:10 
dilution series was then prepared in methanol to give final dilutions of 10, 1, 0.1, 0.01, 
0.001 mg/mL-1 and each dilution was mixed gently using a desktop vortex (Vortex 
Genie 2T shaker, Fisher Scientific, UK) for 15 seconds.  
Using a fresh capillary pipette 25 µL of each dilution was removed and spotted onto 
the surface of a thin layer chromatography (TLC) plate (50 mm x 75 mm, 0.20 mm 
Silica).  The TLC plate was then placed horizontally within a fume cupboard at room 
temperature and pressure for 10 minutes to allow any excess solvent on the TLC plate 
to evaporate.  TLC separation of the hop extract was dependant on the solvent system 
(mobile phase) and several ratios of the organic solvents hexane, ethyl acetate, 
methanol and ethanol were optimised to allow for optimum analyte separation. The 
solvent system methanol : ethyl acetate (ratio 1:1) was chosen for all future 
separations.   
50 mL of freshly prepared solvent system was decanted into a TLC developing tank 
(100 mm2 x 100 mm2) and the TLC plate loaded with extract was placed into the 
solvent system allowing 1 cm between the surface of the solvent and the extract. The 
tank was then covered and the solvent allowed to run for 45 minutes or until the 
solvent covered 18 cm of the plate. The distance that the solvent travelled on the plate 
was recorded and the plate was examined under visible and UV light (365 nm, UVitech, 
UK). Each visible separated analyte was then measured for its total distance travelled 
from the baseline.  
The Rf values of analytes could then be determined by using the following equation:  
 
 
This method was repeated on three occasions under the same conditions and the Rf 
values recorded. 
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4.3.4 Bacterial overlay assay 
The bacterial overlay assay utilises the TLC separation as described previously (4.3.3) 
but includes the addition of bacteria to allow visualisation of bioactive analytes as 
originally described by Fleming, (1942) and adapted from Rahalison, (1991).  
Each hop variant (n=50) was extracted and a 0.1 mg/mL-1 solution of crude hop extract 
in methanol was prepared. As a control, Streptomycin solution (stock concentration 1 
mg/mL-1 in 1 mM EDTA, Sigma-Aldrich, UK) was also diluted in methanol to give a final 
concentration of 6 µg/mL-1. 
All samples were then spotted onto the surface of a TLC plate as described earlier 
(Method 4.4.3) and were separated using the previously described solvent system. 
Once separated, each plate was dried within a fume cupboard at room temperature 
and pressure to ensure that no solvent remained on the plate. As a control, on each 
occasion a TLC plate without samples was also run and dried for the same amount of 
time, this was to ensure solvent evaporation.  
A 72 hour Mycobacterium smegmatis suspension was prepared as described (Section 
2.2.2), and was centrifuged at 5000 x g for 15 minutes (Avanti J-20 XP, Beckman 
Coulter Inc. UK) at which time a bacterial pellet was formed. Supernatant was removed 
and discarded; the remaining pellet was washed twice with diH2O. The pellet was then 
re-suspended in 25 ml of sterile LB broth, mixed using a desktop vortex (Vortex Genie 
2T) for 30 seconds at full power (3000 rpm) and standardised to 1 × 105 cfu /mL-1 as 
described in Section 2.2.3.  
The inoculated broth was then spread evenly over the TLC plate which was then rested 
horizontally within a laminar flow cabinet for 5 minutes to allow evaporation of excess 
solution. The inoculated TLC plate was transferred to a sterile container and stored 
vertically in an incubator at 37 °C in high humidity for 72 hours.   
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The TLC plate was then removed from the incubator and placed inside a laminar flow 
cabinet. The tetrazolium salt, 2,3,5-triphenyltetrazolium chloride (20 µg/mL-1), was 
prepared by diluting to 3 µg/mL-1 in SDW and then transferring to a  spray equipped 
bottle. The solution was then sprayed evenly onto the surface of the plate, which was 
then re-incubated at 37 °C for 4 h in high humidity.  
Upon visualisation, metabolically active bacteria convert the tetrazolium salt into an 
intensely coloured formazan; inhibitory compounds appear as clear spots against a red 
background. The Rf values of antibacterial analytes were recorded on three separate 
occasions. This method gives a qualitative indication of inhibitory activity from 
separated analytes and has been successfully used in antibacterial bio-autographic 
assays in other studies (Rahalison, 1991; Valgas, 2007; Waksmundzka-Hajnos, 2008). 
This method is used as a high-throughput screen to further guide separation of 
potentially inhibitory compounds.  
4.3.5 Column chromatography  
Column chromatography is another useful method of separation based on the TLC 
method and utilises the same solvent system. Separated analytes elute through a 
column with a stationary phase which can be made of either silica or Sephadex® (Reid 
and Sarker, 2012). Column chromatography has several advantages over the 
preparative TLC method. Perhaps most importantly is that a larger sample volume can 
be eluted through the column and larger amounts of the sample collected 
(Hostettmann et al., 1998; Reid and Sarker, 2012).  
4.3.6 Silica gel column chromatography 
Silica gel is the most commonly used stationary phase in chromatography and 
separates compounds based on their polarity (Reid and Sarker, 2012). For this method, 
15 g of silica (60Å 45 µm) was packed into a glass column (60 cm x 15 cm) so that it 
was 2/3 full. The column was then flushed with 1 L methanol : ethyl acetate (1:1) and 
600 mL was then eluted and discarded.  
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Hops were extracted as previously described in Section 4.4.1, the solvent evaporated 
(Section 4.4.2) and 5 g of resulting crude hop extract was re-suspended in 10 mL of 
methanol.  
The solution was mixed using a desktop vortex and the hop suspension was added 
drop-wise to the surface of the silica gel using a Pasteur pippete. Once loaded, the 
column was eluted under gravity and 20 mL fractions were collected until all visible 
bands were collected.  
Each fraction was then concentrated to 5 mL and analysed using the bacterial overlay 
assay (Section 4.3.4), Rf values of antibacterial analytes were recorded and the 
relevant fractions of identical Rf values combined, concentrated and weighed. They 
were then stored at 3 °C in the dark until required. This method was repeated on 2 
separate occasions.  
4.3.7 Sephadex® LH-20 Column chromatography 
Although silica gel is a useful method of separating compounds, it also has several 
problems. Yield/recovery of extracts can be low as compounds can bind to the silica, 
thus not eluting from the column. Since silica chromatography separates compounds 
based on polarity, the methanol extraction method extracts polar compounds and thus 
further polarity based separations can be problematic.  
Another stationary phase which can be used is Sephadex®, a cross linked dextran gel 
that separates compounds based on their molecular size and is mostly used for high 
molecular weight molecules such as proteins, but Sephadex® LH-20 is commonly used 
in natural product separation (GE-Healthcare, 2011).  Sephadex® LH-20 is a cross-
linked dextran gel composed of macroscopic beads synthetically derived from a 
dextran polysaccharide.  
To prepare a column, 15 g Sephadex® LH-20 was mixed with 200 mL of the solvent 
system (methanol : ethyl acetate (1:1)) to allow the dry powder to become swollen 
and form a slurry. The slurry was then transferred to a glass column (60 cm x 1.5 cm), 
suspended in 1000 mL of the solvent system and allowed to stand for 12 hours.  
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After resting, 600 mL of the solvent system was eluted under gravity through the 
column twice and 5 mL of the previously re-suspended crude hop extract (0.5 g/mL-1 in 
methanol) was added drop-wise to the surface using a Pasteur pippete. 
To load the hop extract into the column, 25 mL of the solvent system was eluted under 
gravity so that the extract visually entered the Sephadex®; the column was then re-
filled with 1000 mL of the solvent system and elution begun under gravity. Fractions of 
20 mL were collected at a flow rate of 5-10 cm/hr-1, until 250 mL of eluent had passed 
after the last visible band had eluted from the column.  
Each fraction was then concentrated to 5 mL re-examined for antibacterial activity 
using the bacterial overlay assay and the Rf values of antibacterial analytes were 
recorded. Fractions which demonstrated antibacterial activity and had identical Rf 
values were combined, concentrated and stored at 3 °C in the dark until required.  
4.3.8 Mass spectrometry 
Antibacterial analytes separated and isolated from the crude hop mixture were 
primarily checked for purity and identification using liquid chromatography mass 
spectrometry (LC-MS). LC-MS is commonly used for the identification of hop 
compounds (Taylor et al., 2003; Vu et al., 2008), it is useful tool for detecting analytes 
of a low concentration and limited purity (Reusch, 2013; Vu et al., 2008) such as those 
extracted from natural products (Imperato, 2006).  
4.3.8.1 Sample preparation for mass spectrometry  
The sample was firstly prepared by identifying an antimicrobial spot on the TLC plate 
following overnight incubation (section 4.3.4) and separating the appropriate ‘spot’ on 
using column chromatography from the overall mixture. The Rf value of the compound 
was checked against the original inhibitory spot using TLC.  
The solvent used in the extraction process was then evaporated using Method 4.3.2 
and the remaining solid material weighed. This material was then re-suspended in 
acetonitrile to give a concentration of 1 mg/mL-1 and were finally filtered (0.45 µm 
Whatman) prior to analysis.  
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4.3.8.2 Sample analysis using mass spectrometry  
The analysis was carried out using an Agilent 1100 series (Agilent Technologies, Polo 
Alto, CA, USA) chromatographic system equipped with a series binary pump, 
microvacuum degasser, series thermostatted column compartment and variable 
wavelength UV–vis detector. Sample injections were made through an autosampler. 
Data collection and processing were performed using an Agilent ChemStation 
software, version A.10.01 (Agilent Technologies).  
The columns Agilent Zorbax SB-C18 (5 μm particle size, 250 mm × 4.6 mm) (Agilent 
Technologies, Polo Alto, CA, USA) and Waters XTerra® with hybrid particles containing 
both inorganic (silica) and organic (organosiloxane) components (5 μm particle size, 
150 mm × 4.6 mm) (Waters, Milford, MA, USA) were used. Water for chromatography 
was obtained applying the System Simplicity 185 (Millipore, Billerica, MA, USA) 
purification system. The mobile phase and the solution to be injected were degassed 
and vacuum filtered prior to use through a Whatman 0.45 μm nylon membrane filter 
(Whatman International, Maldstone, UK) (Zivanovic et al., 2006). 
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4.3.9 High resolution mass spectrometry (HRMS)  
Whilst LC-MS was used to identify dominant ions within hop extracts, high resolution 
mass spectrometry (HRMS) can be employed to precisely identify compounds by their 
high resolution mass values. HRMS is a double focusing technique meaning peaks of 
compounds can be differentiated by their molecular mass determined accurately to at 
least three decimal places (Reusch 2013). 
On this basis it is possible for HRMS to distinguish precisely between empirical 
formulas with similar nominal masses which would only be determined to 1 decimal 
place in MS as demonstrated in Table 4.1. 
Formula C6H12 C5H8O C4H8N2 
Mass 84.0939 84.0575 84.0688 
 
Table 4. 1 An example of different empirical formulas of compounds separated using HRMS 
with similar molecular masses  Adapted from (Reusch, 2013) 
This makes HRMS a useful tool in natural product compound identification initially as it 
can distinguish between compounds of a similar nominal mass, but also using attached 
software it is able to estimate the elemental composition of potential compounds.  
Sample analysis was undertaken by the EPSRC National Mass Spectrometry Service at 
Swansea University, using an LTQ Orbitrap XL.  
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4.3.10 HPLC  
 
A Waters 2695 liquid chromatograph system comprising of a vacuum degasser, 
quaternary pump, auto- sampler, thermostatic column compartment and photodiode 
array detector was used. The column used was a C18 reversed phase Kingsorb 5 mm 
(150 x 4.6 mm) (Phenomenex Ltd., UK) with a Kingsorb 5 mm C18 (30 x 4.6 mm) guard 
column. Mobile phases consisted of 0.1 % ortho-phosphoric acid in ultra-purified water 
(v/v) (mobile phase A) and 0.1 % (v/v) ortho-phosphoric acid in methanol (mobile 
phase B). The gradient elution was performed as shown in Table 4.2. 
 Mobile Phase (%) 
Time (min) A B 
0 - 5 80 20 
5 - 7 76 24 
7 - 10 76 24 
10 - 20 60 40 
20 - 25 50 50 
25 - 25.5 80 20 
25.5 - 30 80 20 
 
Table 4. 2 Composition of the mobile phase in the gradient elution system between 0 and 30 
min. Mobile phase A consists of 0.1% ortho-phosphoric acid in ultra-purified water and 
mobile phase B 0.1 %(v/v) ortho-phosphoric acid in methanol (eluent B). All gradients were 
linear. 
Post-run time was 5 min. Elution was performed at a solvent flow rate of 1 mL/min-1. 
Detection was accomplished with a diode array detector and chromatograms were 
recorded at 210 and 280 nm. The column was maintained at 30 °C. The sample 
injection volume was 15 μL.  
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4.4 Results 
4.4.1 Identification of optimum polar organic solvent for the extraction 
of hop components.  
The organic solvents (methanol, ethanol and ethyl acetate) were used in the organic 
extraction method as described in (Method 4.3.1).  The total yield from each hop 
following extraction in each solvent is displayed in Figure 4.1. 
 
Figure 4. 1 Comparison of the total yield (g) of hop varieties Citra, Galena, Northdown, 
Cascade and Fuggles following organic solvent extraction (72h) of 20 g of hop material  in 1 
litre (L) of methanol, acetone and ethyl acetate (n=3; ±SD)  
The recoverable yield of hop extracts following extraction was assayed by using five 
hop varieties (Citra (pellets); Galena; Northdown; Cascade and Fuggles) and extracting 
in three solvents (methanol, acetone and ethyl acetate) as described in Method 4.3.1. 
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Upon initial observation of Figure 4.1, it is apparent that the recoverable yield of the 
Citra pellets is increased when compared to the other hop variants. This, as explained 
in Chapter 3, may be due to the relative stability of the hop compounds after the 
pelleting process or the fact that maceration prior to pelleting of the hop materials 
increases the available surface area of the Citra hop variant.  
To determine if there was a statistically significant difference between the total yield 
of extracted hop material after exposure to the organic solvents A one-way ANOVA 
was carried out on the data using SPSS software (Method 2.3). Results indicated a P 
value > 0.05 indicating no statistically significant difference between the extraction 
solvents and total recoverable yield.  
On inspection of the Tukey Post Hoc analysis (Method 2.3) the methanol extraction 
produced an average 7.788 g ± SD 0.556 g yield per 20 g of dry hop material (38.9%) 
compared to acetone (6.708 g ± SD 0.478 (33.4%)) and ethyl acetate (6.986 g ±SD 
0.442 g (34.93%)). It was on this basis that methanol was used in all future extractions. 
  
 
110 
 
4.4.2 Optimisation of a solvent system for the separation of organic 
solvent extracts of hops 
Thin layer chromatography relies on the separation of the crude hop extracts using a 
mobile phase consisting of a solvent system of one or more solvents. Previous 
methods for hop natural product isolation reported several solvent systems (Bhandari, 
1964; Hamburger and Cordell, 1987; Hostettmann et al., 1998) utilising ratios of 
hexane, ethyl acetate, methanol and acetone. In Table 4.3 the ratios of several solvent 
systems used in typical natural product separations are listed; and were trialled for 
separation of crude hop extracts. 
 
 
 
 
 
 
 
 
Table 4. 3 The ratios of organic solvents used for the determination of an optimum solvent 
system for hop extract separation using thin layer chromatography. Each ratio is defined as a 
number (e.g. 1:1:1:1 where each solvent would be in an equal volume) Adapted from 
(Bhandari, 1964; Hamburger and Cordell, 1987; Hostettmann et al., 1998) 
Optimum separation was determined by ultraviolet (UV) light at 365 nm (UVitec, 
Cambridge, UK) and visible light. In the following Figure (4.2) separation of the Citra 
crude hop extract using methanol : ethyl acetate (1:1) (ratio 14) and using ratio 2, 
hexane : ethyl acetate (8:2) are shown.  
 
 
Ratio 
number Hexane Ethyl Acetate Methanol Acetone 
Ratio 1 1 1 1 1 
Ratio 2 8 2 0 0 
Ratio 3 7 3 0 0 
Ratio 4 2 8 0 0 
Ratio 5 3 7 0 0 
Ratio 6 4 6 0 0 
Ratio 7 5 5 0 0 
Ratio 8 0 0 8 2 
Ratio 9 2 4 4 0 
Ratio 10 2 4 0 4 
Ratio 11 6 4 0 0 
Ratio 12 0 1 1 0 
Ratio 13 0 0 1 1 
Ratio 14 1 1 0 0 
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Figure 4. 2 Comparison of Citra crude hop extract (0.1 mg/ml) after separation using TLC and 
the solvent system methanol : ethyl acetate (1:1) (left) and using  hexane : ethyl acetate (8:2) 
(right) 
Solvent system optimisation relied on visual inspection of separated spots on the TLC 
plate. This was evident in Figure 4.2 where ratios 2 and 14 are compared; as it can be 
observed that ratio 14 (methanol : ethyl acetate (1:1) (left) has a much better 
compound resolution than ratio 2 (hexane : ethyl acetate (8:2) on the right.  
The reason for the separation in different solvents is due to the polarity of the 
compounds present. The crude hop extracts used were extracted using the polar 
solvent methanol. It was hypothesised that the majority of compounds present will be 
polar and separation can be enhanced by using a more polar solvent system.  
Based on these results the solvent system methanol : ethyl acetate (1:1) was used for 
all future separations.  
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4.4.3 Thin layer chromatography separation of hop extracts 
TLC analysis of each hop variety (n=50) was completed and the Rf values of isolated 
hop analytes were recorded. In Figure 4.3 hops 1-14, were extracted in methanol and 
separated using TLC. The Rf values of separated spots were then calculated.  
 
Figure 4. 3 The separation of hops 1 -14  using the TLC assay and calculation of Rf values of 
separated hop analytes (representative of 3 separate repeats) 
After separation, six individual spots could be isolated and the Rf values were recorded 
and shown in the following Table (4.4). In several hop samples including sample 6 
separation of the complete extract was challenging. This method however, was a 
precursor to antibacterial testing. Therefore, before further separation techniques 
were used, the antibacterial overlay assay was employed to guide further component 
purification. 
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Hop variety 
Rf value 1 Rf value 2 Rf value 3 Rf value 4 Rf value 5 Rf value 6 
± SD 0.001 ± SD 0.003 ±SD 0.002 ±SD 0.003 ±SD 0.004 ±SD 0.011 
Amarillo 0.02 0.23   0.38 0.62 1.00 
Amarillo Pellets 0.02 0.23   0.38 0.62 1.00 
Apollo 0.02 0.24 0.32 0.38 0.62 1.00 
Aurora 0.02 0.24 0.32 0.38 0.62 0.99 
Boadicea 0.02 0.23 0.32 0.38 0.62 1.00 
Bobek 0.02 0.23 0.32 0.38 0.62 0.99 
Brambling Cross 0.02 0.23 0.32   0.62 1.00 
Cascade 0.02 0.23 0.32 0.38 0.62 1.00 
Cascade Pellets 0.02 0.23 0.32 0.38 0.62 1.00 
Centennial 0.02 0.23 0.32 0.38 0.62 0.99 
Centennial 
Pellets 
0.02 0.24 0.32 0.38 0.62 1.00 
Challenger 0.02 0.23 0.32 0.38 0.62 0.99 
Chinnok 0.02 0.24 0.32 0.38 0.62 1.00 
Chinook Pellets 0.02 0.23 0.32 0.38 0.62 1.00 
Citra 0.02 0.23 0.32 0.38 0.62 0.99 
Citra Pellets 0.02 0.23 0.32 0.38 0.62 0.99 
Colombus 0.02     0.38 0.62   
Delta 0.02   0.32 0.38 0.62   
First Gold 0.02   0.32 0.38 0.62 1.00 
Fuggles 0.02 0.23 0.32 0.38 0.62 1.00 
Fuggles Pellets 0.02 0.23 0.32   0.62 1.00 
Galaxy 0.02 0.23 0.32   0.62 0.99 
Galena 0.02 0.23 0.32 0.38 0.62 0.99 
Glacier 0.02 0.23 0.32 0.38 0.62 0.99 
Goldings 0.02 0.23 0.32 0.38 0.62   
Green Bullet 0.02 0.23 0.32 0.38 0.62 1.00 
Hallertauer  0.02   0.32 0.38 0.62 1.00 
Liberty 0.02   0.32 0.38 0.62 1.00 
Magnum 0.02 0.23   0.38 0.62 0.99 
Motueka Pellets 0.02     0.38 0.62   
Nelson Sauvin 0.02   0.32 0.38 0.62 1.00 
Northdown 0.02   0.32 0.38 0.62 0.99 
Northern Brewer 0.02   0.32 0.38 0.62   
NZ Pacifica 0.02   0.32 0.38 0.62 0.99 
NZ Rakau 0.02 0.24 0.33 0.38 0.62   
Pacific Gem 0.02 0.23   0.38 0.62 0.99 
Pacific Jade 0.02   0.32 0.38 0.62 0.99 
Perle 0.02   0.32 0.38 0.62   
Progress 0.02 0.23   0.38 0.62 1.00 
Savinjski 
Goldings 
0.02 
  
0.32 0.38 0.62 1.00 
Simcoe 0.02   0.32 0.38 0.62   
Sonnet 0.02   0.32 0.38 0.62   
Sorachi Ace 0.02   0.32 0.38 0.62 0.99 
Styrian Goldings 0.02   0.32 0.38 0.62 1.00 
Summer Pellets 0.02   0.32 0.38 0.62   
Summit 0.02 0.23 0.32 0.38 0.62   
Target 0.21 0.23 0.32 0.38 0.62 0.99 
Tettnang 0.21 0.23 0.32 0.38 0.62   
Warrier 0.02 0.23 0.32 0.38 0.62   
Williamette   0.23 0.32 0.38 0.62 0.99 
Table 4. 4 Hop variants (n=50) were separated using the TLC assay and the Rf values 
separated spots (analytes) were recorded. Values are representative of 3 repeats; ± SD as 
described 
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4.4.4 The bacterial overlay assay  
Whilst the TLC method is a useful assay for separation, this study was bioassay guided. 
The bacterial overlay assay is a useful means of determining the inhibitory activity of 
TLC separated hop analytes. Each hop (N=50) was overlaid with M. smegmatis using 
(Method 4.3.4). Inhibitory activity was recorded as clear spots and the corresponding 
Rf value was recorded. Figure 4.4 is a representative example of the bacterial overlay 
assay showing 6 clear areas of inhibition. 
 
Figure 4. 4 The bacterial overlay assay using M. smegmatis against methanol hop extracts of 
hops 1-18 (Table 2.2). Inhibition is highlighted by unstained white spots in contrast to the 
stained (red) background indicating growth of the bacteria. Rf values refer to the Rf of 
separated spots. Figure representative of 3 separate repeats. Positive control Streptomycin 
(6 µg/ml-1) 
Using the bacterial overlay assay, six separate Rf values proved to be inhibitory 
towards the growth of M. smegmatis. Each hop variety was assessed for the presence 
and antibacterial activity of these analytes, and corresponding Rf values of inhibitory 
analytes, are detailed in the following Table (Table 4.5). 
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Hop variety 
Rf value 1 Rf value 2 Rf value 3 Rf value 4 Rf value 5 Rf value 6 
±SD 0.001 ±SD 0.001 ±SD 0.000 ±SD 0.000 ±SD 0.000 ±SD 0.001 
Amarillo 0.02 0.23   0.38 0.62   
Amarillo Pellets 0.02 0.23   0.38 0.62   
Apollo 0.02 0.24 0.32 0.38     
Aurora 0.02   0.32 0.38     
Boadicea 0.02 0.23 0.32 0.38     
Bobek 0.02   0.32 0.38     
Brambling Cross 0.02 0.23 0.32       
Cascade 0.02 0.23 0.32 0.38     
Cascade Pellets 0.02 0.23 0.32 0.38     
Centennial 0.02 0.23 0.32 0.38     
Centennial Pellets 0.02 0.24 0.32 0.38     
Challenger 0.02 0.23 0.32       
Chinnok 0.02 0.24 0.32   0.62   
Chinook Pellets 0.02   0.32   0.62   
Citra 0.02 0.23 0.32 0.38 0.62 0.99 
Citra Pellets 0.02 0.23 0.32 0.38 0.62 0.99 
Colombus 0.02     0.38 0.62   
Delta 0.02   0.32   0.62   
First Gold 0.02   0.32 0.38 0.62 1.00 
Fuggles 0.02 0.23 0.32   0.62 1.00 
Fuggles Pellets 0.02 0.23 0.32   0.62 1.00 
Galaxy 0.02 0.23 0.32   0.62 0.99 
Galena     0.32   0.62   
Glacier 0.02     0.38 0.62   
Goldings 0.02 0.23 0.32 0.38 0.62   
Green Bullet 0.02 0.23     0.62 1.00 
Hallertauer  0.02   0.32 0.38 0.62   
Liberty 0.02   0.32 0.38 0.62   
Magnum 0.02 0.23  0.38 0.62 1.00  
Motueka Pellets 0.02     0.38 0.62   
Nelson Sauvin 0.02   0.32 0.38 0.62   
New Zealand Rakau 0.02 0.24 0.33 0.38 0.62   
Northdown 0.02   0.32 0.38 0.62   
Northern Brewer 0.02   0.32   0.62   
NZ Pacifica 0.02   0.32   0.62   
Pacific Gem 0.02 0.23   0.38     
Pacific Jade 0.02   0.32       
Perle 0.02   0.32 0.38     
Progress 0.02 0.23   0.38 0.62   
Savinjski Goldings 0.02   0.32       
Simcoe 0.02   0.32       
Sonnet 0.02   0.32       
Sorachi Ace 0.02   0.32 0.38   0.99 
Styrian Goldings 0.02         1.00 
Summer Pellets 0.02   0.32 0.38     
Summit 0.02 0.23   0.38     
Target 0.21   0.32     0.99 
Tettnang 0.21   0.32   0.62   
Warrier 0.02     0.38 0.62   
Williamette   0.23 0.32 0.38   0.99 
Table 4. 5 The Rf values of separated hop components in which inhibitory activity in the 
bacterial overlay assay against M. smegmatis 8159 was observed. Rf values are a result of 3 
separate repeats (± SD) 
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Based on the results of the bacterial overlay assay (Table 4.5), it was observed that 
antibacterial activity resided in the six separated spots. However, each antimicrobial 
spot was not present in each hop variant. 
As an example, the hop variant Citra has six separated compounds from the TLC 
analysis and when the bacterial overlay assay is used, each separated component has 
inhibitory activity against M. smegmatis. Compared to the hop variant Galena, which 
upon TLC separation also had six compounds, but only two (Rf 0.32; 0.62) were 
observed to be inhibitory against M. smegmatis.  
In Table 4.6 each separated Rf value is logged alongside the number of instances where 
it was recognised using the TLC method and from the total number of hops (n=50). By 
using the bacterial overlay assay the number of hop extracts that this component was 
shown to be inhibitory against M. smegmatis is also displayed.   
Rf 
Value  
The total number of hop variants 
which contain the component 
 
 (Out of a total of 50) 
The total number of hop 
variants where the 
component is inhibitory 
against M. smegmatis 
The % of hops in 
which component is 
present and has 
inhibitory activity 
0.02 49 48 98 % 
0.23 32 24 75 % 
0.32 43 38 88.4 % 
0.38 47 31 65.9 % 
0.62 50 28 56  % 
0.99 37 11 29.7 % 
Table 4. 6 A summary of the total number of hop varieties that analytes are present and 
antibacterial against M. smegmatis as identified using the bacterial overlay assay (n=3) 
It is reasonable to assume, from the data presented in Table 4.6 that each hop variant 
may have several different components leading to differences in the antibacterial 
activity observed.  
For example, Rf value (0.02) is present in 49 out of 50 hops and 48 varieties, (98 %), of 
these have inhibitory activity against M. smegmatis. However, Rf value 6 (0.99) is 
present in 37 hop varieties but only antibacterial in 11, (29.7 %), of these. 
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 As only six antimicrobial spots were separated from the crude hop extracts, it is 
possible that each spot contains a mixture of compounds or similar polarity which have 
not been fully separated by the TLC assay. However, to determine if there was any link 
between the Rf values and that of known antimicrobial compounds from hops, a 
literature search was undertaken though no related compounds were identified on this 
basis.  
This was not surprising as TLC separation can be highly affected by the use of different 
solvent systems and local conditions (Reed, 2007). There are several reasons why the 
TLC assay is limited. The first is that only a low sample weight can be used. In each 
bacterial overlay assay, each hop variety was assayed at the same weight. In varieties 
which had lower concentrations of antibacterial analytes, the activity could be missed 
leading to negative results and the possibility of missing potential bioactive 
compounds. By using a higher initial sample weight separation of the extract would be 
reduced as the TLC plate would become overloaded.  
However, even though separation is restricted; the bacterial overlay and TLC assay are 
used here solely for primary separation of hop extracts and to ascertain the 
antibacterial activity, so that further separation and purification methods can be 
guided.  
A conclusion gained from using this assay was that several hop compounds may 
contribute to the overall biological activity and these may have similar polarities, 
leading to restricted separation in the TLC assay. For this reason, a further separation 
technique was used: column chromatography. Due to the laborious nature of the 
method and the use of high amounts of solvent, two hop variants were chosen for 
further investigation. The first hop variety, Citra, was chosen because all of the 
components separated using the TLC assay had inhibitory activity against M. 
smegmatis, the highest of all hop extracts tested. The other, Galena, had only two 
inhibitory components. This mirrors the result found in the previous chapter and may 
go some way to explain the different levels of activity.  
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4.4.5 Separation of antimicrobial hop components using silica gel 
column chromatography 
Although the TLC assay is a useful method to separate an initial mixture of compounds, 
it is limited by the amount of sample that can be loaded and therefore collected. For 
this reason column chromatography was employed.  
 
Once all fractions had been collected, Citra (n=126) Galena (n=130) solvent was 
removed by evaporation and each resulting extract was re-suspended in 1 mL of 
methanol. Each fraction was then assayed using the bacterial overlay assay against M. 
smegmatis; fractions with the same Rf values and antibacterial activity were 
combined, the solvent evaporated and extract weighed (Table 4.7). 
   Hop variety  
Galena 5 g of extract Citra 5 g of extract  
Total weight of recovered sample (g) including  
(1-6) 
2.3 g 
(total loss of 2.7 g) 
2.4 g 
( total loss of 2.6 g) 
1) Recovered Weight of Rf 0.02 Recovered (0.015 g) not 
inhibitory  
Recovered (0.035 g) 
Inhibitory 
2) Recovered weight of Rf 0.23 Not recovered Not recovered 
3) Recovered weight of Rf 0.32 Recovered (0.024 g) 
Inhibitory 
Recovered (0.037 g) 
Inhibitory 
4) Recovered weight of Rf 0.38 Recovered (0.023 g) not 
inhibitory 
Recovered (0.048 g) 
Inhibitory  
5) Recovered weight of Rf 0.62 Not recovered Not recovered 
6) Recovered weight of Rf 0.99 Recovered (0.035 g) not 
inhibitory 
Recovered (0.094 g) 
Inhibitory  
Total weight of recovered antibacterial analytes 0.024 g 0.214 g  
 
Table 4. 7 The recovered weight (g) of hop components from the Galena and Citra hop 
variants separated using silica gel column chromatography. Bold text highlights recovered 
antibacterial components as a result of 3 separate repeats 
Several differences between the two hop variants and the recovered antimicrobial 
components were observed in Table 4.8. Firstly component 1 (Rf 0.02) was shown to 
have antibacterial activity against M. smegmatis using the bacterial overlay assay in 
the Citra variant only. This was also observed using the TLC overlay assay previously. 
Another difference was observed in that the recovered weight of component 1 
differed between variant; with 0.035 g recovered from Citra and 0.015 g recovered 
from Galena.  
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In neither case was component two or five recovered. This was perhaps surprising as it 
was shown to be inhibitory in the Citra variant and as the solvent system was the same 
as previously used, suggests that the component had either become ‘stuck’ within the 
column or had eluted with other components.  
Component three was recovered from both varieties and was observed to also still be 
inhibitory towards the growth of M. smegmatis. Again, a difference in the recovered 
weight was noticed between the two variants with Galena (0.024 g) having a 
considerably less yield than Citra (0.037 g).  
As in component one, components four and six were also recovered, but again 
observed inhibitory activity in the Citra variant only, matching that of the TLC overlay 
assay, but also observed a much lower yield of the components in the Galena variant.  
The differences in the recovered weight of the components highlights that there may 
be a difference in compounds separated between the two variants. However, it may 
indicate a problem with the separation and recovery method as Table 4.6 also details 
the total amount of hop extract that was recovered following column chromatography 
separation. Significant loss of extract was experienced in both Citra   (-2.6 g) and 
Galena (-2.7 g) extracts as can be expected in column chromatography. This is due to 
the use of silica as a stationary phase (Moldoveanu and David, 2002),  non-polar 
compounds which are absorbed into the silica should elute first followed by the more 
polar compounds. Depending on the solvent system in use, compounds adsorbed can 
bind to the silica reducing elution and the degree of separation. 
This may be true of analytes 2 and 5, both of which were present in the original TLC 
analysis but where not recovered from the column.  
Overall this method highlights that a high yield of analytes from the TLC analysis can be 
separated using column chromatography, isolated and assayed against bacteria for 
their biological activity. The method also highlights that there is a significant loss of 
yield due to the potential polarity of compounds within the hop extract. It was also 
noticed that no more separation of compounds was observed using this method.  
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4.4.6 Sephadex® LH-20 Column chromatography  
Due to the ability of column chromatography to separate and recover a high yield of 
components from the extract, another form of stationary phase was used: sephadex® 
LH-20. As in the silica column chromatography method the hop variants Citra and 
Galena were again chosen for further separation and identification.   
Once all fractions had been collected Citra (n=103) Galena (n=93). Each fraction was 
assayed for biological activity against M. smegmatis; fractions from the same variant 
with the same Rf values and antibacterial activity were combined, the solvent 
evaporated and extract weighed (Table 4.8). 
 Extract weight and Hop variety  
Galena 5 g of extract Citra 5 g of extract  
Yield of recovered sample (g) 
Loss of sample (g)  
4.99 g 
Total loss – 0.01 g 
4.98 g 
Total loss – 0.02 g 
1) Recovered Weight of Rf 0.02 Recovered (0.141 g) not 
active 
Recovered (0.128 g) 
Active 
2) Recovered weight of Rf 0.23 Recovered (0.103 g) 
Not active 
Recovered (0.116 g) 
Active 
3) Recovered weight of Rf 0.32 Recovered (0.086 g) 
Active 
Recovered (0.095 g) 
Active 
4) Recovered weight of Rf 0.38 Recovered (0.112 g) not 
active 
Recovered (0.134 g) 
Active 
5) Recovered weight of Rf 0.62 Recovered (0.103 g) 
Active  
Recovered (0.126 g) 
Active 
6) Recovered weight of Rf 0.99 Recovered (0.995 g) not 
active 
Recovered (0.136 g) 
Active 
Total weight of Recovered antibacterial 
analytes 
0.189 g  0.735 g 
Table 4. 8 The total weight of recovered hop extracts and the weight of antibacterial hop 
components as determined by the bacterial overlay assay against M. smegmatis following 
separation using Sephadex® LH-20 column chromatography 
By comparing this method to the silica column chromatography, the first difference is 
the overall yield of the hop extracts. In this method 4.99 g of the Galena extract and 
4.98 g of the Citra extract was recovered, compared to 2.3 g and 2.4 g respectively 
using silica gel. The second difference is that all components identified in the TLC 
method were isolated from the column. In comparison using silica gel, analytes 2 and 5 
were not recovered which shows the difference in the nature of the stationary phase.  
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4.5 Mass spectrometry 
Mass spectrometry is a commonly used tool for the identification of natural products 
and has been used for the characterisation of hop extracts (Taylor et al., 2003; Vu et 
al., 2008). 
Each component separated using Sephadex® column chromatography was assayed 
using mass spectrometry to determine the mass of dominant compounds. The masses 
of the compounds detected using mass spectrometry were compared to known 
antimicrobials previously isolated from hops (Table 4.9 below). Known antimicrobial 
compounds (Table 4.9) were discounted from further investigation. 
 
Table 4. 9 molecular weight (MW; MW+H₂; MW+Na; 2MW+Na) and chemical formula of 
known compounds from hops 
Chemical formula search was conducted using the NCBI chemical search engine (NCBI, 
2014). 
Compound 
M 
(molecular Weight) 
M + H
+ M + Na
+ 
2M + Na
+ 
Formula 
Adhumulone 579.003 580.003 602.003 1181.006 C₂₁H₃₀O₅ 
Adlupulone 428.290 429.290 451.290 879.580 C₂₇H₄₀O₄ 
Co-humulone 348.43 349.433 371.433 719.866 C₂₀H₂₈O₅ 
Co-lupulone 400.550 401.550 423.550 824.101 C₂₅H₃O₄ 
Farnesol 222.366 223.366 245.366 467.732 C₂₅H₂₆O 
Geraniol 154.249 155.249 177.249 331.498 C₁₀H₁₈O 
Geranyl acetate 196.286 197.286 219.286 415.572 C₁₂H₂₀O 
Humulone 362.459 363.459 385.459 747.919 C₂₁H₃₀O₅ 
Isocohumulone 332.433 333.433 355.433 687.867 C₂₀H₂₈O₄ 
Limonene 136.234 137.234 159.234 295.468 C₁₀H₁₆ 
Linalool 154.249 155.249 177.249 331.498 C₁₀H₁₈O 
Lupulone 414.577 415.577 437.577 852.155 C₂₆H₃₈O₄ 
Myrcene 136.234 137.234 159.234 295.468 C₁₀H₁₆ 
Trans-2-nonenal 140.222 141.222 163.222 303.445 C₉H₁₆O 
Xanthohumol 354.396 355.396 377.396 731.792 C₂₁H₂₂O₅ 
α-humulene 204.351 205.351 227.351 431.702 C₁₅H₂₄ 
β-carotene 536.872 537.872 559.872 1096.745 C₄₀H₅₆ 
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4.5.1 Mass spectrum analysis of components isolated from Rf 6  
The Citra hop extract was separated using Sephadex®® column chromatography and 
the component identified as Rf 6 was isolated, the mass spectrum of this the 
component is displayed in Figure 4.5. 
 
Figure 4. 5  Mass spectrum of component 6 extracted from Citra hop variant using column 
chromatography 
The mass spectra of component presented a baseline peak with an m/z of 385.2, with 
a second lower intensity peak with an m/z of 747.2. Using the information gained from 
the literature search, it became apparent that this molecule was humulone with the 
peak at m/z 385.2 matching the MW+ Na from Table 4.10, the second peak with an 
m/z of 747.2 was determined as the 2M+Na species of this compound.  
The Galena hop extract was also extracted and separated using Sephadex®® column 
chromatography and the MS of the component isolated is displayed in the following 
Figure (4.6)   
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Figure 4. 6 Mass spectrum of Rf 6 extracted from Galena hop variant using column 
chromatography 
From the mass spectra observed in Figure 4.6, it is possible to note the presence of a 
peak with an m/z 385.2, which was previously identified from the Citra extract as 
humulone. It is also noticeable that there are multiple secondary peaks within the 
fraction (m/z 273.2; 283.3; 768.0; 1454 and 2359.6). 
It is hypothesised that the presence of these compounds has an antagonistic effect on 
the antibacterial activity of humulone. As the dominant compound humulone has been 
previously shown to be antibacterial and is well described in literature no further 
separation and purification was undertaken on this component (Erdmann, 1951; Stavri 
et al., 2004) 
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4.5.2 Mass spectrum analysis of components isolated from Rf 5 
Component Rf 5 was separated from both the Citra and Galena extracts using 
Sephadex® column chromatography, and each extract was weighed to 1 mg/mL-1 and 
suspended in HPLC grade methanol. In Figure 4.7 the resulting spectra is displayed.  
 
Figure 4. 7 Mass spectrum of Rf value 0.62 extracted from Citra hop variant using column 
chromatography and analysed using mass spectrometry (representative of 2 repeats) 
The mass spectra of Citra has one baseline peak at m/z 379.2 Comparing the mass to 
published literature, this peak corresponds with the research carried out by (García-
Villalba et al., 2006) who identified this mass as an oxidised derivative of humulone 
using a similar technique. Humulone and its oxidised derivatives have been shown to 
be inhibitory towards the growth of bacteria (Cornelison, 2008). The analysis was also 
carried out using the Galena variety as shown in the following Figure (Figure. 4.8).  
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Figure 4. 8. Mass spectrum of Rf 0.62 extracted from galena hop variant using column 
chromatography and analysed using mass spectrometry (representative of 2 repeats) 
After initial observation, it is possible to notice that the Galena extract, like the Citra 
extract has the oxidised humulone derivative at m/z 379.2. Several other peaks were 
also observed at m/z 569.4; 706.5; 708.5 and 871.  
The bacterial overlay assay indicated that this component was inhibitory towards the 
growth of M. smegmatis in extracts from both the Citra and Galena varieties. Further 
investigation using mass spectrometry on this component reveals a dominant 
compound which can be identified using current literature as an oxidised humulone 
derivative which has been previously identified as antibacterial (Cornelison, 2008). 
Therefore, the inhibitory activity can be linked to this compound and no further 
separation or isolation procedures were undertaken. 
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4.5.3 Mass spectrum analysis of components isolated from Rf 4   
Component four (Rf 0.38) was also separated from the both the Citra and Galena hop 
extracts using Sephadex® column chromatography and by using the bacterial overlay 
assay was shown to be inhibitory towards the growth of M. smegmatis in the Citra 
variant only. In Figure 4.9 the mass spectra of component three from the Citra variant 
is displayed. 
 
Figure 4. 9 Mass spectrum of Rf value 0.38 extracted from Citra hop variant using column 
chromatography 
From the initial mass spectra several peaks were observed; the first with an m/z of 
401; corresponds using Table 4.10 with the compound co-lupulone. Co-lupulone 
(C₂₅H₃₆O₄) is another example of a bitter acid related to lupulone, and differs in the 
number of carbonyls; co-lupulone is a well-researched bioactive compound commonly 
isolated from hops (Van Cleemput et al., 2009a) 
Further investigation reveals that lupulone (m/z 415.1) can also be identified from the 
Citra hop extract. Based on the fact that both the lupulone and co-lupulone are the 
most dominant compounds, it can be assumed that the majority of antimicrobial 
activity can be associated with these compounds. Another peak identified (m/z 537.2) 
is associated with the pigment β-carotene and is a common pigment found within the 
majority of plant products (Vu et al., 2008) and has not been reported as antimicrobial.  
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The component 3 (Rf 0.38) was extracted from the Galena variety was also assayed 
using mass spectrometry and the mass spectrum is displayed in Figure 4.10.  
 
Figure 4. 10 Mass spectrum of Rf value 0.38 extracted from Galena hop variant using column 
chromatography 
As can be seen from the mass spectra of component 0.383, there is a peak at 414.3 
which was also previously identified in the Citra extract. A peak with an m/z of 301.1 
was also observed but after investigation was shown to be a common contaminant 
within the mass spectrum. Peaks with an m/z of 659.3 and m/z 768.0 were also 
observed in the mass spectrum, although due to the lack of inhibitory activity against 
M. smegmatis no further investigation was undertaken. In conclusion, the inhibitory 
activity observed in the bacterial overlay assay by the Citra extract with an Rf of 0.383 
can be associated with the presence of both lupulone and co-lupulone, this activity can 
be further associated with previous research (Erdmann, 1951; Siragusa et al., 2008). 
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4.5.4 Mass spectrum analysis of components isolated from Rf 3 
Both Galena and Citra hop extracts were separated using Sephadex®® column 
chromatography and the analytes at Rf 0.32 present in both the Citra and Galena 
variants were observed to be inhibitory to the growth of M. smegmatis.  In Figure 4.11 
the mass spectrum of the Citra extract is displayed. 
 
Figure 4. 11 Mass spectrum of Rf value 0.32 extracted from the Citra hop variant using 
column chromatography 
Several peaks were observed in the mass spectrum analysis, the first (m/z 301.0) can 
be identified as a contaminant which is commonly observed in mass spectrometry and 
is not a concern. 
The baseline peaks (m/z 439.0 and m/z 413.1) were observed and after a literature 
search compound m/z 413.1 was identified as the oxidised lupulone derivative, 
adlupulone as previously described by (Ceslova et al., 2009) . The second component 
with an m/z 439 can be identified as a fragment of the m/z 416.1, which identified by 
(Ceslova et al., 2009) is also an oxidised derivative of lupulone. Another peak at m/z 
273.0 has also been previously identified as an epicatechin a catechin isomer (Shui and 
Leong, 2004). 
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The Galena extract which also showed inhibitory activity at Rf value 0.32 was also 
assayed using mass spectrometry and the mass spectrum is displayed in Figure 4.12. 
 
Figure 4. 12 Mass spectrum of Rf value 0.32 extracted from the galena hop variant using 
column chromatography 
Again fragments in the instrument are observed at m/z 301.0 and are ignored from the 
investigation. Several peaks are observed from the Galena extract which are similar to 
the Citra extract namely m/z 273.0; previously identified as catechin; m/z 413.1; 439.0 
which were also previously identified as the lupulone derivative adlupulone.  
In conclusion, component 3 (Rf 0.32) separated from both the Citra and Galena hop 
extracts exhibited inhibitory activity against M. smegmatis in the bacterial overlay 
assay. Mass spectrum analysis revealed 3 dominant compounds with a m/z of 439.0; 
413.1 and 273.0, relevant literature was searched and it was found that these m/z 
corresponded to compounds lupulone, adlupulone and epicatechin; all of which have 
previously been shown as antibacterial. Therefore no further identification was 
undertaken on this extract.  
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4.5.5 Mass spectrum analysis of components isolated from Rf 2 
Component two (Rf 0.23) was also separated from the both the Citra and Galena hop 
extracts using Sephadex® column chromatography and by using the bacterial overlay 
assay  the extract was  shown to be inhibitory towards the growth of M. smegmatis in 
the Citra variety only. In Figure 4.13 the mass spectra of the Citra extract is displayed. 
 
 
Figure 4. 13 Mass spectrum of Rf value 0.23 extracted from the Citra hop variant using 
column chromatography 
 
From the mass spectra two peaks were identified (m/z 413.3 and m/z 768.0). Previous 
identification showed that peak m/z 413.3 was lupulone and whilst being present in 
the previous fraction, the compound has eluted from the column within this fraction 
also. Another peak at m/z 768.0 and 1454.9 was discounted from further studies as it 
was shown to be a common plasticiser.  
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The component from the Galena variety, although not inhibitory towards the growth 
of M. smegmatis was also assayed using mass spectrometry and the mass spectrum is 
displayed below in Figure 4.14. 
 
Figure 4. 14 Mass spectrum of Rf value 0.23 extracted from the Galena hop variant using 
column chromatography 
 
The mass spectra of the Galena variety showed that there was an absence of m/z 
413.3. Due to the lack of antibacterial activity from the fraction no further separation 
of the extract was undertaken.  
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4.5.6 Mass spectrum analysis of components isolated from Rf 1 
Component one (Rf 0.02) was also separated from the both the Citra and Galena hop 
extracts using Sephadex® column chromatography and by using the bacterial overlay 
assay was shown to be inhibitory towards the growth of M. smegmatis in the Citra 
variety only. In Figure 4.15 the mass spectrum of the Citra extract is displayed. 
 
Figure 4. 15 Mass spectrum of Rf value 0.02 extracted from the Citra hop variant 
using column chromatography 
 
This component was inhibitory towards the growth of M. smegmatis on the baseline of 
the bacterial overlay assay. This suggests that this component may contain compounds 
which are weakly non-polar and thus would not elute through the TLC plate.  
Mass spectrometry analysis shown in Figure 4.15 above reveals the presence of 
lupulone (m/z 413.1),  
The second peak of interest m/z 439.0 has been previously identified as adlupulone 
and was therefore not subject to any further investigation. 
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It was observed that there was a high amount of corresponding peaks within the 
mixture. It may be that these components are of a low polarity, meaning that 
separation using the current solvent system is not possible. Whilst it may be possible 
to further investigate this sample for any other antimicrobial compounds, it was 
hypothesised that the previously identified compounds were responsible for any 
antimicrobial activity.  
Although component one isolated from the Galena extract did not exhibit any 
inhibitory activity, it was also analysed using mass spectrometry and the mass 
spectrum is displayed in the following Figure (4.16).  
 
Figure 4. 16 Mass spectrum of Rf value 0.02 extracted from the galena hop variant 
using column chromatography 
The mass spectrum of Rf 0.02 from the Galena extract also has a mass with an m/z of 
413). The component also does not have a peak at m/z 439.0 which corresponded to 
adlupulone. These differences may allude to the variation in activity between the two 
varieties. It was also observed as in the Citra variant that that there were also a 
number of peaks. However, as this component did not produce any inhibitory activity 
towards the growth of M. smegmatis no further isolation techniques were undertaken. 
These compounds were also identified in the Citra component this was also another 
reason why no further separation was undertaken.  
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4.6 High Resolution Mass Spectrometry (HRMS)  
High resolution mass spectrometry was used to determine more precisely the 
structure of any identified compounds and to help locate the predominant 
antimicrobial polyphenol xanthohumol (XN). It is known that the compound has a 
molecular weight of 354.39 and a chemical formula of C₂₁H₂₂O₅. By combining 
separated active extracts of both the Galena and Citra extracts and then analysing at 
molecular weights between m/z 200 and 400 it was hypothesised that XN could be 
identified. 
In the following Figure 4.17 the HR-MS of the crude Citra hop extract is displayed with 
emphasis on the m/z between 200 and 500.  
 
Figure 4. 17 High resolution mass spectra of the crude Citra hop extract 
It can be initially observed from Figure 4.17 that the baseline compound has an m/z at 
210.1274. Upon investigation this was reported to be a contaminant within the mass 
spectra and was therefore discounted from any further investigation.  
The second compound of interest (m/z 463.1719) had not been previously observed in 
any of the previous mass spectras’. To further identify the compound, a more intense 
mass spectra is displayed in the following Figure 4.18.  
135 
 
 
Figure 4. 18 High Resolution Mass Spectra of compound m/z 463.1719 isolated from the 
antibacterial Citra crude hop extract 
By using high resolution mass spectrometry it is possible to use the instrument to 
estimate the theoretical mass and potential elemental composition of compounds 
isolated to an accuracy of ± 3 ppm. By estimating the chemical composition of the 
compounds, further investigations would be performed using databases such as 
SciFinder to try and match the compound with those previously identified.   
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In Figure 4.19 the estimations of the chemical formula of this compound are displayed 
 
Figure 4. 19 Estimated elemental composition report (± 3 ppm) of m/z 463.1719 isolated 
from the Citra crude hop extract provided by the high resolution mass spectrum. Red arrow 
indicates most likely compound composition 
The elemental composition report of m/z 463.1719 highlights 25 possible elemental 
compositions for m/z 463, upon observation it was apparent that all but one of these 
included a nitrogen compound. The presence of nitrogen indicates alkaloid 
compounds, of which according to current literature, none have been isolated from 
hops. After searching relevant literature and an advanced search on SciFinder® 
(www.scifinder.cas.org) no matching chemical entities were found. Therefore on this 
basis, a novel chemical entity isolated from the antibacterial Citra crude hop extract 
with the chemical formula C₂₅ H₂₈ O₇ m/z 440 is presented.  
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4.7 UPLC-HR-MS determination of compounds isolated from the 
Citra crude hop extract 
4.7.1 UPLC separation of crude Citra hop extract 
Ultra pressure liquid chromatography (UPLC) coupled to HR-MS was used to further 
prove the methodology. In the following Figure (4.20) the chromatogram of the Citra 
crude hop extract is displayed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 20 UPLC chromatogram of Citra crude hop extract with selected peaks circled in  
red; image is representative of two separate repeats 
Reviewing the chromatogram and comparing the peak molecular weight to that 
reviewed in Table (4.10) three peaks were apparent (m/z 353; 361 and 414).  
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4.7.2 Elemental composition of m/z 361 
Firstlty the peak (m/z 361.200) was reviewed by using the attached high resolution 
mass spectrometer and was able to identify the chemical composition (± 3 ppm) in 
negative ion absorption as shown in the following Figure 4.25.  
 
 
 
 
 
 
 
 
 
 
Figure 4. 21 UPLC HR-MS chromatogram and elemental composition report of m/z 361.200 
isolated from the crude Citra hop extract 
Figure 4.21 details 3 possible chemical compositions for the compound isolated within 
UPLC. The first with the lowest variation had a calculated m/z 361.2015 and a formula 
of C₂₁ H₂₉ O₅. This compound can therefore be positively identified as humulone (hop 
alpha acid) which has an m/z of 362 and a formula of C₂₁ H₃₀ O₅. One hydrogen is 
missing from the isolated compound due to the negative ion absorption.  
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4.7.3 Elemental composition of m/z 414 
The next peak isolated had a m/z of 414.981 (ES+), after observing the data collected in 
Table 4.10 this mass matched that of lupulone. In the following Figure 4.22 the 
elemental composition report of the isolated compound. 
 
 
  
 
 
 
 
 
 
 
Figure 4. 22 UPLC HR-MS chromatogram and elemental composition report of m/z 414.981 
isolated from the crude Citra hop extract 
The elemental composition report of m/z 414.9809 identified four possible elemental 
compositions. The most probable match was hypothesised to be m/z 414.9879 with 
the elemental composition of C₂₅ H₃ O₇  which can be positively identified as lupulone 
(hop beta acid). 
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Finally a third peak was also identified with an m/z 353.134. This peak was of particular 
interest as the mass matched that of xanthohumol as previously identified in Table 
4.10. The chromatogram and elemental composition report of this component is 
displayed in the following Figure (4.23). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 23 UPLC HR-MS chromatogram and elemental composition report of m/z 353.1389 
isolated from the crude Citra hop extract 
The elemental composition report of m/z 353.134 gives one possible formula: C₂₁H₂₁O₅ 
with a calculated mass of m/z 353.1389 (ES-). This matches the chemical formula for 
xanthohumol as previously described.  
Previous analyses did not locate the polyphenol xanthohumol. It is hypothesised that 
this compound did not elute up the TLC plate remaining in the mixture on the baseline 
and was masked by other compounds. Another possibility is that the compound 
concentration when separated using TLC is diluted therefore preventing its ability to 
inhibit the growth of the bacteria. It may also be the case that when separated based 
on the polarity an antagonistic effect is seen preventing any antimicrobial activity 
being observed from the compound.  
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4.8 Discussion 
The use of plants in their crude form or purified extracts for the exploitation of their 
healing powers is an ancient theory (Cowan, 1999). It is therefore unsurprising that in 
the present day nearly 50 % of all pharmaceuticals worldwide have originated from 
plant derived sources (Beutler, 2009; Cragg and Newman, 2013). 
However, since the development of antibacterials in the 1950’s the use of plant 
derived natural products to treat bacterial infections have declined. Ever since the 
development of antimicrobials there have been incidences with bacterial resistance as 
a consequence there is a lack of new antibiotics and multidrug and extensively drug 
resistant organisms are becoming more apparent.  
The main aim of this chapter was to build on the information gained in Chapter 4 and 
determine the chemical constituents of the antimicrobial hop extracts. A suitable 
volatile organic solvent was firstly identified. It is true that some antimicrobial 
constituents may be present in the non-polar extract. However, as antimicrobial 
activity has been identified in beer, a polar extraction method was employed.  
Three solvents were trialled and the total yield of hop extract of five hop variants 
following 72 hour extraction was investigated. No statistically significant difference 
between the level of total yield (g) of hop material between the solvents used was 
observed. Previous research by (Verzele and Keukeleire, 2013) identified that 
methanol has been traditionally used for the extraction of hop alpha and beta acids, so 
therefore it was on this basis that methanol was used in all future extractions.  
Upon initial observation of Figure 4.1 it appeared that the Citra hop pellet had a higher 
yield than the other hop variants when extracted in methanol, This, as previously 
explained in Chapter 3, may be due to the relative stability of the hop compounds after 
the pelleting process or the fact that maceration prior to pelleting of the hop materials 
increases the available surface area of the Citra hop variant. 
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The next stage of the extraction process was to separate the hop extracts on a TLC 
plate, several solvent systems were trialled to give an optimum separation. The solvent 
systems generated were as a result of a literature search concerning natural product 
separation and isolation. A solvent system of a 1:1 ratio of methanol : ethyl acetate 
was finally used. This predominantly polar solvent mix was based on the principle that 
the majority of the extract was from the polar fraction and therefore produced the 
most optimum separation.  
Each hop variant (n=50) was then extracted in methanol and separated using TLC. It 
was observed from this method that 6 individual spots could be visualised. Several 
methods of visualisation (UV, Vanillin staining, etc) were also trialled but it was found 
that due to the pigments within the hops each spot could be observed by eye (data not 
shown). By calculating the Rf values of each separated spot it was possible to locate 
the spots at a later date if further analysed.  
Upon analysis there were a total of 6 clear spots separated. However, in each hop 
variant there was a mixture of present and absent spots. To determine if the presence 
or absence of these spots had a positive effect on the antimicrobial activity employed a 
bacterial overlay assay.  
The bacterial overlay assay employed was originally described by Fleming, 1942, and 
was adapted for use within this report. Briefly, a bacterial film suspended in growth 
media is applied to the surface of a solvent free TLC plate and is then incubated under 
high humidity at 37 °C. Bacteria can then be stained and metabolising cells visualised 
as a red colour against areas of no growth (clear). As a control, in each case a TLC plate 
which had not been used for separation of hop components was also inoculated and 
examined. A TLC plate which had been exposed to the solvent system and dried in the 
same way as the test plates was also used. In each case bacterial growth was observed.  
It was interesting to observe that bacterial inhibition resided in the six spots separated 
in the initial TLC. However, this was not the same for every spot of equal Rf value, 
indeed comparing the most inhibitory hop variant Citra (6 antimicrobial spots) to the 
least active hop variant Galena (2 antibacterial spots) several differences could be 
noticed.  
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The most common (98% of variants) inhibitory spot was found to be close to the 
baseline of the TLC plate (Rf 0.02) and was hypothesised to contain a mixture of hop 
components of mixed polarity so therefore would not elute along the TLC plate using 
the mobile phase employed. It may also be the case that due to the number of 
components which may have been extracted, optimum separation was not possible 
using this method. In comparison, the least common (11 %) inhibitory spot was found 
to be at the solvent front of the TLC separation (Rf 0.99) and it was hypothesised that 
these compounds were the most polar and so therefore were readily dissolved into the 
solvent system. 
To try and identify potential components of the antibacterial spots and to ascertain if 
there were differences in the chemical composition of the Galena and Citra hop 
variants, both variants were further separated using column chromatography. It was 
found that by using a stationary phase of silica gel a high amount of extract was lost 
within the column, possibly due to the compounds becoming ‘stuck’. Therefore 
another form of stationary phase, Sephadex®, which separates compounds based on 
size was used and it was found that a much higher yield was achieved.  
Upon fractionation of the hop extract, each fraction was further analysed using TLC 
and the solvent system previously identified. Post further TLC analysis each fraction 
was again assessed for inhibitory activity against M. smegmatis and the Rf values of 
inhibitory spots calculated. On no occasion was a new spot identified so therefore 
fractions with the same antimicrobial Rf value spots were combined, dried and 
weighed.  
There were considerable differences in the weights of recovered components between 
the hop variants. This was the same for both non-inhibitory and inhibitory 
components. Reviewing the total yield from the extraction it is clear that these 
components were not lost within the column. It is hypothesised that the differences 
could be due to the differences in the chemical constituents of each component.  
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To help identify any known components of each fraction, mass spectrometry was used, 
as Citra had so far been the most inhibitory hop variant and Galena the least, these 
were chosen for further investigation. A literature search was conducted to identify 
the molecular weights and empirical formulas of known antimicrobial compounds from 
hops and was adjusted to show the common species detected in the mass 
spectrometer M, M+H, M+Na and 2M+Na..   
Each separated spot from the hop variants Citra and Galena was isolated using column 
chromatography and analysed using mass spectrometry.  
Component 6 (Rf 0.99) of the Citra hop variant was first investigated, and it was 
possible to hypothesise based on the molecular weight, that the compound humulone 
was present. This was also the case for the Galena extract. This compound was 
thought to be present in both hop variants antibacterial activity was only observed in 
the Citra variant. Upon further investigation the spectra from the Galena extract 
recognised a range of other peaks, it was hypothesised that the presence of these 
peaks, ultimately other compounds, may have an antagonistic effect on the 
antibacterial activity of humulone. It may also be the case that the concentration of 
this compound in the Galena variety may be lower than the Citra variant.  
The next component investigated, 5, had an Rf value of 0.62 and it was found based on 
the mass of 379.2 that an oxidised derivative of humulone was present in the Citra 
variant. Humulone and its oxidised derivatives are known to be antimicrobial 
(Cornelison, 2008; García-Villalba et al., 2006). Component 5 was antimicrobial when 
isolated from the Galena variant and the same molecular weight peak was also 
identified from this extract. It may be that as this was the most dominant peak that the 
presence of this compound was responsible for the antibacterial activity of this spot.  
Component 4 (Rf 0.38) was also investigated and several peaks were observed, notably 
from the Citra extract the peaks matched the molecular weights of the known 
antimicrobial compounds; lupulone and co-lupulone (Van Cleemput et al., 2009a). 
Based on the fact that both lupulone and co-lupulone are the most predominant 
compounds it can be assumed that, at least, the majority of antimicrobial activity can 
be associated with the presence of these compounds. 
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Interestingly as was the case with humulone, a compound with a mass matching 
lupulone was also detected in the Galena hop extract but no inhibitory activity was 
observed against M. smegmatis. Other peaks were observed with a molecular weight 
of m/z 659 and 768, but as there was no inhibitory activity, no further identification or 
separation procedures were undertaken. In conclusion the inhibitory activity observed 
in the bacterial overlay assay by the Citra extract with an Rf of 0.38 can be associated 
with the presence of both lupulone and co-lupulone, this activity can be further 
associated with previous research (Erdmann, 1951; Siragusa et al., 2008) 
Component 3 (Rf 0.32) was also analysed and from the Citra hop variant and the 
relevant masses were matched to a hop beta acid adlupulone which has been 
previously described as antibacterial (Ceslova et al., 2009); Reed, 2007). Another peak 
at m/z 273.0 was matched to the mass of epicatechin. Catechin is a secondary plant 
metabolite belonging to the group flavan-3-ol, part of the natural family of flavonoids, 
found in many plant species, it has been described as an antioxidant and has been 
shown to be antibacterial (Bhandari, 1964; Ceslova et al., 2009; Stevens and Page, 
2004). Catechin typically has two benzene rings and a dihydropyran heterocycle ring 
with an hydroxyl group (Figure 4.24). This configuration allows for two chiral centres 
on the molecule which can produce four diasteroisomers; two in trans configuration 
(catechin) and two in cis configuration (epicatechin) (Ceslova et al., 2009).  
 
 
 
 
 
Figure 4. 24 the structure of epicatechin isolated from component 3 present in both Citra and 
Galena hop extracts 
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Several peaks are observed from the Galena extract which are similar to the Citra 
extract namely m/z 273.0: previously identified as catechin; m/z 413.1; 439.0 which 
were also previously identified as the lupulone derivative adlupulone. In conclusion, 
component 3 (Rf 0.32) separated from both the Citra and Galena hop extracts 
exhibited inhibitory activity against M. smegmatis in the bacterial overlay assay. Mass 
spectrum analysis revealed 3 dominant compounds with a m/z of 439.0; 413.1 and 
273.0, relevant literature was searched and it was found that these m/z corresponded 
to compounds lupulone, adlupulone and epicatechin; all of which have previously been 
shown as antibacterial. Therefore no further identification was undertaken on this 
extract.  
Component 2 (Rf 0.23) was also separated from the both the Citra and Galena hop 
extracts using Sephadex® column chromatography and by using the bacterial overlay 
assay  the extract was  shown to be inhibitory towards the growth of M. smegmatis in 
the Citra variety only. From the mass spectra 2 peaks were identified (m/z 413.3 and 
m/z 768.0). Previous identification showed that peak m/z 413.3 was lupulone and 
whilst being present in the previous fraction, the compound has eluted from the 
column within this fraction also. This is a hazard of TLC separation as a high starting 
weight of compound will elute throughout the whole plate possibly masking other 
compounds present (Reed, 2007). 
Mass spectrum analysis was also carried out on the Galena extract, although as no 
inhibitory activity was observed, no further investigation was carried out. It was also 
noticed that this fraction did not contain any peaks with a molecular weight which 
matched that of previously identified antimicrobial hop compounds.  
The final component, component 1, was isolated from the baseline of the TLC 
separation (Rf 0.02) and was hypothesised to contain the largest amount of 
compounds due to the lack of separation of non-polar compounds. Analysis revealed 
peaks with matching molecular weights to lupulone. Lupulone has been reported as 
weakly non-polar (Van Cleemput et al.,2009a) and therefore would be able to elute in 
mixtures with other compounds of mixed polarity (Hamburger and Cordell, 1987) 
which may explain why lupulone and related compounds are found at multiple points 
on the plate. 
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It was observed that there was a high amount of corresponding peaks within the 
mixture. It may be that these components are of a low polarity, meaning that 
separation using the current solvent system is not possible. Whilst it may be possible 
to further investigate this sample for any other antimicrobial compounds, it was 
hypothesised that the previously identified compounds were responsible for any 
antimicrobial activity.  
The mass spectrum of Rf 0.016 from the Galena extract also has a mass with an m/z of 
413 which matched that of lupulone. The component also does not have a peak at m/z 
439.0 which corresponded to adlupulone. These differences may allude to the 
variation in activity between the two varieties. It was also observed as in the Citra 
variant that that there were also a number of peaks. However as this component did 
not produce any inhibitory activity towards the growth of M. smegmatis no further 
isolation techniques were undertaken.  
It may be the case that several other compounds in each component are also 
inhibitory towards the growth of the bacteria but are outside the limits of detection 
using the relatively crude isolation technique. It is hypothesised that several 
compounds within each component are antibacterial and potentially act in a 
synergistic manner. When these compounds are separated using the TLC method and 
or column chromatography the synergistic activity is reduced which may lead to 
antagonistic combinations; or, that upon separation the relative concentration of 
these compounds is reduced so that no inhibitory activity is observed.  
This may be the case for xanthohumol (XN). Xanthohumol is widely regarded as the 
most bioactive compound found within hops (Acworth et al., 2012; Ceh et al., 2007; 
Narvaez et al., 2013; Stevens and Page, 2004). However using the developed extraction 
method it was not apparently separated from the crude mixture. To try and identify 
this component and any other potential compounds, the entire bioactive Citra hop 
extract was isolated and analysed using high resolution mass spectrometry. As 
mentioned in the introduction, HR-MS is able to estimate to ± 3 ppm the elemental 
composition of separate peaks within a mixture. Interestingly, xanthohumol was not 
isolated using this method. However, a peak was observed at a mass of m/z 440 with 
an estimated elemental composition of C₂₅ H₂₈ C₇.   
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This peak was analysed further by searching SciFinder for corresponding compounds. 
In total 458 compounds with the same mass and formula were found from the 
database, which contains over 60 million (Ruddigkeit et al., 2012). Further refining of 
the results by search for “hops” revealed no corresponding literature. By searching 
“Humulus lupulus”, 2 corresponding articles were identified (Hideo, 2007; Schaefer et 
al., 2005), but were not related to this compound in any way. On this basis the novel 
compound C₂₅ H₂₈ C₇ is presented as part of the antimycobacterial fraction of the Citra 
hop extract. This is an area that will require more investigation to secure a precise 
characterisation, further research would be required.  
To further confirm the presence of xanthohumol ultra-high pressure liquid 
chromatography coupled to high resolution mass spectrometry was used. The initial 
separation revealed three peaks of interest (m/z 353; 361 and 414) which by using HR-
MS were hypothesised to be humulone, lupulone and xanthohumol. This result shows 
that the initial biological assay and subsequent determination was able to successfully 
isolate both the alpha and beta acids; but was unable to separate xanthohumol.  
This may be due to several reasons: the concentration of XN is reduced upon 
separation and therefore is not antibacterial when tested; extraction of the compound 
in methanol or other volatile solvents leads to an oxidation reaction of the compound, 
this would potentially lead to compound to form a polymer effectively taking it outside 
the limits of the chosen mass spectra limits. It may also be the case as previously 
mentioned that when separated the compound is in contact with antagonistic 
compounds preventing antibacterial activity.  
This chapter therefore highlights the main difficulties of natural product separation 
and identification. An array of compounds can make separation difficult even when 
separation is based on polarity or molecular size. If separation is achieved, another 
problem that can arise is achieving a sufficient compound weight for identification 
purposes.  
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This chapter has successfully demonstrated that it is possible to separate each of the 
50 hop variants and further confirmed that the Citra hop extract is the inhibitoriest 
whilst the Galena variant is the least inhibitory. Furthermore differences between 
these two variants have been identified and this has preluded to a hypothesis on the 
differences in antibacterial activity.  
A novel compound which was associated with the antibacterial fraction of the crude 
Citra hop extract was isolated. This is a promising result and will need future 
investigation to purify and further characterise. It may be possible that alone this 
compound does not have any inhibitory activity but when combined with other 
separated hop compounds it may exhibit synergism.  
Finally the principle of the methods used has been proven by isolating the most 
common antimicrobial compounds; humulone, lupulone and xanthohumol from the 
crude Citra hop extract using ultra pressure liquid chromatography.  
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Chapter 5 
 
 
 
 
 
Synergistic Activity between Hop Extracts and Antibiotics 
and their Mode of Action 
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5.0 Synergistic activity between hop extracts and antibiotics and 
their mode of action 
5.1 Introduction 
The first antibiotic that was discovered to be inhibitory towards the growth of 
Mycobacterium tuberculosis was streptomycin.  It was discovered in 1943 by Dr. Albert 
Schatz and is considered one of the top 20 discoveries of the 20th century (Pringle, 
2013). Its mode of action is to inhibit protein synthesis. It functions by binding to the 
16s rRNA of the 30S subunit of the bacterial ribosome thus preventing the binding of 
formyl-methionyl tRNA to the 30S subunit  (Tanoira et al., 2014). Although a successful 
inhibitor of the pathogen the, toxicity to the antibiotic is well described and has been 
acknowledged since 1947, as has the emergence of bacterial resistance (McDermott, 
1947; Avent et al., 2011; Siddiqui and Qureshi, 2014; Tanoira et al., 2014).  
Antibiotic resistance can be defined as the ability of an organism to survive following  
exposure to one or more antibiotics. Organisms resistant to multiple antibiotics are 
considered multidrug resistant  (MDR) (Conly, 1998; O’Brien et al., 2014).  
The World Health Organisation (WHO) periodically completes global surveillance 
surveys on the level of M. tuberculosis to antibiotics and it is estimated that out of 100 
clinical isolates of M. tuberculosis at least 23.8 % will be resistant to streptomycin 
(Cohn et al., 1997; Dooley et al., 2013; Gandhi et al., 2010); For these reasons 
streptomycin is infrequently used for the treatment of tuberculosis.  
Resistance of M. tuberculosis to antimycobacterial drugs is not a new phenomenon as 
shown by streptomycin. However, resistance of TB to other mycobacterial drugs is 
increasing exponentially leading to the emergence of multidrug (MDR-TB) and 
extensively drug resistant (XDR-TB) strains (Murray et al., 2014). One of the most 
extensive studies undertaken to report the incidences of MDR-TB and XDR-TB 
worldwide analysed 17,690 clinical isolates and found that 20 % were MDR and were 2 
% XDR (Centers for Disease Control and Prevention (CDC), 2006).  
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One of the ways to combat the development of resistance is to employ a combination 
therapy approach consisting of two or more antibiotics (Acar, 2000). This offers a 
number of potential advantages: (1) broad-spectrum coverage for the initial treatment  
of infected patients; (2) the ability to treat polymicrobial infections; (3)  avert the 
selection of resistant microorganisms; (4) reduce dose-related toxicity; and (5) increase 
the potential for synergistic activity (Lienhardt et al., 2010). 
The current treatment regime for pulmonary TB utilises a combination of antibiotics 
comprising of isoniazid and rifampicin (every day for 6 months) which provides broad 
spectrum coverage of the initial infection. This is supplemented by  pyrazinamide and 
ethambutol which are taken every day for the first 2 months to avert the selection of 
resistant microorganisms. In the case of extra-pulmonary TB, the same combination 
therapy is used but treatment is extended to 12 months (Centers for Disease Control 
and Prevention (CDC), 2006). 
There are two main reasons for using a combination therapy approach to treat M. 
tuberculosis infection. The first is to reduce the possibility of resistant organisms by 
using antibiotics with several modes of action. For example isoniazid (INH) inhibits the 
formation of mycolic acids on the cell surface effectively inhibiting the growth of the 
bacterium. As previously mentioned, INH is used in combination with rifampicin. 
Rifampicin inhibits RNA polymerase which inhibits DNA transcription, therefore 
reducing the ability of the bacterium to gain antibacterial resistance.  
In this chapter the antibacterial activity of several antibiotics was assayed against 
antibiotic resistant clinical isolates of M. abscessus a fast growing organism related to 
M. tuberculosis. It is a poorly understood multidrug resistant organism which has been 
shown to cause abscesses in the lungs of patients with cystic fibrosis (Henry, 2014).  
The antibiotics assayed in this chapter are commonly used to treat both M. 
tuberculosis and M. abscessus and as a consequence drug resistance is often 
encountered  (Meziane-Cherif and Courvalin, 2014). 
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One of the antibiotics commonly used to treat mycobacterial infection is isoniazid 
(INH) which is a pro-drug activated by a bacterial peroxidase. The mode of action is to 
inhibit the synthesis of mycolic acids which are key components of the mycobacterial 
cell wall (Simons et al., 2010) and thus prevent the growth of the bacteria (bactericidal 
activity). Although commonly used, the drug has several severe side effects such as 
liver damage which can lead to morbidity (Murray et al., 2014; Zhang et al., 1992). 
Another commonly used antibiotic, Ethambutol (EM), also works by disrupting the 
formation of mycolic acids which increasing the permeability of the bacterial cell wall 
to antibiotics. Ethambutol, unlike INH is bacteriostatic so is commonly used in 
combination therapy with INH, rifampicin and pyrazinamide which have bactericidal 
effects. EM has several severe side effects including decreased vision and chronic liver 
failure (Coban et al., 2014). 
Rifampicin (RIF) was introduced in 1967 and is used in combination therapy to treat 
tuberculosis and other Mycobacterial infections. Its mode of action is to prevent 
bacterial DNA-dependent RNA synthesis by inhibiting the action of RNA polymerase 
(Calvori, 2005). Bacterial resistance to RIF is common and occurs as a result of 
mutations in the rpoB gene which alters the rifampicin binding site on RNA polymerase 
and thus prevents the antibiotic from binding.  For this reason RIF is always used in 
combination with other antibiotics (BNF.org). A further complication of using the drug 
is its hepatotoxicity which requires regular liver function tests to ensure patient health, 
(Coban, et al., 2014).  
Pyrazinamide (PYR) is a prodrug which is commonly used in combination with INH and 
RIF to treat tuberculosis.  Uniquely, PYR diffuses across the cell wall of the bacterium 
where the enzyme pyrazinamidase converts the drug into the active form pyrazinoic 
acid which increases internal pH (Cabellero, 2009).  There are several theories as to the  
mode of action of the drug but it is  generally assumed that pyrazinoic acid acts by 
disrupting membrane potential which prevents energy production (Zhang, et al., 
2008). The drug is also thought to inhibit the action of fatty acid synthase  required by 
the bacterium to synthesise fatty acids and  binds to ribosomal protein S1 (RpsA) 
inhibiting trans-translation of tRNA (Coates et al., 2011; Shi et al., 2011).  Pyrazinamide 
is also hepatotoxic and is the most common cause of drug induced hepatitis. 
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Pyrazinamide has no activity against actively growing TB bacilli  at neutral pH but 
instead targets non-replicating bacteria at acid pH such as those found inside 
macrophages  (McDermott and Tompsett, 1954; Shi et al., 2011; Tarshis and Weed, 
1953). 
Mycobacterium tuberculosis is just one bacteria within the mycobacterial species, 
other related organisms such as M. avium and M. abscessus  can also cause serious 
healthcare associated infections (Petrini, 2006). To treat these pathogens and to 
counter the rise of multidrug resistant isolates two additional antibiotics, imipenem 
and ciprofloxacin, which have been shown to have inhibitory activity against these 
pathogens, have been employed to treat infected individuals (Inderlied et al., 1989; 
LaBombardi and Cataldo-Caputzal, 1993). 
Imipenem (IM) is an intravenous β-lactam antibiotic and a member of the carbapenem 
class of antibiotics which is generally used to treat Gram negative bacteria such as 
Escherichia coli and Pseudomonas aeruginosa; it has also been shown to be active 
against several species of Mycobacterium such as M. abscessus (Dooley et al., 2013; 
Singh et al., 2014).   
Beta lactam antibiotics act by binding to penicillin binding proteins (PBP’s). In Gram 
negative organisms the PBP’s which imipenem has the most affinity for are, PBP-1a, 1b 
and PBP-2. The binding of imipenem to PBP’s results in inhibition of cell wall synthesis; 
in addition, direct binding PSP-2 and PBP-1b results in rapid cell lysis and death without 
filament formation (Inderlied et al., 1989; Rodloff et al., 2006; Carvela et al., 1984). 
Commonly mycobacteria are recognised as being intrinsically resistant to beta lactam 
antibiotics. This is due, in part, to the presence of β-lactamase (an enzyme which 
inhibits the binding to PBP’s). In addition to this, the lipid rich mycobacterial cell wall is 
thought to be a virtually impenetrable barrier to polar molecules such as beta-lactam 
antibiotics (Chambers et al., 1995). In a recent study however by Singh et al, (2014) the 
susceptibility of 67 clinical isolates of Mycobacterium abscessus to imipenem was 
investigated and it was found that only 14% were resistant; (MIC50 5 µg) (Singh et al., 
2014).  
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Imipenem has also been shown to be synergistic in vitro, with other anti-mycobacterial 
drugs (Singh et al., 2014) as well as being inhibitory towards the M. tuberculosis strain 
H37Ra (Chambers et al., 1995). Side effects are uncommon although it has been 
reported that when used in high concentrations IM can cause seizures (BNF.org). 
Ciprofloxacin (CIP) is a broad spectrum, second generation, fluoroquinolone (BNF.org) 
and is commonly used in the treatment of a wide range of Gram positive and negative 
bacterial infections. Ciprofloxacin is also commonly used alone or in combination with 
other antibacterial drugs in the treatment of infections for which the bacterial 
pathogen has not been identified, including urinary tract infections and abdominal 
infections (Naber et al., 2006; Solomkin et al., 2010). CIP prevents cell division by 
inhibiting DNA gyrase, necessary to separate bacterial DNA (Drlica and Zhao, 1997; 
Inderlied et al., 1989; LaBombardi and Cataldo-Caputzal, 1993). 
Given the ability of bacteria to evolve it is perhaps not surprising that they have 
developed resistance to the antibiotics which are currently in use.  The situation is not 
helped by the fact that the cost of developing new antimicrobials far outweighs any 
financial gain to the pharmaceutical companies and as a consequence there are no 
new classes of antibiotic in the developmental pipeline, indeed no new classes of 
antibiotics have been  brought to the market since 1980 (Phillips, 2013).  
An alternative to discovering new antibiotics would be to identify natural compounds 
which restore the activity of redundant antibiotics or enhance their current level of 
antibacterial  activity (Coates et al., 2011; Cragg and Newman, 2013).  One such 
combination was identified by Cooper, et al., where synergistic activity was observed 
between Manuka honey and beta lactam antibiotics against an oxacillin resistant strain 
of S. aureus (Jenkins and Cooper, 2012). In another study Mossa (2004) and colleagues  
observed that plant derived compounds such as diterpenes, totarol, ferulenol and 
plumbagin increased the potency of isonicotonic acid hydrozide against M. smegmatis, 
M. chelone, M. xenopei and M. intracellulare (Mossa et al., 2004).  
  
156 
 
Another example of a natural product derived antibacterial is clavulanic acid which is 
derived from Streptomyces clavuligerus. Clavulanic acid or augmentin, is a Beta-lactam 
antibiotic which when used alone is not itself inhibitory but when used in combination 
with the penicillin type antibiotics such as amoxicillin,  it can overcome antibiotic 
resistance in bacteria that secrete β-lactamase enzymes (Reading and Cole, 1977). 
When reporting the activity of combinations of antibiotics there has been confusion 
regarding the classification of synergy, additive, co-active and indifferent. In this report 
I have used several methods to determine the interaction of the test compounds and 
therefore it is important to define the terminology used. In this report I class the 
activity of hop-antibiotic combinations as antagonistic (one will reduce the activity of 
the other); indifferent (the combination does not enhance or reduce the activity of 
each drug); co-active (appearance of increased activity in one, or both drugs); additive 
(statistically significant (FIC = >1 : <2) decrease in MIC of one compound when in 
combination); synergy (statistically significant (FIC < 0.5) decrease in MIC of both test 
compounds when in combination.  
In this chapter the antibacterial activity of hop derived extracts against clinical isolates 
of M. abscessus including those resistant to multiple antibiotics was investigated. The 
ability of these extracts to potentiate the activity of the following antimicrobials: 
isoniazid, ethambutol, ciprofloxacin, pyrazinamide, imipenem and rifampicin were also 
studied. Finally the effect of exposure to hop extracts and antibiotics, alone and in 
combination on M. abscessus structure using scanning electron microscopy (SEM) was 
also investigated.   
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5.2 Materials and Methods 
5.2.1 Clinical isolates of Mycobacterium abscessus 
Clinical isolates were kindly provided by Dr. Joachim Burget and Dr. Mike Ruddy, 
University Hospital of Wales, Cardiff (UHW) and were collected from patients during 
July 2012 (Table 5.1); each isolate was characterised by a unique reference number 
(assigned by UHW) which is displayed in Table 5.1 alongside the known antibiotic 
resistance profiles.  
Unique UHW strain 
number 
Known antibiotic resistance 
(MIC > 128 µg/mL-1) 
Collection date 
8899 Imipenem, Rifampicin 11/07/2012 
9495 Rifampicin Imipenem 11/07/2012 
9568 Rifampicin 12/07/2012 
9723 Rifampicin, Ciprofloxacin, 12/07/2012 
10006 Rifampicin, Ciprofloxacin, 
Imipenem 
21/07/2012 
10332 Rifampicin 22/07/2012 
11365 Rifampicin Ciprofloxacin, 
Imipenem 
23/07/2012 
11490 Rifampicin 24/07/2012 
 
Table 5. 1 The UHW unique clinical isolate strain number, known antibiotic resistance 
(determined by an MIC > 128 µg/mL-1), and isolation date of Mycobacterium abscessus 
strains 
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5.2.2 Growth media 
Clinical isolates of M. abscessus were isolated using lysogeny agar (LA) and were 
supplied as actively growing cultures in lysogeny broth (LB). All subsequent 
antibacterial assays utilising M. abscessus were undertaken using LA and LB and were 
prepared according to manufacturer’s instructions (10 g (LA/LB) / 500 mL of SDW) and 
were autoclaved at 121 °C for 15 minutes and 15 PSI before use (Prestige, 9 L classic 
bench top autoclave, LabShop, UK).  
 
5.2.3 Antibiotics 
The antibiotics used in this study were; isoniazid, ciprofloxacin, rifampicin, imipenem, 
ethambutol and pyrazinamide. For the agar incorporation assay; Etest strips which had 
a concentration gradient (0 µg to 256 µg) of each antibiotic were used.  For the zone of 
inhibition assay each antibiotic was supplied as a sensitivity disc (Fisher Scientific, UK) 
and concentrations of 5, 10, 25, 50 and 100 µg were used.  All antibiotic containing 
reagents were stored at -20 °C prior to use. 
5.2.4 Crude hop extract 
Based on the results presented in Chapter 3 the hop variant Citra demonstrated the 
highest level of antibacterial activity and was used to generate the extracts which were 
used in these studies. The method for obtaining aqueous hop extract was described in 
detail in Chapter 3.; briefly, 5 g of pelleted Citra hop variant was machine macerated 
into a powder with a diameter less than 2 mm. Macerated hop material was then 
suspended in 200 mL of SDW at 100 °C for 60 minutes and was then allowed to cool to 
room temperature. Solid hop material was removed by filtration (Whatman® size 2 
filter), under gravity and resulting supernatant was used neat and termed crude hop 
extract; the crude hop extract was made fresh prior to each assay. 
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5.2.5 Purified hop extracts 
The compounds in the Citra hop variant were separated as described in Chapter 4; 
briefly 1 mL of a 1 g/mL-1 Citra aqueous hop extract was separated using preparative 
thin layer chromatography and was assayed for antibacterial activity using the 
bacterial overlay assay (Method 4.3.4). Separated spots which displayed antibacterial 
activity towards M. abscessus 9495 were isolated, weighed and identified UPLC, as 
previously described in Chapter 4. The hop compounds isolated by this process are 
presented in Table 5.2.  
 
Extract Number 
Predominant 
compound as 
identified by mass 
spectrometry 
 
Compound weight 
as tested (µg) 
2737 G Humulone 5 
2737 Y Lupulone 5 
1426 G Adlupulone 5 
 
Table 5. 2 Extracted hop compounds used in the synergy assays. Compounds were separated 
from preparative thin layer chromatography based on their antibacterial activity and the 
predominant compound identified using mass spectrometry. 
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5.2.6 Characterisation of bacterial structure following exposure to 
antibacterial compounds using scanning electron microscopy 
Fresh cultures of M. abscessus and M. smegmatis were prepared as previously 
described in section 2.2.2 and were standardised to 1 x 106 cfu/mL-1. 
Prior to fixing, 1 mL of bacterial culture was suspended in 1 ml of ciprofloxacin (0.12 
µg/mL-1), imipenem (8 µg/mL-1) and Citra crude hop extract (0.125 % v/v). For synergy 
studies, antibiotics were prepared in 0.125 % v/v Citra crude hop extract at the 
concentrations previously mentioned. Controls consisted of M. abscessus and M. 
smegmatis suspended in SDW. Each sample (test and control) was incubated statically 
at 37 °C for 1, 6 10, 12, 18 and 24 hours on three separate occasions.  At each time 
point the appropriate sample was prepared for imaging as descried below. 
5.2.6.1 Sample preparation and imaging  
Treated bacterial cultures were pelleted by centrifuging at 2600 x g for 10 min and the 
supernatant removed. Cultures were then fixed at room temperature for 1 h by 
suspending in 500 μL of 2 % glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 
7.4). The samples were then centrifuged at 2600 xg for 10 min and the supernatant 
was removed. To each sample, 500 μL of a solution containing a ratio of 2:2:1 of 2 % 
osmium tetroxide: 0.1 M sodium cacodylate (pH 7.4): 25 % glutaraldehyde and 
incubated for 1 h at room temperature. 
Samples were centrifuged again and the supernatant was removed. The samples were 
re-suspended in 50 % ethanol in diH₂O for 1 minute and then centrifuged at 5000 x g. 
After removing the supernatant this process was repeated with 70, 80 and 95 % 
ethanol in diH₂O followed by three washes with absolute ethanol. The samples were 
stored in 1 mL of absolute ethanol at room temperature before dehydration under 
vacuum on carbon grids, sputter coating with platinum and imagining on a scanning 
electron microscope. 
For each sample, 25 different fields of view were examined at 10,000 x and 50,000 x 
magnification using a Zeiss SIGMA FEG-SEM scanning electron microscope. 
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5.3 Methods to characterise the combined antibacterial activity of 
hops and antibiotics 
5.3.1 Modified zone of inhibition assay 
This method is a variation of the agar well diffusion assay (Section 3.6.1. In this assay 
LA was prepared as per manufacturer’s instructions (10 g per 500 mL-1 SDW) and 20 
mL of sterile, molten LA was transferred to a petri dish and allowed to set. A 1 x 106 
cfu/mL-1 suspension of each test strain of M. abscessus (Section 2.2.2 and 2.2.3) was 
evenly spread onto the surface of the agar using a sterile spreader (Fischer Scientific, 
UK) and incubated statically at 37 °C for 3 hours.  
Two agar based radial assays were employed to assess interaction.  In the first, 80 µl of 
crude hop extract was added to a 6 mm diameter well which had been bored into the 
agar.  An antibiotic impregnated disc was then placed 5 cm from the centre of the well 
after which the plate was incubated at 37 °C for 24 hours. In the second assay, sterile 
paper sensitivity test discs were loaded with hops compounds at a concentration of 5 
µg/mL-1 and left to dry.  Discs containing antibiotics and hop compounds were then 
placed 5 cm apart on the surface of an inoculated agar and incubated at 37° C for 24 
hours. Following incubation the agar plates were inspected for the presence of zones 
of inhibition. The shape of the interaction between the zones of inhibition generated 
by each disc was used to indicate the type of interaction between the two agents 
(Figure 5.1).  
 
 
 
 
 
 
Figure 5. 1 The possible types of interaction between two antibacterial agents. Depending on 
the appearance of the interaction it is classified antagonistic, no effect or Co-active. Adapted 
from Piddock, (1990). 
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5.3.2 Modified agar incorporation assay  
To further characterise the interaction of hop derived compounds and antibiotics, the 
hop agar incorporation assay was employed. This allowed the minimum inhibitory 
concentration (MIC) of each hop extract to be determined against each test organism.  
To determine the interaction of hop extracts and antibiotics the following method was 
employed. A sub MIC concentration of hop compound was incorporated into agar 
using a variant of the previously described method (Method 3.6.2). Following 
inoculation of the surface of the agar plate with the test organism the plate was 
incubated at 37 °C for 3 hours. 
To determine the sensitivity of the organism to a chosen antibiotic the E-test or 
episolmeter test was employed. The Etest consists of a predefined gradient (usually 
between 256 µg – 0 µg) of antibiotic concentrations on a plastic strip, allowing the MIC 
value of antibiotics, antifungal and antimycobacterial agents. The addition of a 
concentration gradient allows for the results to be less subjective, in the zone of 
inhibition assay the pattern of growth is used to describe positive co-action whereas 
using the E-test a reduction in the MIC value is used (Reed, 2007; Wanger et al., 1995) 
An Etest strip containing the chosen antibiotic was then positioned onto the surface of 
the agar and the plate was returned to the incubator at 37 °C for 24 hours. As a control 
the assay was performed using agar from which the hop compound had been omitted. 
 
 
 
 
 
 
 
Figure 5. 2 Determination of the MIC value of Gentamicin against E.coli using an Etest strip.  
The clear zone represents the area of inhibition and the point at which the edge of the zone 
meets the scale on the strip represents the MIC. 
MIC Value 
Zone of no 
growth 
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An example of an E-test strip test plate following incubation can be seen in Figure 5.2. 
A clear area of no growth is observed which leads to a narrowing point indicating the 
minimum inhibitory concentration. When crude hop extract is incorporated into the 
agar the zone is again read, and depending on the result the combination was classed 
as co-active (decrease in MIC), antagonistic (increase in MIC) or indifferent (no change 
to MIC).  All assays were repeated on no less than 3 separate occasions unless 
otherwise stated.  
To identify a change in the MIC rather than experimental error a 3 dilution decrease in 
the MIC value was used. Any changes below this value were taken to be experimental 
error or ‘no effect’. The 3 dilution rule has been previously used to determine additive 
effects using this assay (Reed, et al., 2007). 
5.3.3 Identification of synergy using a checkerboard method  
To test for synergy, indifference or antagonism the checkerboard method was used 
and was adapted from White et al., 1996. The combinations tested against each clinical 
isolate of M. abscessus were ciprofloxacin plus Citra crude hop extract and imipenem 
plus Citra hop extract. The concentration range for each antimicrobial was 0.015 – 32 
µg/mL-1 and was prepared from a stock solution prepared in diH₂O. For the Citra crude 
hop extract concentration ranged from 0.05 % - 0.8 % v/v and was prepared as 
previously described. 
Each inoculum of M. abscessus was prepared as previously described and standardised 
to a concentration of 1 x 106 cfu/mL-1 in double concentrated lysogeny broth (20 g/l). 
Within an MIC plate (Sterlin, UK) 80 µL of standardised bacterial suspension along with 
50 µL of fresh double concentrated broth was added. To each well a 100 µL 
combination of ciprofloxacin or imipenem (Range 0.015 µg/mL-1 – 32 µg /mL1) 
prepared in Citra hop extract (Range 0.05 – 0.8 % v/v) was added to give a range of 
concentrations of each test antibacterial. Plates were then incubated at 37 °C for 24 
hours with shaking at 50 rpm. 
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Controls consisted of imipenem and ciprofloxacin and Citra hop extract only at the 
concentrations listed above; sterile distilled water; and 80 µL of M. abscessus 
suspended in 50 µL of double concentrated broth with 100 µL of SDW. Growth was 
observed by eye as either turbid (growth) or clear (no growth) in each well.  
To evaluate the effect of different combinations of antibiotics and hops the fractional 
inhibitory concentration (FIC) was calculated for each antibiotic in each combination. 
The following formula was used to calculate the FIC: 
Definitions: 
 MICA  -  The MIC of ciprofloxacin/ imipenem (Drug A) alone 
 MICB –  The MIC of Citra hop extract (Drug B) alone  
 MICAB – The MIC of drug A in combination with B  
 MICBA – The MIC of drug A in combination with A 
 
FIC (fractional inhibitory concentration) index calculations: 
FIC Index = MICAB / MICA + MIC BA / MIC B 
MICAB = MIC of A in the presence of B; MICBA = MIC of B in the presence of A 
Results were then interpreted as follows: 
Interpretation FIC 
Synergy < 0.5 
Additive > 0.5 and < 1.0 
Indifference > 1 and < 4.0 
Antagonism > 4.0 
 
Table 5. 3 Interpretation of the FIC to identify synergy, additive, indifference or antagonism 
between antibiotics and crude hop extract 
Adapted from Acar, (2000); White et al., (1996) 
 
 
. 
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5.4 Results 
5.4.1. Determination of the antibiotic sensitivity of clinical isolates of 
M. abscessus 
To confirm the antibiotic sensitivity of the clinical isolates of M. abscessus provided by 
the UHW a disc diffusion assay was employed (Method 5.3.1). The following range of 
antibiotics and disc concentrations were used; rifampicin, imipenem, ciprofloxacin and 
pyrazinamide at concentrations of 5 and 10 µg.  The resulting zone of inhibition 
following overnight incubation is shown in Table 5.4; no inhibition is indicated by (NI).   
 
Imipenem Ciprofloxacin Pyrazinamide Rifampicin Ethambutol 
Strain 
number 5 µg 10 µg 5 µg 10 µg 5 µg 10 µg 5 µg 10 µg 5 µg 10 µg 
 The mean zone of inhibition (mm)  
8899 NI NI 22.8    46.2 NI NI NI NI NI 1.2 
9495 22.3 48.3 22.6 44.3 NI NI NI NI NI 1.4 
9568 25.3 49.6 28.6 52.6 1.4 3.7 NI NI NI 1.1 
9723 26.7 51.6 NI NI NI 1.4 NI NI NI NI 
10006 NI NI NI NI NI NI NI NI NI NI 
10332 22.6 46.2 25.3 49.7 1.6 3.5 NI 1.1 NI 1.2 
11365 25.8 50.2 NI NI NI NI NI NI NI NI 
11490 26.4 51.3 29.4 50.5 NI NI NI NI NI NI 
Table 5. 4 The zone of inhibition (mm) of 5 and 10 µg antibiotic sensitivity discs (imipenem; 
ciprofloxacin; pyrazinamide; rifampicin and ethambutol) against clinical isolates of M. 
abscessus as a result of 3 separate repeats (NI= no inhibition). Controls consisted of +ve 
Gentamicin at 10 µg/mL-1 and –ve an inoculated filter disc with 50 µL of SDW 
Imipenem was found to be the most effective antibiotic at the concentrations tested 
for these isolates while rifampicin was the least.  
Comparing the results obtained from Table 5.1 the bacterial sensitivities to the 
antibiotics appears to match those expected.  This is especially the case for strain 
number 10332 which appears sensitive to all antibiotics assayed at both 10 µg/mL-1, in 
comparison; strain 11365 is the most resistant.  
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5.4.2. Determination of the sensitivity of clinical isolates of M. 
abscessus to Citra hop extract 
The antibacterial activity of the Citra crude hop extract was next determined by the 
using the previously developed zone of inhibition assay (method 3.6.1). The average 
zone of inhibition was calculated on 3 separate occasions against all of the clinical 
isolates of M. abscessus and the results displayed in Figure 5.3. 
 
Figure 5. 3 The average zone of inhibition (mm) of Citra crude hop extracts against clinical 
isolates of M. abscessus. Results shown are the mean of 3 separate repeats, error bars 
represent ± Standard deviation (SD) 
All of the clinical isolates of M. abscessus were susceptible in varying degrees to the 
hop extract. To determine if there was a statistically significant difference in the level 
of antibacterial activity observed against theses isolates, a one way ANOVA and Tukey 
post hoc analysis of the zones of inhibition generated by strains 11365 and 8899 was 
performed.  A p value (>0.05) indicated that there was no significant difference in the 
zones of inhibition suggesting that all of the isolates demonstrated a similar level of 
sensitivity to the hop extract. The fact that antibiotic resistant isolates were as 
susceptible as there antibiotic susceptible counterparts suggests that the extract 
contains compounds that may act in a manner which differs from that of the particular 
antibiotics and  that they may have  utility as antimicrobial agents. 
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5.4.3 Characterisation of the combined antibacterial activity of  hops 
and antibiotics against clinical isolates of M. abscessus 
To characterise the interaction of individual antibiotics and the hop extract, an agar 
diffusion assay was used (section 3.6.1). An antibiotic sensitivity disc containing 10 µg 
of the antibacterial agent was placed 5 cm from a well containing Citra hop extract and 
was incubated overnight. The resulting growth was examined for evidence of 
synergism, antagonism or no effect.  
Figure 5.4 shows an example of an antibiotic/ hop interaction which demonstrated   
coactivity against M. abscessus 9495. 
 
 
 
 
 
 
 
 
Figure 5. 4 Synergistic interaction  between the antibiotic imipenem (10 µg/mL-1) and  crude 
Citra hop extract against the clinical isolate Mycobacterium abscessus 9495. Zones of 
inhibition shown in black indicate normal inhibition whilst zones in red indicate synergism. 
Figure shown is representative of 3 separate repeats. 
Figure 5.5 is an example of the zone of inhibition assay between the Citra crude hop 
extract and the antibiotic ethambutol (10 µg) against the clinical isolate M. abscessus 
9568. The figure details ‘no effect’ (Figure 5.1), meaning that no coactivity or 
antagonistic activity was observed.  
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Figure 5. 5 An example of the  zone of inhibition assay detailing no effect between the 
antibiotic ciprofloxacin (10 µg/mL-1) and the crude Citra hop extract against the clinical 
isolate Mycobacterium abscessus 9568.  Figure shown is representative of 3 separate repeats 
For ease of analysis the interaction for each clinical isolate has been collated and is 
presented in Table 5.5 
M. abscessus 
strain 
numbers 
Imipenem 
10 µg 
Ciprofloxacin 
10 µg 
Pyrazinamide 
10 µg 
Rifampicin 
10 µg 
Ethambutol 
10 µg 
8899 NE NE NE NE NE 
9495 CO NE NE NE NE 
9568 CO CO NE NE NE 
9723 CO NE NE NE NE 
10006 NE NE NE NE NE 
10332 CO CO NE NE NE 
11365 NE NE NE NE NE 
11490 CO CO NE NE NE 
Table 5. 5 A summary of the activity of crude hop extract and antibiotics against clinical 
isolates of M. abscessus determined using an agar diffusion assay. (Key – CO = Co-active; NE 
= No effect; A = antagonism. Results determined on three separate occasions 
As can be seen from Table 5.5 the degree of antibacterial interaction varied depending 
on the type of antibiotic and the test organism. Antimicrobial co-action was observed 
between hop extracts and imipenem (n=5) followed by Ciprofloxacin (n=3). In no case 
was antagonism observed.  
Citra crude 
 
hop extract 
Ciprofloxacin 
 
(10 µg/mL-1) 
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While the Citra hop extract demonstrated antibacterial activity against all strains of M. 
abscessus tested, the isolates varied in their response to particular combinations of 
hop extract and antibiotics. Isolates 9568, 10332 and 11490 demonstrated coactivity 
with two of the antibiotics tested. 
Strain numbers 10006, 8899 and 11365 showed no effect with any of the antibiotics 
which suggests fundamental differences between the sensitivity of these bacteria. It is 
interesting to note that 10332 demonstrated the greatest range of antibiotic 
sensitivities while 10006 was the most resistant. 
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5.4.4. Determination of the sensitivity of clinical isolates of M. 
abscessus to individual compounds isolated from the Citra hop extract 
To determine the degree of antibacterial activity of the Citra hop purified components, 
isolated in Chapter 4, 5 µg of test compound was transferred to a paper sensitivity disc 
and employed in a zone of inhibition assay (Method 3.6.1). The assay was repeated on 
3 separate occasions and the results are presented in Table 5.6.  
 
M. abscessus strain 
numbers 
Extract 2737 G 
Mean ZOI ±SD 
(mm) 
Extract 2737 Y 
Mean ZOI ±SD 
(mm) 
 
Extract 1426 G 
Mean ZOI ±SD 
(mm) 
8899 18.3 ± 0.45 14.2 ± 0.10 16.5 ± 0.33 
9495 12.3 ± 0.11 15.3 ± 0.11 17.3 ± 0.42 
9568 12.3 ± 0.21 16.6 ± 0.32 15.4 ± 0.18 
9723 11.6 ± 0.44 14.8 ± 0.88 18.2 ± 0.14 
10006 11.2 ± 0.52 14.1 ± 0.23 15.6 ± 0.77 
10332 10.9 ± 0.19 12.4 ± 0.31 14.7 ± 0.11 
11365 12.3 ± 0.18 13.6 ± 0.54 15.2 ± 0.46 
11490 12.2 ± 0.16 13.4 ± 0.44 14.9 ± 0.14 
Table 5. 6 The antibacterial activity of Citra hop sub-fractions (2737G; 2737Y and 1426G)  
against clinical isolates of M. abscessus  determined using a zone of inhibition assay. Each 
value is a mean ZOI ± SD (mm) based on three separate repeats 
As can be observed in Table 5.6 all three extracts demonstrated varying degrees of 
inhibitory activity against all of the clinical isolates of M. abscessus. The data was 
subjected to Tukey HSD Post Hoc analysis to determine if there was a statistically 
significant difference in the sensitivity of the strains. A p value of > 0.05 indicated that 
there was no difference in strain sensitivity to any of the hop extracts tested. 
Comparing the sensitivity data from Table 5.3 and Table 5.6, initial observations 
indicate that there is a decrease in the average zone of inhibition (mm) of the purified 
extracts when compared to the crude hop extract. A one way ANOVA compared the 
average ZOI (mm) of the crude hop extract against all strains with the average ZOI of 
the purified hop extracts against all strains. It was found that there was a statistically 
significant difference (p=<0.05) in the level of antibacterial activity, therefore a 
reduction in the overall activity.  
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This is perhaps not surprising as hops are known to contain more than 800 separate 
compounds of which more than 20 have been reported to be antibacterial (Sumner, 
2010). It is possible that individually these compounds do not possess a measurable 
level of antibacterial activity but when in combination, as in the crude extract, an 
antibacterial affect can be observed. It may be the case that the separation and 
purification of these fractions actually increases the availability of these compounds 
compared to the original extract. It may be the case that other compounds can act 
antagonistically preventing their antibacterial activity.  
  
5.4.5. Determination of synergy between hop derived compounds and 
antibiotics using an agar based zone of inhibition assay 
 
The interaction between the antibacterial hop sub-fractions with antibiotics was 
assayed using an agar based method. No effect between any of the hop extracts and 
antibiotics assayed was observed.  
Given that coactivity was observed using the crude hop extract these results suggest 
that either the hop compounds necessary for synergy were missing from the purified 
fractions or that synergy is the consequence of the combined activity of a number of 
compounds found in the crude hop extract. 
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5.4.6 Determination of the MIC of Citra hop extract against clinical 
isolates of M. abscessus using an agar incorporation assay 
To further determine if there was a positive co-action between the crude hop extract 
and the antibiotics a modified agar incorporation assay utilising E-test strips was used 
(section 5.3.2). By measuring changes in the MIC I hypothesised that the any changes 
in antimicrobial activity could be more accurately determined. 
The first stage of this process was to determine the level of sensitivity of the bacterial 
isolates to the crude hop extract so that the level of hop extract to incorporate into the 
agar for the E-strip assay could be determined. As can be seen in Table 5.7 all isolates 
were sensitive to the Citra hop extract.  A p value of > 0.05 using a one way ANOVA 
indicated that there was no statistically significant difference between the MIC of the 
crude hop extracts and the bacterial isolates 
 
M. abscessus strain number 
The MIC of crude Citra hop extract 
(% concentration of hop extract v/v) 
8899 1.25 
9495 0.625 
9568 1.25 
9723 1.25 
10006 1.25 
10332 0.625 
11365 0.625 
11490 0.625 
Table 5. 7 The MIC of crude Citra hop extract against clinical isolates of M. abscessus 
determined using an agar incorporation assay. Results represent the mean of three separate 
assays 
It was interesting to observe in Table 5.7 that even though the organisms were 
resistant or sensitive to different antibiotics there was no variation in their sensitivity 
to the hop extract. This highlights fundamental differences in the mode of action(s) of 
the hop extract and the antibiotics previously assayed.  
This assay also supported the findings of previous research (Table 5.3) which detailed 
the zone of inhibition and showed no variation in the sensitivity of the isolates to the 
hop extract.  
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5.4.7 Determination of the MIC of antibiotics against clinical isolates of 
M. abscessus using the E-strip test.  
The method employed was a variant of the agar incorporation method developed in 
Chapter. A sub-inhibitory concentration of Citra hop extract was incorporated into the 
agar prior to the addition of the E-strip. As a control the hop extract was omitted. 
Typical examples of the results generated with this method are presented in the 
following figures (5.6 and 5.7).  
 
 
 
 
 
 
Figure 5. 6 The effect of imipenem 0-256 µg on the left and with the incorporation of a sub-
inhibitory concentration (0.3125 % (v/v)) of Citra crude hop extract on the right. Figure 
representative of 3 separate repeats. 
Figure 5.6 shows the effect of hop extract at a concentration of 0.3125 % v/v on the 
sensitivity of M. abscessus 10332 to imipenem. In the presence of the hop extract, the 
zone of inhibition was larger and the MIC value reduced from 6.0 µg to 0.03 µg 
suggesting a synergistic effect.  
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As can be observed in Figure 5.7 the addition of a ciprofloxacin Etest had an inhibitory 
effect on the growth of M. abscessus 10332 (MIC – 0.12 µg). When compared to the 
image on the right, in which 0.3125 % (v/v) Citra hop extract was incorporated into the 
agar. The zone of inhibition surrounding the Etest strip was much larger, the MIC value 
had also decreased to 0.06 µg from 0.12 µg. Although not considered a significant 
decrease in MIC to be synergistic, a positive co-action was assumed due to the 
increase in the zone of inhibition.  
 
 
 
 
 
 
Figure 5. 7 The Etest of ciprofloxacin (256 – 0 µg) against M. abscessus 10332 without the 
incorporation of Citra hop extract (0.0625 % v/v) (left) and with the incorporation of extract. 
A summary of the results for all of the isolates of M. abscessus examined in this study 
to determine the interaction between hop extract and antibiotics is shown in the 
following Table (Table 5.8). 
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Table 5. 8 The effect of Citra hop extract on the antibiotic sensitivity of clinical isolates of M. 
abscessus. The MIC of imipenem; ciprofloxacin; pyrazinamide; rifampicin and ethambutol 
was determined using the Etest before and after the incorporation of Citra hop extract 
(0.312 % v/v).  The numerals in red denote a reduction in the MIC, suggesting coactivity.  
Results are representative of 3 separate repeats. 
In this assay the concentration of the hop extract did not change, instead a variation of 
the MIC of the antibiotic was used to determine an antagonistic (> MIC); indifferent 
(no change in MIC); co-active (< 3 fold decrease in MIC). 
Therefore on this basis, the antibiotic which demonstrated the highest level of Co-
activity, was imipenem, specifically in strains 10332 and 11365.  
 
 
  
 Imipenem Ciprofloxacin Pyrazinamide Rifampicin Ethambutol 
Strain 
numbers 
MIC 
(µg) 
MIC with 
Hop Ext. 
(0.312%v/v) 
(µg) 
MIC 
(µg) 
MIC with  
Hop Ext. 
(0.312%v/v) 
(µg) 
MIC 
(µg) 
MIC with   
Hop Ext. 
(0.312%v/v) 
(µg) 
MIC 
(µg) 
MIC with  
Hop Ext. 
(0.312%v/v) 
(µg) 
MIC 
(µg) 
MIC with  
Hop Ext. 
(0.312%v/v) 
(µg) 
8899 >32 >32 6 6 >32 >32 >32 >32 >32 >32 
9495 8 2 6 6 >32 >32 >32 >32 >32 >32 
9568 8 2 0.12 0.06 >32 >32 >32 >32 >32 >32 
9723 8 2 >32 >32 >32 >32 >32 >32 >32 >32 
10006 >32 >32 >32 >32 >32 >32 >32 >32 >32 >32 
10332 6 0.03 0.12 0.06 >32 >32 >32 >32 >32 >32 
11365 6 0.12 >32 >32 >32 >32 >32 >32 >32 >32 
11490 8 2 1 0.5 >32 >32 >32 >32 >32 >32 
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It has been proposed that hops contain compounds which induce the release of 
bacterial cell wall degrading enzymes which contribute to their antibacterial activity 
(Carder, 1987). Given that imipenem also targets the bacterial cell wall it is interesting 
to speculate that the effect seen in these studies is a consequence of an interaction 
which enhances the access of either drug to its target. The fact that the purified 
antibacterial hop compounds failed to interact with imipenem suggests that their 
mode of action does not involve any form of direct cell wall damage. 
The interaction between hops and ciprofloxacin although detectable was not as 
dramatic as that seen with imipenem. Whilst no evidence of co-activity was observed, 
an increase in the size of the zone of inhibition was seen suggesting a form of positive 
interaction. 
Ciprofloxacin is a broad spectrum antibiotic used against both Gram positive and Gram 
negative organisms and works by inhibiting DNA gyrase enzymes inhibiting cell 
division.   Resistance to ciprofloxacin has been linked to a lack of cell wall permeability 
which is a classical defence mechanism in mycobacteria (Chatterje., 1997; Jarlier., 
1994) 
As previously discussed in this chapter, each hop extract had observable antibacterial 
activity against the M. abscessus isolates. Therefore it may be that the hop extract is 
degrading the bacterial cell wall, leading to intracellular exposure to ciprofloxacin. In 
each case between the hop extract and pyrazinamide; rifampicin and ethambutol an 
indifferent result was given. Interestingly all isolates had an MIC value of more than 32 
µg/mL-1 to the anti-tuberculosis drugs ethambutol, pyrazinamide and rifampicin. This 
highlights previous research which suggests that Mycobacterium abscessus is 
intrinsically resistant to these antibiotics (Brown-Elliott et al., 2012; Griffith et al., 
2007; Medjahed et al., 2010). 
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5.4.8 Checkerboard method for determining synergy between 
imipenem, ciprofloxacin and hop extracts against M. abscessus 9568, 
10332 and 11490  
To further determine and quantify if the combinations of hop extract and antibiotic 
were synergistic, additive, indifferent or antagonistic. The checkerboard method was 
used. 
Based on the results gained from Table 5.8, three strains of Mycobacterium abscessus 
were employed: 9568, 10332 and 11490. These strains were chosen due to the 
changes in MIC values of the antibiotics (imipenem and ciprofloxacin) seen in the 
previous assay 5.4.7. Results are presented in Tables 5.9 and 5.10 and represent 3 
separate repeats.  
Definitions: 
 MICA  -  The MIC of ciprofloxacin/ imipenem (Drug A) alone 
 MICB –  The MIC of Citra crude hop extract (Drug B) alone  
 MICAB – The MIC of drug A in combination with B  
 MICBA – The MIC of drug A in combination with A 
 
M. abscesuss Single Drug 
Imipenem   Hop 
ext. 
Combination FIC 
Index 
Interpretation 
MIC A MICB MICAB MICBA 
9568 8 1.25 2 0.625 0.77 Additive 
10332 6 0.625 0.03 0.156 0.255 Synergistic 
11490 8 0.625 2 0.625 1.25 Indifference 
Table 5. 9 Results of the checkerboard assay determining the MIC of imipenem and Citra 
crude hop extract alone and in combination with subsequent interpretation of the FIC index. 
Values of 3 separate repeats ±SD 0.00 
 
M. abscessus Single Drug 
CIP            Hop ext. 
Combination FIC 
Index 
Interpretation 
MIC A MICB MICAB MICBA 
9568 0.12 1.25 0.06 0.625 1.0 Indifference 
10332 0.12 0.625 0.06 0.312 0.99 Additive 
11490 1 0.625 0.5 0.625 1.5 Indifference 
Table 5. 10 Results of the checkerboard assay determining the MIC of ciprofloxacin (CIP) and 
Citra crude hop extract alone and in combination with subsequent interpretation of the FIC 
index. Values of 3 separate repeats ±SD 0.00 
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The checkerboard method represents the gold standard in synergy testing and its 
effectiveness has been evaluated previously by researchers in the field of antibiotic 
synergy (Petersen et al., 2006; Harada et al., 2014; Zuo et al., 2014). 
The advantages of this method allow the subsequent MIC’s of both test agents, in this 
case the antibiotics imipenem and ciprofloxacin and Citra crude hop extract, to be 
determined alone and in combination. Furthermore the method allows for the 
fractional inhibitory concentration (FIC) to be defined and a synergistic, additive, 
indifferent or antagonistic result being given for each combination. The FIC was first 
described by Elion (1954) and determines the statistical significance that two separate 
drugs will act in a synergistic or antagonistic manner based on a number determined 
between 0 and > 4 (Elion et al., 1954; Hall et al., 1983b). 
In the case of imipenem, 3 different interpretations of interaction were determined. 
Interestingly the MIC of imipenem in the checkerboard method matched that as 
determined in the modified agar incorporation method, however, several 
concentrations of hop extract were used in combination with the antibiotics. An 
observed synergistic effect (FIC = 0.255) between imipenem (MIC 0.03 µg/mL-1 in 
combination with Citra crude hop extract 0.156 % v/v) against the strain 10332 was 
seen. This is a reduction from 6 µg/mL-1 of imipenem and 1.25 % v/v of Citra hop 
extract when used alone.   
An additive effect (FIC = 0.77) between imipenem (2 µg/mL-1) and Citra crude hop 
extract (0.625 % v/v) from an original concentration of 8 µg/mL-1 and 1.25 % v/v 
against strain number 9568 was also observed. 
In the third bacterium trialled 11490, although the MIC of imipenem dropped from 8 
µg/mL-1 to 2 µg/mL-1 when in combination with a 0.625 % v/v hop extract. The FIC 
(1.25) indicated that this was an indifferent effect.  
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When compared to results of ciprofloxacin alone and in combination with the hop 
extract similar activity to the results obtained in the modified agar incorporation assay 
against the test bacterium was observed.  
Whilst the FIC in each case indicated that there was no synergistic effect, an additive 
interaction was seen against M. abscessus 10332. This  is identified by the MIC of 
ciprofloxacin reducing to 0.06 µg/mL-1 from 0.12 µg/mL-1 and the Hop extract MIC 
being reduced to 0.312 % v/v from 0.625 % v/v which resulted in an FIC of 0.99 which 
was just below the threshold of indifferent (FIC >1 and <4).  
Whilst an indifferent effect was seen between the test agents against strains 9568 (FIC 
= 1.0) and 11490 (FIC = 1.5) a decrease in both the MIC of the ciprofloxacin and hop 
extract in both cases was observed. This is considered statistically insignificant 
‘indifferent’ according to the FIC.  
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5.5 Scanning Electron Microscopy (SEM) imaging of antibiotic and 
hop combinations  
To characterize the interaction of hop derived compounds and antibiotics with the 
bacteria used in this study scanning electron microscopy was employed. The structures 
of two species of mycobacteria: M. abscessus and M. smegmatis was firstly compared.  
Figure 5.8 below a scanning electron microscopy image at 100k magnification of M. 
smegmatis 8159 is presented. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. 8 SEM image of Mycobacterium smegmatis 8159 at 100 k magnification. 
As can be seen from Figures 5.8 and 5.9 both bacteria are covered in what appears to 
be a rough, variegated surface which probably corresponds to the waxy outer layer 
which is known to coat mycobacteria. 
A comparison of the size of M. smegmatis to M. abscessus revealed that these bacteria 
varied in size with M. smegmatis (approx. 1 µm) being shorter in length than M. 
abscessus (approx. 2 µm). 
181 
 
 
Figure 5. 9 SEM image of Mycobacterium abscessus 10332 at 50, 000 x magnification 
representative of 25 separate images. 
Figure 5.9 represents 25 separate images of the bacteria in situ. Several observations 
can be made; notably there is a lack of single cells. This may be due in part to the waxy 
surface of the bacteria comprised of hydrophobic lipids and glycoproteins which allow 
the bacteria to adhere (Brennan, 2003; Ryan et al., 2004; Tyagi and Sharma, 2002). The 
lipid rich cell wall is a well-known virulence factor in mycobacteria and aids in drug 
resistance by acting as a permeability barrier (Ryan et al., 2004). 
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5.5.1 Characterisation of bacterial structure following exposure to 
Citra hop extract using SEM  
To determine if exposure to Citra hop extract  had any effect on cellular morphology,  
cells of Mycobacterium abscessus  10332 were incubated for 10 hours with  (0.3125 % 
v/v) of hop extract. After which, they were examined using SEM (Figure 5.10). 
 
Figure 5. 10 SEM image of M. abscessus 10332 (50k magnification) after 10 h incubation with 
0.3125 % (v/v) Citra crude hop extract- representative of 25 separate images 
In comparison with the control M. abscessus (Figure 5.9), the hop extract is having a 
demonstrable effect on the cell structure, whilst size does not seem to be affected, 
pitting of the cells forming crevices is clearly visible. 
 
 
 
183 
 
5.5.2 Characterisation of bacterial structure following exposure to 
Ciprofloxacin using SEM  
To determine if exposure to ciprofloxacin had any effect on cellular morphology, cells 
of Mycobacterium abscessus 10332 were incubated for 10 hours with 6 µg/mL-1    
ciprofloxacin after which they were examined using SEM (Figure 5.11).  
 
Figure 5. 11 SEM image of M. abscessus 10332 at 50k magnification after incubation with 
ciprofloxacin (6 µg/mL-1) for 10 hours. representative of 25 separate images 
Comparison of these images with those of untreated bacteria (Figure 5.9) revealed 
obvious differences in the appearance of the cell.  The waxy cell surface has been lost 
and the cells are noticeably larger (approx. 3-4 µm) and are visibly pitted.  These 
differences may be due to the antibiotic inhibiting the action of DNA gyrase and 
thereby     preventing cell division and cell surface differentiation. 
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5.5.3 Characterisation of bacterial structure following exposure to 
imipenem using SEM  
Next investigated was the effect of exposure to the bet-lactam antibiotic, imipenem, 
on the cellular morphology of M. abscessus following incubation with imipenem (6 
µg/mL1) for 10 hours. As was the case for ciprofloxacin treatment the bacteria exposed 
to imipenem had smoother cell surfaces than those of the untreated control. 
Imipenem is known to interact with penicillin binding proteins in the cell wall which 
may explain the effect on cell surface morphology (Chambers et al., 1995). 
 
Figure 5. 12 SEM image of M. abscessus 10332 at 50 k magnification after incubation with 
imipenem (6 µg/mL-1) for 10 hours. Figure representative of 25 separate images 
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5.5.4 Characterisation of bacterial structure following exposure to 
Citra hop extract and ciprofloxacin using SEM  
To determine the effect of a combination of Citra hop extract and ciprofloxacin, M. 
abscessus 10332 was incubated with 0.312 % v/v hop extract and 0.06 µg/mL-1 
ciprofloxacin for 10 hours (Figure 5.13). 
 
 
Figure 5. 13 SEM image of M. abscessus 10332 after incubation with ciprofloxacin (0.06 
µg/mL-1) and Citra crude hop extract (0.312 % v/v)  for 10 h. Representative of 25 separate 
images 
A large decrease in the number of intact cells was observed. This suggested that the 
combination of agents had resulted in the destruction of the cell wall of the bacterium. 
Those cells which had not been destroyed displayed a similar appearance to the 
ciprofloxacin treated bacteria in Figure 5. 11. 
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5.55 Characterisation of bacterial structure following exposure to Citra 
hop extract and imipenem using SEM  
The effect of imipenem and the Citra crude hop extract on the structure of M. 
abscessus 10332 was next investigated.  The bacterium was incubated for 10 hours 
with a sub-inhibitory concentration of hop extract (0.156 % (v/v) and 0.03 µg/mL-1 of 
imipenem and then visualised (Figure 5.14).  
 
Figure 5. 14 SEM image of M. abscessus 10332 after incubation with imipenem (0.03 µg/mL-1) 
and Citra crude hop extract (0.156 % v/v) for 10 h. Representative of 25 separate images 
A large decrease in the number of intact cells was observed, suggesting that the 
combination of agents had resulted in the destruction of the bacterial cell wall.  
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To confirm that this cellular disruption was not a localised artifact, additional images 
were captured at a lower magnification (10,000 versus 50,000) which  also showed 
extensive cellular disruption suggesting that the combination of hops and imipenem 
was extremely effective at  destroying cells of M. abscessus 10332 (Figure 5.15)  
 
Figure 5. 15 SEM image  of M. abscessus 10332 at  a magnification of 10 k after incubation 
with Imipenem (0.03 µg/ml) and Citra crude hop extract (0.156 % v/v) for 10 h detailing the 
lack of visible cells representative of 25 separate images 
 
 
 
 
 
  
188 
 
5.6 Discussion 
The organism Mycobacterium abscessus has been described as a new antibiotic 
nightmare (Nessar et al., 2012). While the bacterium is intrinsically resistant to some 
classes of antibiotics, its ability to acquire resistance to other front line drugs makes it 
a difficult pathogen to treat, particularly when encountered in patients with cystic 
fibrosis (CF) (Cullen et al., 2000; Petrini, 2006; Seddon et al., 2013). 
Distinguishing M. abscessus from other chronic bacterial pulmonary infections found in 
the advanced stages of CF is extremely challenging, as such, there is a concern that the 
use of broad spectrum antibiotics may simply select for the emergence of antibiotic 
resistant isolates of M. abscessus (Cullen et al., 2000). 
Incidences of M. abscessus infections are increasing: the CDC assessed 3,805 adults 
and 3,317 children with cystic fibrosis and found that 5.0 % and 3.3 % of these patients 
respectively had been diagnosed with an mycobacterial infection, of those, only 44 % 
of adults and 47 % of children were receiving or had received treatment (Seddon et al., 
2013). 
M. abscessus is often a neglected infection and as a consequence is becoming a major 
healthcare concern. As was shown in Chapter 3 hop extracts contain compounds which  
inhibit the growth of Mycobacterium smegmatis  and for this reason, the antibacterial 
activity of Citra hop extract and compounds isolated from this extract against clinical 
isolates of Mycobacterium abscessus was determined.  
Clinical isolates were obtained from patients treated at the University Hospital of 
Wales, Cardiff during July 2012.  In total eight clinical isolates which varied in their 
susceptibility to commonly used antibiotics were assayed for their susceptibility to 5 
and 10 µg antibiotic discs of imipenem, ciprofloxacin, pyrazinamide, rifampicin and 
ethambutol. From this it was observed that the most sensitive organism was M. 
abscessus 10332 whilst in comparison strain 11365 was the most resistant.  
  
189 
 
As had previously been shown in Chapter 3, the Citra hop extract is effective at 
inhibiting the growth of Mycobacterium smegmatis for this reason this extract was also 
trialled against clinical isolates of Mycobacterium abscessus. This was achieved by 
determining antibacterial activity using a previously developed zone of inhibition 
assay. No significant difference in the sensitivity of the isolates to the crude Citra hop 
extract was observed. This was an interesting result due to the fact that several of the 
isolates were multidrug resistant but were as susceptible as their antibiotic susceptible 
counterparts, suggesting that the extract contains compounds that exerted inhibitory 
activity in a manner which differs from that of the antibiotics.  
Natural products offer a great resource of novel antimicrobials due to the presence of 
compounds which have multiple modes of action. For example, the bioactive 
compound in garlic, allicin, has been shown to stimulate the immune system, 
attracting macrophages and lymphocytes to its site of injection (Cseke et al., 2010). In 
the case of hops, the constituents humulone and lupulone have been shown inhibit 
the efflux pumps responsible for nutrient supply to the cell (Teuber and Schmalreck, 
1973). 
In addition to direct antimicrobial activity it has also been shown that natural products 
can potentiate the activity of antibiotics (Obiang-Obounou and Jang, 2011; Shami et 
al., 2013). To identify if there was any potential co-action between the hop extract and 
the antibiotics in use, three commonly used agar and broth based methods were 
compared for their suitability. Previous research has shown that methods differ in their 
predictive efficacy (Orhan et al., 2005a; White et al., 1996).  
The first method used a modified zone of inhibition assay. This relied on observing the 
shape of the zones of inhibition generated around the test compounds.  Using this 
approach co-action between the crude hop extract and the following antibiotics: 
imipenem (5 isolates) and ciprofloxacin (3 isolates) was observed. No effect was 
observed when using pyrazinamide, ethambutol and rifampicin.  
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It was also observed that strains 10006 and 11365 showed no increased sensitivity to 
any of the antibiotics tested and that strain 10332 demonstrated the greatest range of 
antibiotic sensitivities whilst 10006 was the most resistant.  
To further investigate antibacterial coaction, the antibacterial compounds: humulone, 
lupulone and adlupulone were also trialled using the same method. Unfortunately in 
each case, no effect was observed between the combinations. This suggested that 
synergistic activity is a consequence of the combined activity of a number of 
compounds present in the crude hop extract.  
As previously mentioned in Chapter 4, compound extraction relies on the 
demonstration of antibacterial activity. Thus, it may be the case that the compounds 
responsible for the co-active effect with antibiotics lack any direct antibacterial activity 
and therefore would not have been selected for extraction.  
To further identify if there was a coactive effect, the agar incorporation assay 
previously described in Chapter 3 was employed. Determination of the MIC of the 
crude Citra hop extract against each clinical isolate of M. abscessus revealed no 
statistically significant difference in the level of sensitivity to the extract.  
Based on these results, a sub MIC concentration (0.312 % v/v) was chosen for all 
bacterial isolates and incorporated into the agar and an Estrip of each antibiotic placed 
on the surface of the inoculated agar. The results obtained were compared to those 
generated in the absence of the hop extract. In the context of this project coactivity 
was determined by a 3 fold decrease in the antibiotic MIC, indifference as no change in 
MIC and antagonism as an increase in MIC. In previous studies a single dilution change 
in MIC was considered coactive (White et al., 1996). 
The advantage of utilising agar incorporation over that of the zone of inhibition assay is 
that it allows for the measure of different levels of antibiotic sensitivity and thus 
generates a semi quantitative result. By using this technique it was found that this was 
most apparent in strains 10332 and 11365 when in conjunction with imipenem and 
9568 and 10332 when subjected to ciprofloxacin. In each case between the hop 
extract and pyrazinamide, rifampicin and ethambutol an indifferent result was given. 
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There are several possible reasons for the different results observed between the two 
assays:  
1. The zone of inhibition is observed by eye and therefore the observed ‘pattern’ 
of growth is subjective. A pattern which is suggestive of coactive may indeed 
represent  indifferent. 
 
2. The Estrip gives a much more quantifiable result which enables a determination 
to be made of any changes in relative antibiotic sensitivity. However, the strip is 
not designed for the purposes of synergy and therefore small changes in MIC 
below the limits of detection on the E-strip may go unnoticed.  
 
In the context of this study, these two agar based screening assays were used as a 
means of selecting hop and antibiotic combinations worthy of a more detailed study 
such as checkerboard method. This method represents the “gold standard” assay with 
which to determine potential synergistic interactions (Petersen et al., 2006; Harada et 
al., 2014; Zuo et al., 2014). 
Using this method a synergistic effect for the combination of imipenem and hop 
extract against strain 10332, an isolate which was sensitive to all of the antibiotics 
examined in this study was observed. An additive effect was seen against strain 9568 
while 11490 demonstrated indifference. This differs from the results obtained using 
the agar assays which found a coactive effect highlighting the need to appreciate the 
limitations of each assay.  
For example, while the zone of inhibition assay is a classical method for determining 
synergy, the interpretation of the results can be subjective and is dependent on 
several factors including; the confluence of bacterial growth on the surface of the agar 
and the chance of human error when spreading organisms.  The E-test method suffers 
from the same drawbacks and is considerably more expensive than the zone of 
inhibition assay.  Also whilst the effects of different concentrations of antibiotic could 
be assessed, only one fixed concentration of hop extract is employed.  
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While the checkerboard method is considerably more labour intensive than the other 
assays, it does overcome many of these issues and has the added advantage that 
several concentrations of the test agents can be analysed at the same time. This allows 
for any changes in the MIC of both test agents to be determined (Orhan et al., 2005a; 
White et al., 1996). The checkerboard assay is also more reproducible than the E-test 
in that White (1996) reports a 25% discrepancy between the two assays when used to 
assess the coactivity of the same antibiotic combination (White et al., 1996) 
In conclusion, the separate assays presented different results. In using the 
checkerboard assay, synergy was observed between imipenem and the hop extract 
against 10332 and an additive effect against strain 9568. When compared to the Etest, 
an additive effect was seen against strain 10332 when exposed to ciprofloxacin and 
hop extract, and an indifferent effect against 9568 using the Etest method.  
While M. abscessus 10332 appeared to be sensitive to clinically relevant levels of 
imipenem, the occurrence of isolates of M. abscessus which are resistant to the drug is 
becoming increasingly common (Medjahed et al., 2010). This is due to the expression 
of β-lactamase enzymes that degrade the activity of β-lactam antibiotics such as 
imipenem.   A number of the isolates examined in this study demonstrated a level of 
drug resistance indicative of the production of β-lactamase enzymes. Unfortunately, 
none of the resistant isolates examined in this study demonstrated any evidence of co-
activity with hop extracts 
To determine the potential mode of action of the hop extract and the antibiotics alone 
and in combination, scanning electron microscopy was used. One of the limiting 
factors of SEM is the fixing and dehydration steps. This severe process can adversely 
affect the structure of the bacterium and even destroy intact cells. This was a major 
concern and for this reason the method utilised a short (30 seconds) contact time with 
100 % alcohol to avoid dehydrating the cells. 
Another problem that can be encountered when using SEM is  to ensure that  enough 
field of view are examined to ensure that the  images seen are representative of the 
entire sample.  Each image presented in this project is representative of a minimum of 
25 separate images (all images are available in the appendix in CD form).   
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Firstly the structures of M. smegmatis 8159, the surrogate organism of M. tuberculosis 
and the clinical isolate M. abscessus 10332 (chosen because it showed the most 
promising interactions between hop extracts and antibiotics) were compared. No 
obvious evidence of any cell damage (cell destruction, pitting) due to the fixing process 
was observed in any of the bacteria visualised.    
The two bacteria appeared to differ in size in that the mean length of M. smegmatis 
was approximately 1 µm while M. abscessus was approximately 2 µm.  Examination of 
the bacterial surface revealed a rough, crenulated surface which presumably is 
evidence of the waxy coat which is known to surround these bacteria (Ryan et al., 
2004) 
Exposure to a sub-inhibitory concentration of Citra hop extract (0.3125 % v/v) had a 
noticeable effect on the surface of the bacteria in that it became much smoother and 
the cells were visibly pitted. Previous studies to identify the mechanism of 
antimicrobial action of hop extracts have found that it was due to changes in the 
permeability of the cell wall or membrane (Simpson and Smith, 1992; Teuber and 
Schmalreck, 1973) with subsequent inhibition of respiration  and of DNA and RNA 
synthesis (Behr and Vogel, 2009). It may be the case that the hop extract exerts both of 
these properties; firstly by breaking down the waxy outer layer of the cell wall which 
secondly allows the compounds to access the cell and disrupt cellular mechanisms.  
Indeed the intrinsic resistance of mycobacteria to antibiotics has been linked to the 
impermeability of the mycolic acid containing cell wall which is responsible for the 
bacterium’s natural resistance to antibiotics such as tetracycline, fluoroquinolones and 
aminoglycosides. 
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Exposure of M. abscessus to ciprofloxacin and imipenem and its effect on cell wall 
structure was next investigated. In the case of ciprofloxacin, the apparent waxy cell 
surface was lost and the cells were noticeably larger (approx. 3-4 µm) and as was seen 
following exposure to hop extract, visibly pitted.  These differences may be due to the 
antibiotic inhibiting the action of DNA gyrase and thereby preventing cell division and 
cell surface differentiation. 
A similar effect was noticed after the bacteria had been exposed to imipenem. The 
bacteria had a much smoother surface than the untreated control. Imipenem is known 
to interact with penicillin binding proteins involved in cell wall biosynthesis which may 
explain the effect on cell surface morphology (Chambers et al., 1995).  
Exposure of the bacterium to a combination of hop extract and ciprofloxacin at the 
concentrations identified as being synergistic in the checkerboard assay resulted in a 
marked reduction in whole bacterial cells. This was surprising given that the mode of 
action of ciprofloxacin is to inhibit bacterial DNA synthesis. At this moment in time 
there is no reasonable explanation of this phenomenon.  Exposure of the bacterium to 
a combination of hop extract and imipenem, at the concentrations identified as being 
synergistic, had a similar effect on cellular morphology, in that the majority of bacteria 
were lysed. 
It has been reported that several hop compounds, namely the alpha and beta acids 
(Orhan et al., 2005a) and xanthohumol (Stevens and Page, 2004), have antimicrobial 
effects and demonstrate coactivity with several antimicrobials (Natarajan et al., 2008). 
In the case of imipenem, both the hop extracts and the antibiotic have been shown to 
act on the cell wall of the bacterium by inhibiting efflux pump mechanisms. 
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In conclusion, this chapter demonstrates that the Citra hop extract contains 
compounds capable of inactivating multidrug resistant clinical isolates of M. abscessus. 
It has also been shown that the extract contains compounds which enhance the 
activity of the   antibiotics imipenem and ciprofloxacin; the mechanisms by which this 
enhancement is achieved and the identity of the compounds responsible has yet to be 
determined.  Electron microscopy studies suggest that these compounds affect the cell 
wall of the bacterium in a manner which when give together result in the destruction 
of the bacterium. 
These encouraging results suggest that further research is merited to identify the hop 
derived compounds responsible for these effects with a view to developing next 
generation therapeutics for the treatment of drug resistant mycobacterium such as M. 
tuberculosis. 
  
196 
 
 
 
 
 
 
Chapter 6 
 
 
 
 
 
General Discussion, Conclusions and Future work  
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6.0 General Discussion 
Bacterial resistance to antibiotics is a worldwide problem; indeed It is estimated that 
almost one third of the world’s population is infected with M. tuberculosis of these 
approximately 10% of cases are resistant to first line antibiotics (Murray et al., 2014) 
The current cost of $1.5 billion required to bring a new antibiotic from the benchtop to 
the market, coupled with the velocity of bacterial resistance has led to a lack of novel 
antibiotics over the last 20 years. Due to this, current research into plant derived drug 
discovery has seen resurgence. Indeed, over 50% of the drugs used today are derived 
from natural products, and recent evidence suggests that as the general public are 
being made aware of the decline of antibiotics, natural therapeutics are becoming 
more accepted. 
One such natural product which has been utilised for its antibacterial activity for 
hundreds of years is the hop plant. Beer was originally produced without the addition 
of hops. However, it was observed that during summer months ‘unhopped’ beer did 
not last as long as its hopped counterpart due to bacterial contamination. As a 
consequence the popularity of hopped beer increased (Sumner 1988).  During the mid-
19th century, drinking water was heavily contaminated by faecal pathogens due to 
poor sanitary arrangements. Beer was considered a safer drink due to the fact that 
bacteria present were reduced due to a combination of boiling and the presence of 
hop derived antimicrobial compounds (Sumner 1988).  
The majority of research to date has been focused on  characterising  the antimicrobial 
activity of hops against Gram positive bacteria such as lactobacillus which represent 
the principal spoilage agents of beer (Ahn et al., 2007; Sagdic et al., 2003). Surprisingly 
little attention has been paid to determine if these plants contain compounds that 
have inhibitory activity against clinically important bacteria such as Mycobacterium. 
This thesis sought to characterise the antibacterial activity of hops and their extracts 
against a range of medically important Gram negative and positive bacteria; 
Escherichia coli, Staphylococcus aureus and Mycobacteria. 
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Due to the pathogenicity of M. tuberculosis and its slow rate of growth on laboratory 
media two simulant organisms: M.smegmatis and M. bovis BCG were used. Both 
organisms have been shown to have similar sensitivities to antibiotics compared to M. 
tuberculosis (Chaturvedi et al., 2007b; Tyagi and Sharma, 2002). M. smegmatis and M. 
bovis both grow at a higher rate than M. tuberculosis and due to their lack of virulence 
can be handled within a category II laboratory.  
To determine the antibacterial activity of individual hop varieties an extraction process 
was developed which mirrored that used during the brewing process. It was found that 
the degree of maceration, extraction temperature and time influenced the inhibitory 
activity of the crude extract. Furthermore, by increasing the time that machine 
macerated hop material was exposed to 100 °C, the antibacterial activity was 
increased. 
The effect of heat on the antibacterial activity of the hop extracts is likely to have been 
the consequence of two processes: energy drive release of compounds from plant 
material into the aqueous solution and the isomerisation of released compounds such 
as the alpha and beta acids. Isomerisation of these compounds due to heating has 
been shown to increase the antibacterial activity of hop extracts. This was further 
shown by the fact that when heated at room temperature (25 °C) there was little or no 
antimicrobial effect. Prolonged heating of the extracts resulted in a loss of activity. 
Increasing the time of heating increases isomerisation, and concurrently causes 
thermal degradation. It has been suggested that prolonged heating could have an 
adverse effect on the antibacterial activity (Jaskula-Goiris, 2010) 
In this study two agar based screening methods were used to determine the 
antibacterial activity of 50 hop variants.  A broth based micro dilution method had 
been considered. However,  progress using this approach was inadequate due to the 
inherent turbidity of the hop extracts following heating  (Zgoda and Porter, 2001)  
  
199 
 
While the zone of inhibition assay proved to be a useful tool with which to screen the 
activity of multiple hop extracts it lacked sensitivity.  For this reason, an agar 
incorporation assay was developed which allowed for the determination of the 
minimum inhibitory and bactericidal concentrations (Roberts 1998). Using this assay it 
was found that all of the hop variants demonstrated an inhibitory effect against all of 
the test bacteria with the exception of Escherichia coli. Gram negative organisms such 
as E.coli are often resistant to antibiotic substances due to the nature of their cell wall, 
as such natural products rarely have an inhibitory effect against these organisms 
(Yadav et al., 2012). 
As has been hypothesised previously, an investigation into the correlation between 
alpha and beta acid content of a particular hop variant and its antibacterial activity was 
undertaken. No statistically significant correlation was observed. This was surprising 
given that the hop alpha and beta acids have been reported to be antibacterial (In 
Acworth et al., 2012). I hypothesise that other compounds in the hop extract are 
responsible for the observed antibacterial activity.  Hops have been shown to contain 
over 800 compounds some of which may be directly antibacterial or act in a synergistic 
manner to enhance the activity of other antibacterial compounds (Barbara Jaskula-
Goiris, 2010; Cornelison, J.M., 2008).  
The results suggest that the antimicrobial activity demonstrated by the hop variants 
was not due to a single component but was more likely due to a mixture of 
components acting in a synergistic manner; the individual components were next 
investigated. 
To identify the antibacterial compounds present in the hop extracts an extraction and 
identification system based on a combination of solvent extract and thin layer 
chromatography (TLC) was developed.  The technique was modified by overlaying the 
separated compounds on the TLC plate with a layer of M. smegmatis. Following 
incubation the plate was stained and for the presence of viable bacteria and any spots 
of non-staining were taken to indicate the presence of antibacterial compounds. 
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Using this approach it was observed that the Citra hop variant (the variant with the 
greatest antibacterial activity: (Chapter 3) had the greatest number of antimicrobial 
spots, whilst the Galena variant (the least antimicrobial: Chapter 3) had the least 
number of antimicrobial spots. These results support the methodology used in Chapter 
3 which ranked the hops based on their antimicrobial activity and shows that the TLC 
overlay method was a reliable means of determining antimicrobial activity.  
A limitation of this approach is that it separates compounds on the basis of their 
polarity, and as a consequence separated spots may contain a mixture of antimicrobial 
and non -antimicrobial components of similar polarity. Based on the information 
gained from Chapter 3 the Citra and Galena hop variants were selected for further 
analysis. To further enhance the separation of compounds, column chromatography 
was used. 
The advantage of column chromatography in comparison to TLC was that a greater 
quantity hop extract could be separated and as a consequence higher yields of 
components of interest could be achieved. It is recognised that it’s possible for more 
than one compound to be present of equal polarity in a single spot and that 
conventional techniques could not separate them.  
To identify the active components of the Citra and Galena spots selected based on 
antimicrobial activity; both were analysed using mass spectrometry to elucidate the 
compounds present.  The compounds:  adhumulone, lupulone, colupulone, adlupulone 
and epicatechin were found to have similar masses to those extracted from the hop 
extracts. There were differences in the isolation of these compounds from both 
variants which suggested that their presence has an effect on the antimicrobial 
activity.  
The bioassay guided extraction technique failed to identify all of the antibacterial 
compounds that are known to be present in hops.  The most notable missing 
compound was the antibacterial polyphenol, Xanthohumol which  has been  isolated 
by others from this plant and is known to be active against mycobacteria (Acworth et 
al., 2012; Ceh et al., 2007; Stevens and Page, 2004).   
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Further analysis was conducted to screen for the presence of XN via ultra-pressure 
liquid chromatography which is an approach that has been used for a number of years 
to identify natural product derived compounds (Acworth et al., 2012; Ahuja and 
Rasmussen, 2011; Baker et al., 2008). Comparison of the crude extracts of the Citra 
and Galena hop variants confirmed the presence of known antibacterial compounds 
humulone and lupulone. Xanthohumol was also identified, it may have been the case 
that this polyphenol was at a low concentration when separated from the hop extract 
and therefore was missed during the initial screening process.  
The presence of a new compound was detected and isolated from the antibacterial 
fraction of the Citra hop variant; however it was found that this compound was not 
itself antimicrobial. Although not singularly antimicrobial, as with many plant extracts, 
compounds within an antimicrobial mixture are often synergised or potentiated by 
each other. It is hypothesised that this is the case. However, more research is needed 
to investigate the synergies between this compound and others from the extract.  
By using several different methods of characterisation it was possible to gain an insight  
into the constituents responsible for the antimicrobial activity of the extracts.   
Natural product derived compounds have been successfully used to potentiate the 
activity of antibiotics. As bacterial resistance increases, antibiotics are used at ever 
increasing concentrations to the point where they are no longer efficacious and could 
produce harmful side effects. A synergistic combination of antibiotics and a natural 
product not only decreased the efficacious concentration but due to multiple 
mechanisms of action, substantially decreases the likelihood of bacterial resistance 
(Ahn et al., 2007; Jenkins and Cooper, 2012; Mossa et al., 2004; Shami et al., 2013).  
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Mycobacterium abscessus is a clinically relevant multidrug resistant organism which 
has been shown to be intrinsically resistant to many first line antibiotics (Nessar et al., 
2012). To determine if hop extract contained compounds which potentiated the 
activity of antibiotics the ability of the extract alone and in combination with 
antibiotics to target clinical isolates of M. abscessus was investigated. In recent years 
this fast growing non-tuberculosis mycobacterium and opportunistic pathogen has 
emerged  as a major burden to patients with cystic fibrosis (Cullen et al., 2000).  
Variants  have developed  high level resistance to commonly prescribed antibiotics 
which has resulted in the pathogen being described as an emerging antibiotic 
nightmare (Nessar et al., 2012).  
To investigate the potential synergistic activity between antibiotics and hops the 
previously isolated hop compounds; (humulone; lupulone and xanthohumol) were 
assayed against 8 clinical isolated of M. abscessus. Surprisingly, no synergistic effect 
was observed.  
As previously stated, antibacterial activity of hops is often as a result of a combination 
of separate compounds. Therefore, the interaction between the whole crude extract 
and antibiotics against clinical isolates of M. abscessus was characterised. To 
determine the nature of these interactions three methods were employed.  
Using the previously developed zone of inhibition assay, a positive coaction between 
the Citra crude hop extract and the following antibiotics; imipenem and ciprofloxacin, 
was identified. In no case was antagonism observed.  To confirm these results, an agar 
incorporation assay was used. For this, a sub MIC concentration of hop extract was 
incorporated into the agar and an E-test strip of the antibiotic was placed on the 
surface of an M. abscessus inoculated agar plate. As there is no standard regimen for 
identifying a synergistic effect using this method, a threefold decrease in the MIC when 
in combination with a sub-inhibitory concentration of hop extract indicated a positive 
co action.  
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This method gave a quantifiable result as decreases in the MIC value could be 
measured and thus were less subjective than relying on visualising the shape of the 
interaction of zones of inhibition as in the previous method. While the two methods 
agreed with regards the co-action between the hop extract and imipenem and 
ciprofloxacin, no change in the MIC against any organism when the hop extract was 
assayed alongside pyrazinamide, rifampicin and ethambutol.  
As no co-activity had been observed from pyrazinamide, rifampicin and ethambutol, 
the antibiotics ciprofloxacin and imipenem were assayed using the checkerboard 
method. The checkerboard method is recognised as the old standard in characterising 
antibiotic synergy and allows the classification of the interaction between the 
antibiotics: imipenem and ciprofloxacin and the Citra crude hop extracts into the 
following groups; synergistic, additive, indifferent or antagonistic (Hall et al., 1983a; 
Orhan et al., 2005b). 
For imipenem a synergistic interaction with the Citra hop extract against strain 10332; 
an additive effect against strain 9568 and an indifferent effect against 11490 was 
observed. These results differed from those seen with the other methods which 
reported coactivity in each case. The results obtained for the interaction between 
ciprofloxacin and hop extract also differed from the earlier assays in that an additive 
effect against strain 10332 was observed. Whilst against strains 9568 and 11490 the 
interaction showed an indifferent effect. 
Taken together these results suggest that the hop extract contains compounds which 
are capable of inhibiting the growth of mycobacteria and of enhancing the activity of 
the cell wall damaging antibiotic imipenem. 
 The activity against antibiotic resistant strains suggested that the hop extract 
contained compounds whose antimicrobial mode or modes of action differed from 
that of the antibiotics assayed in this study.  It is known that certain hop constituents 
such as humulone can degrade the cell wall of Gram positive organisms (Cornelison, 
2008) and therefore it was hypothesised that this compound could act synergistically 
with other cell wall damaging antibiotics such as imipenem. 
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To determine if the hop extract damaged the architecture of the cell wall of the 
Mycobacteria, selected bacteria were exposed to hop extract alone, and in 
combination with antibiotics and examined the effect on the structure of M. abscessus 
10332 by using scanning electron microscopy.    
Exposure of M. abscessus 10322 to a sub-inhibitory concentration of hop extract 
changed the topography of the cell wall from a rough to a smooth surface. It also 
caused the cells to pit.   One of the mechanisms of antimicrobial action of hop extracts  
is thought to be  due to changes in the permeability of the cell wall and  membrane 
(Simpson and Smith, 1992; Teuber and Schmalreck, 1973) which leads to the  
subsequent inhibition of respiration and  of  DNA and RNA synthesis (Behr and Vogel, 
2009).  These images support the idea that exposure to hop derived compounds can 
alter cell wall structure. 
Exposure of the test bacteria to imipenem and ciprofloxacin also affected the cell 
surface in a similar manner.  In the case of ciprofloxacin this result was surprising in 
that this antibiotic does not target the cell wall but rather interferes with the activity of 
DNA gyrase which in turn inhibits the uncoiling of DNA gene expression. Indeed 
following exposure to the ciprofloxacin the individual bacterial cells were noticeably 
larger (approx. 3-4 µm); as was also the case with the imipenem exposed cells.  
The exposure of the bacteria to both hop extract and ciprofloxacin, at the synergistic 
concentration identified in the checkerboard assay, appeared to cause no additional 
morphological changes to those seen when the bacteria were treated with 
ciprofloxacin alone. Interestingly, a marked reduction in the number of intact bacterial 
cells suggested that the combination of treatment had breached the cell wall. 
A similar effect was also observed between the hop extract and imipenem. This 
destructive interaction is perhaps not surprising given  that  both agents are known to 
act on the cell wall of the bacterium (Vaughan et al., 2005).  
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6.1 Conclusions 
The overall aim of this research was to identify hop derived compounds which had the 
potential to be developed as drugs capable of treating antibiotic resistant strains of 
mycobacteria.  Using M. smegmatis, a fast growing simulant for M. tuberculosis, as a 
screening tool it was found that hop varieties differed markedly in their ability to 
inhibit bacterial growth.  Subsequent studies showed that the most active hop variant, 
Citra, was also able to inhibit the growth of clinical isolates of M. abscessus, a known 
pathogen of humans. Of particular interest in the context of multi-drug resistant 
mycobacteria was the fact that the Citra hop extract was equally effective against 
sensitive and drug resistant isolates of M. abscessus suggesting that its mode of action 
differed from that of the ciprofloxacin and imipenem.  
Whilst the study identified the presence of previously described antibacterial 
compounds with activity against mycobacteria it failed to identify any new 
antimicrobial compounds. This could be due to the fact that there are no new 
compounds to find or that the methods lacked the required sensitivity and specificity 
to detect their presence. 
Combined, the developed bioassay guided methods were able to detect the presence 
of known antimicrobial compounds; whilst the detection of these compounds was 
limited by the concentration of the compound and the concentration of bacteria; the 
methodology was found to be successful in identifying differences between the hop 
variants. 
Whilst novel pure compounds were found to have no synergistic activity with 
antibiotics, synergistic activity of the crude hop extract with imipenem against M. 
abscessus raises the possibility that once identified; mixtures of pure compounds could 
be used to potentiate the activity of antibiotics against drug resistant isolates of 
mycobacterium.  
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6.2 Future work 
This research highlights the possibility of the hop plant to successfully be used as an 
antibacterial agent and as such raises several possibilities for further research.  
Firstly, the hop variants should be analysed against more clinical isolates of drug 
resistant M. abscessus and M. tuberculosis. Tubercculosis is going to become a major 
healthcare concern worldwide over the next decade and as such the development of 
novel antibiotics with differing modes of action or the ability to potentiate the activity 
of redundant antibiotics should be of prime concern. 
It would be interesting to separate as many compounds as possible from the hop 
extract and testing different combinations of these to try and identify synergistic 
combinations. By using HPLC or associated techniques to identify individual 
components it may be the case that a new class of antimicrobials could be identified 
which may not be specific to hops but may be wide ranging in nature.  
Of course M. tuberculosis is not the only drug resistant organism, species such as 
MRSA and C. difficle are a common hospital acquired infection and it would be 
interesting to repeat the synergy assays with antibiotics such as methicillin or 
metronidazole to identify other synergistic combinations.  
Following the results of this research, it would be interesting to examine the 
potentiation of intravenous antibiotics used for the treatment of M. abscessus 
infection by hop extracts or hop compounds.   
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8.0 Appendices 
Attached CD with Scanning Electron microscopy images 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
